SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
Protocol  STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  1 CONFIDENTIAL  SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid 
Dendritic Cell Neoplasm  
Sponsor: Stemline Therapeutics, Inc.  
750 Lexington Avenue, 11th Floor 
New York, NY 10022  
Study Product:  SL-401 
Protocol Number:  STML -401-0114 
IND Number:   
Study Contacts:  
Issue 
Date:  17 January  2019 
CONFIDENTIAL – PROPRIETARY INFORMATION 
The confidential information in this document is the property of Stemline Therapeutics, Inc. It is understood that this 
information will not be disclosed to any third party, in any form, without prior written authorization from Stemline 
Therapeutics , Inc. NCT #: [STUDY_ID_REMOVED]

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
Protocol STML -401-0114  
Amen
dment 12 (FINAL ): 17 January 2019  2 CONFIDENTIAL  PROTOCOL APPROVAL  SIGNATURE 
Protocol Title:  SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid 
Dendritic Cell Neoplasm  
Protocol Number:  STML -401-0114  
This study will be conducted in compliance with the clinical study protocol (and amendments), 
International C ouncil for Harmonisation (ICH) guidelines for current Good Clinical Practice (GCP) and 
applicable regulatory requirements. Compliance with GCP standards provides public assurance that the 
rights, safety, and well -being of trial subjects are protected, consistent with the principles that have their 
origin in the Declaration of Helsinki.  

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
Protocol STML -401-0114  
Ame
ndment 12 (FINAL ): 17 January 2019  3 CONFIDENTIAL  INVESTIGATOR PROTOCOL AGREEMENT  
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid 
Dendritic Cell Neoplasm  
I hereby agree to : 
•Conduct the study as outlined in this protocol with reference to national/local regulations and
current International Council for  Harmonisation / Good Clinical Practice guidelines.
•Discuss and agree upon any modification to the protocol with Stemline Therapeutics, Inc. or
representatives hereof.
•Fully co -operate with monitoring and auditing and allow access to all documentation by authorized
individuals representing Stemline Therapeutics, Inc. or Health authorities.
Protocol Version / Date:   Amendment 12: 17 January , 2019 
To be signed by Principal Investigator:  
Print Name  
Signature  Date  
Institution  

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  4 CONFIDENTIAL  Table of Contents 
1 Protocol Synopsis .............................................................................................................. 11 
2 Abbreviations and Definitions .......................................................................................... 24 
3 Introduction and Study Rationale ..................................................................................... 27 
3.1 Blastic Plasmacytoid Dendritic Cell Neoplasm ........................................................ 27 
3.2 Acute Myeloid Leukemia ......................................................................................... 29 
3.2.1 First-line Therapy .............................................................................................. 29 
3.2.2 Second -line Therapy  ......................................................................................... 30 
3.2.3 Third -line Therapy  ............................................................................................ 30 
3.3 Targeting Cancer Stem Cells  .................................................................................... 30 
3.4 IL-3 Receptor (IL-3R) Over-Expression in AML .................................................... 31 
3.5 Mechanism of Action of SL-401 .............................................................................. 32 
3.6 Preclinical Studies  ..................................................................................................... 33 
3.7 SL-401 Clinical Studies ............................................................................................ 37 
3.7.1 Study 50047 ...................................................................................................... 37 
3.7.2 Current Study (STML-401-0114) ..................................................................... 38 
3.8 Discussion and Rationale for Current Study ............................................................. 39 
4 Study Objectives  ............................................................................................................... 42 
4.1 Primar y Objectives .................................................................................................... 42 
4.2 Secondary Objectives ................................................................................................ 42 
4.3 Exploratory Objectives ............................................................................................. 43 
5 Patient Selection  ................................................................................................................ 43 
5.1 Study Population ....................................................................................................... 43 
5.2 Patient Inclusion Criteria  .......................................................................................... 43 
5.3 Patient Exclusion Criteria  ......................................................................................... 45 
5.4 Replacement of Patients  ............................................................................................ 46 
6 Investiga
tional Plan  ........................................................................................................... 46 
6.1 Dose and Schedule Rationale.................................................................................... 46 
6.2 Overall Study Design  ................................................................................................ 47 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  5 CONFIDENTIAL  6.2.1 Stage 1: Dose Escalation  ................................................................................... 47 
6.2.2 Stages 2 -4 .......................................................................................................... 49 
6.3 Study Duration .......................................................................................................... 51 
6.4 Study Completion  ..................................................................................................... 51 
7 Study Treatment Identification, Administration, and Schedule ........................................ 51 
7.1 Product Manufacturing and Characterization ........................................................... 51 
7.2 Recommended Medications Per Institutional Guidelines/Practices  ......................... 52 
7.3 Allowed Medications/Therapies  ............................................................................... 52 
7.4 Prohibited Medications/Therapies ............................................................................ 52 
7.5 SL-401....................................................................................................................... 52 
7.5.1 SL-401 Description and Storage ....................................................................... 52 
7.5.2 Dose, Schedule and Duration of Treatment ...................................................... 52 
7.5.3 SL-401 Premedication and Dose Preparation and Administration ................... 53 
7.5.4 Patient Monitoring Procedures During the SL-401 Dosing Period .................. 54 
7.5.5 Dose Delays/Mo difications and Management Procedures for Toxicities 
Associated with SL -401 .................................................................................... 54 
7.6 Treatment Discontinuation ........................................................................................ 55 
7.6.1 Criteria for Treatment Discontinuation  ............................................................. 55 
7.6.2 Procedures and Follow- up after Treatment Discontinuation  ............................ 56 
8 Study Procedures  .............................................................................................................. 57 
8.1 Patient Selection ........................................................................................................ 57 
8.2 Medical History  ........................................................................................................ 57 
8.3 Disease Confirmation (Patients with BPDCN in Stages 2 -4) ................................... 58 
8.4 Prior and Concomitant Medication ........................................................................... 58 
8.5 ECOG Performance Status  ....................................................................................... 58 
8.6 Physical Examination ................................................................................................ 58 
8.7 Vital Signs  ................................................................................................................. 58 
8.8 Electrocar
diograms  ................................................................................................... 58 
8.9 Clinical Laboratory Tests  .......................................................................................... 58 
8.10 Urine or Serum Pregnancy Test  ................................................................................ 59 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  6 CONFIDENTIAL  8.11 Vision Assessment  .................................................................................................... 59 
8.12 Tumor Assessments and Disease Response Assessment  .......................................... 59 
8.12.1 Stage 1  ............................................................................................................... 59 
8.12.2 Stage 2, Patients with AML  .............................................................................. 60 
8.12.3 Patients with BPDCN (Stages 2 -4) ................................................................... 61 
8.13 Pharmacokinetic Studies  ........................................................................................... 63 
8.14 Immunogenicity Studies  ........................................................................................... 64 
9 Schedule of Events ............................................................................................................ 65 
9.1 Study Day -14 to - 4: Screening  ................................................................................. 65 
9.2 Study Day -1 to 0: Procedures Prior to Start of Treatment ....................................... 65 
9.3 Cycle 1  ...................................................................................................................... 66 
9.3.1 Study Days  1 – 5 (Up to Study Day 10 if Infusion(s) Held): Pre-Infusion ...... 66 
9.3.2 Study Days 1 – 5 (Up to Study Day 10 if Infusion(s) Held): Infusion ............. 66 
9.3.3 Study Day 8 ±3 Days, or 3 ±3 Days after Completion of Infusions if Infusion(s) 
Held  ................................................................................................................... 67 
9.3.4 Study Day 15 ±3 Days ...................................................................................... 67 
9.3.5 Study Day 21 ±7 Days: End of Cycle ............................................................... 67 
9.3.6 Study Day 28 ±3 Days, Then Every 7 ±3 days: Delayed End of Cycle for Toxicit y 
Resolution Only if Required ............................................................................. 68 
9.4 Cycles 2 – 6 ............................................................................................................... 68 
9.4.1 Days 1 – 5 (Up to Day 10 if Infusion(s) Held): Pre-Infusion ........................... 68 
9.4.2 Days 1 – 5 (Up to Day 10 if Infusion(s) Held): Infusion .................................. 69 
9.4.3 Day 8 ±3 Days, or 3 ±3 Days after Completion of Infusions if Infusion(s) Held69 
9.4.4 Day 15 ±3 Days ................................................................................................ 69 
9.4.5 Day 21 ±7 Days: End of Cycle ......................................................................... 69 
9.4.6 Day 28 ±3 Days, Then Every 7 ±3 days: Delayed End of Cycle for Toxicity 
Resolution Only if Required ............................................................................. 70 
9.5 End of Treatment ...................................................................................................... 71 
9.6 Safety M
onitoring: Through 30 Days after Last Infusion ........................................ 71 
9.7 Survival Monitoring: Approximately Every 90 Days after End of Treatment until 
Study Completion  ..................................................................................................... 71 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  7 CONFIDENTIAL  9.8 Schedules of Events .................................................................................................. 71 
10 Adverse Events and Safety Evaluation ............................................................................. 80 
10.1 Definitions ................................................................................................................. 81 
10.1.1 Adverse Event (AE)  .......................................................................................... 81 
10.1.2 Serious Adverse Event (SAE) ........................................................................... 81 
10.2 Period of Observation ............................................................................................... 82 
10.3 Pre-existing Conditions ............................................................................................. 83 
10.4 Pregnancy  .................................................................................................................. 83 
10.5 Documentation and Reporting of Adverse Events by Investigator .......................... 84 
10.6 Assessment of Causal Relationship to SL-401 ......................................................... 85 
10.7 Grading of Adverse Event Severity  .......................................................................... 86 
11 Excluded Prior and Concomitant Medications and Therapy ............................................ 87 
12 Statistical Analysis  ............................................................................................................ 87 
12.1 General Considerations ............................................................................................. 87 
12.2 Populations for Analysis ........................................................................................... 88 
12.3 Determination of Sample Size  .................................................................................. 88 
12.4 Demographics and Baseline Characteristics  ............................................................. 89 
12.5 Analyses of Safety Data  ............................................................................................ 89 
12.6 Analysis of Efficacy Data in First- Line BPDCN  ...................................................... 90 
12.6.1 Order of Statistical Analyses of Efficacy  .......................................................... 90 
12.6.2 Response Rate  ................................................................................................... 91 
12.6.3 Duration of Response ........................................................................................ 91 
12.6.4 Bridge to SCT  ................................................................................................... 92 
12.6.5 Progression-free Survival.................................................................................. 92 
12.6.6 Overall Survival ................................................................................................ 92 
12.6.7 Exploratory and Subgroup Analyses ................................................................ 92 
12.7 Additional Efficacy Analyses  ................................................................................... 92 
12.8 Pharmacoki
netic and Immunogenicity Analyses  ...................................................... 93 
12.9 Blinding..................................................................................................................... 93 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  8 CONFIDENTIAL  12.10 Interim Analyses  ....................................................................................................... 93 
12.11 Final Analysis  ........................................................................................................... 93 
12.12 Study Oversight Committees  .................................................................................... 93 
13 Emergency Procedures  ...................................................................................................... 94 
13.1 Emergency Contact  ................................................................................................... 94 
13.2 Emergency Identification of Investigational Products .............................................. 94 
13.3 Emergency Treatment  ............................................................................................... 94 
14 Ethical and Regulatory Considerations ............................................................................. 94 
14.1 Good Clinical Practice  .............................................................................................. 94 
14.2 Delegation of Investigator Responsibilities  .............................................................. 94 
14.3 Patient Information and Informed Consent............................................................... 95 
14.4 Confidentiality  .......................................................................................................... 95 
14.5 Protocol Amendments ............................................................................................... 96 
14.6 IRB/IEC Approval and Reporting ............................................................................ 96 
14.7 Closure of the Study.................................................................................................. 96 
14.8 Record Retention  ...................................................................................................... 97 
14.9 Liability and Insurance  ............................................................................................. 97 
14.10 Financial Disclosure .................................................................................................. 97 
14.11 Study Monitoring and Auditing ................................................................................ 97 
14.11.1 Study Monitoring and Source Data Verification  .............................................. 97 
14.11.2 Study Documentation ........................................................................................ 98 
14.11.3 Site Audits  ......................................................................................................... 99 
14.12 Documentation and Use of Study Findings .............................................................. 99 
14.12.1 Documentation of Study Findings .................................................................... 99 
14.12.2 Use of Study Findings ....................................................................................... 99 
15 References  ....................................................................................................................... 101 
16 Appendices ...................................................................................................................... 107 
16.1 Appendix A. Tum
or Response Criteria for Patients with AML ............................. 107 
16.2 Appendix B. Tumor Response Criteria for Patients with BPDCN ......................... 108 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  9 CONFIDENTIAL  16.3 Appendix C. Modified Severity Weighted Assessment Tool ................................. 110 
16.4 Appendix D. ECOG Performance Status ................................................................ 111 
16.5 Appendix E. CLS Management Guidance .............................................................. 112 
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  10 CONFIDENTIAL  List of Tables in the Text  
Table 1: Immunophenotypic Marker Expression in BPDCN .................................................. 28 
Table 2: Completed SL- 401 Repeat -Dose Toxicity Studies, Investigator- sponsored IND  ..... 34 
Table 3: Completed SL- 401 Repeat -Dose Toxicity Studies with SL -401, Stemline IND ...... 34 
Table 4: Recommended ELZONRIS Dose Modifications ...................................................... 55 Table 5: Study Events Schedule for Cycle 1 (Study Day -14 to Study Day 21): Stage 1 (All Pts) 
& Stage 2 (AML Pts)  ........................................................................................... 72 
Table 6: Study Events Schedule for Cycles 2-6 and Subsequent Cycles: Stage 1 (All Pts) & Stage 
2 (AML Pts)  ......................................................................................................... 74 
Table 7: Study Events Schedule for Cycles 1 & 2 (Study Day -14 to Study Day 21): BPDCN 
Patients in Sta ges 2 -4 ........................................................................................... 76 
Table 8: Study Events Schedule for Cycles 3-6 and Subsequent Cycles: Stages 2- 4 (BPDCN 
Patients)  ................................................................................................................ 78 
Table 9: Time Points for Pharmacokinetic Blood Draws and ECGs ....................................... 80  
List of Figures in the Text  
Figure 1: Schematic of SL -401 Construction .......................................................................... 32 
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  11 CONFIDENTIAL  1 Protocol Synopsis 
Name of Finished Product:  
SL-401 Injection frozen solution (1 mg/mL) / SL-401 for Injection lyophilized powder, for solution 
(1 mg/mL)  
SL-401 Injection frozen solution (1mg/mL) was approved by the Food and Drug Administration 
(FDA) on 21 December 2018 for the treatment of BPDCN in adults and in pediatric patients 2 years 
and older under the name ELZONRIS (tagraxofusp- erzs) . 
Name of Active Ingredient:  
SL-401 (tagraxofusp -erzs)  
Study Title:  
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm  
Protocol Number:  
STML-401-0114 
Study Phase:  
1 / 2 
Primary Objectives:  
Stage 1 (completed):  
• Determine the maximum tolerated dose (MTD), or the maximum tested dose where multiple 
dose- limiting toxicities (DLTs) are not observed, of SL-401. 
Stage 2  (completed): 
• Determine the efficacy of SL -401 in patients with blastic plasmacytoid dendritic cell neoplasm 
(BPDCN ), as assessed by objective response rate (ORR).  
• Characterize the safety profile of SL -401 at the MTD or maximum tested dose in both patients 
with acute myeloid leukemia ( AML ) and BPDCN.  
Stage 3  (completed): 
• Determine the complete response ( CR) rate ( i.e., CR + CR [clinical] with minimal residual 
skin abnormality [CRc])  in patients with first -line BPDCN . 
• Characterize the safety profile of SL -401 in patients with first- line BPDCN.  
Stage 4:  
• Further characterize the efficacy of SL -401 in first -line and relapsed/refractory ( R/R) patients 
with BPDCN following the completion of Stage 2 and Stage 3, respectively, as assessed by the 
rate of CR (CR + CR with incomplete blood count recovery [CRi] + CRc).  
• Further characterize the safety profile of SL -401 among first- line and R/R patients with 
BPDCN.  
• Characterize the efficacy and safety of a lyophilized formulation of SL-401 among R/R and 
first-line patients with BPDCN.  
Secondary Objectives:  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  12 CONFIDENTIAL  • Determine the CR rate ( i.e., CR + CRi + CRc)  for Stage 1 and Stage 2, and ORR  for Stage 3 
patients.  
• Estimate duration of response (DOR) , progression -free survival (PFS), and overall survival 
(OS) in patients with BPDCN.  
• Enable preliminary characterization of the estimated ORR in patients with R/R AML , 
including in subsets of patients with R/R AML based on pre-treatment blast count, 
cytogenetics, or CD123 measurement.  
• Estimate duration of response, PFS, and OS in patients with AML. 
• Characterize the pharmacokinetics (PK) and immunogenicity of SL-401. 
Exploratory Objectives:  
Exploratory objectives are to characterize expression of the interleukin -3 receptor ( IL-3R)/CD123 (and 
other potentially relevant stem cell and disease markers) on leukemia cells in peripheral blood and 
bone marrow (when feasible), to evaluate potential changes in IL -3R/CD123 (and other potentially 
relevant marker) expressing populations over time, and preliminary correlation of baseline IL-3R/CD123 (and other potentially re levant marker) expression and clinical efficacy (including response 
rates).  
Study Design:  
This is a 4-stage, non-randomized, open- label, dos e escalation  and expansion, multicenter study. A 
cycle of therapy is 21 days. A Data Safety Review  Committee  (DSRC), which will include Sponsor 
representatives, will be established to review the accruing safety data and make safety decisions during the study, including dose escalations in Stage 1.  
Stage 1: Dose Escalation (c omplete d) 
During Stage 1 , app roximately 9-24 patients will be treated wi th SL-401 Injection at doses of 7, 9, 12, 
or 16 µg/kg/day for 5 consecutive days every 21  days . The 16 µg/kg/day dose will be evaluated only in 
patients with AML.  Evaluation of higher doses (in increments of 25% or less) in AML patients may be 
attempted pending evaluation of the safety/tolerability of the 16 µg/kg/day dose level  (these 
evaluations would be attempted to identify an MTD and will be guided by the criteria [stipulated below] defining safety/tolerability of all dose le vels). 
Cohorts of 3-6 patients will be treated at each dose level.  All patients within a cohort must complete 
the first cycle of therapy before patients from a new cohort receive SL -401 Injection at the next higher 
dose. No intra -patient dose escalation is  allowed. The first cohort of patients will receive SL-401 at a 
dose of 7 µg/kg/day.  After all patients in this cohort complete the first cycle of therapy, the dose for the 
second cohort of patients will increase by 29% to 9 µg/kg/day, conditional on the DLT rules described 
below. Similarly, after all patients  in th e second  cohort complete the first cycle of therapy, the dose for 
the third  cohort of patients will increase by 33% to 12 µg/kg/day, conditional on the DLT rules 
described below. Finally, after a ll patients in the third cohort complete the first cycle of therapy, the 
dose for the fourth cohort of patients, consisting only of patients with AML, will increase by 33% to 16 µg/kg/day, conditional on the DLT rules described below.  
During Stage 1, DLT i s defined as any of the following  during the first cycle of therapy : 
• Any treatment -emergent Grade 4 transaminase or creatine phosphokinase (CPK) elevation, 
regardless of duration or relationship to SL-401. 
• Any treatment -emergent  Grade 4 hematologic toxicity (unrelated to persistent leukemia) 
lasting >21 days after the last infusion of SL -401. 
• Any treatment -emergent  Grade ≥3 non- hematologic toxicity  (unrelated to persistent leukemia) , 
with the exception of Grade 3 laboratory toxicities that resolve to  Grade ≤1 or baseline ≤21 
days after the last infusion of SL -401, or the follow ing Grade 3 toxicities if they resolve to 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  13 CONFIDENTIAL  Grade ≤1 or baseline ≤21 days after the last infusion of SL -401: arthralgia, myalgia, fever 
responding to treatment, nausea and/or vomi ting (excluding cases that require tube feeding, 
TPN or hospitalization) or diarrhea associated with suboptimal prophylaxis or treatment . 
Begi nning with the d ose level 7 µg/kg/day of SL -401 Injection, a decision to allow treatment at the 
next higher dose level will depend on the number of patients who experience a DLT during the first 
cycle.  If none of the initial 3 patients treated  (0/3) experiences a DLT, then dose escalation will 
proceed and 3 new patients will be treated at the next higher dose of 9  µg/kg/day. If one of the initial 3 
patient s treated (1/3) experiences  a DLT, the cohort will be expanded to include up to an additional 3 
patients treated  at the same dose 7 µg/kg/day. If only one patient (1/6) from this expanded cohort 
experiences a DLT, then 3 new patients will be treated at the next higher dose 9 µg/kg/day. Expansion 
of the 9 µg/kg/day cohort to 6 patients, if necessary, will follow the same rules as the 7 µg/kg/day 
cohort. The same DLT rules will also apply to the 12 µg/kg/day and 16 µg/kg/day (AML specific) 
cohorts. 
In the event that 2 (or more) patients within a cohort have a DLT, then the MTD will be exceeded and 
further dose escalation will not occur. The MTD is defined as the dose preceding the dose level at 
which  two patients  experience a DLT during treatment Cycle 1.  The MTD will be used in Stages 2-4 of 
the study. If the highest planned treatment dose is completed and determined to be safe and the MTD is 
not exceeded, the availa ble PK  and safety  data will be reviewed to assess whether further dose 
escalation is justified.  A patient who does not complete the first cycle of treatment for reasons other 
than the occurrence of DLT will  be replaced by another patient who will receive the same dose 
regimen.  
In the event that a DLT occur s in two patients treated at the 7 µg/kg/day dose level , 5 µg/kg/day will be 
considered by the D SRC as an alternative starting dose.  In this event, a new cohort of 3 patients will 
receive 5 µg/kg/day for the first cycle. The same DLT rules will apply to this dose level . If two or more 
patients experience a DLT at the 5 µg/kg/day dose level, the study will be halted.  
Stage 1 is complete, with the MTD of SL -401 determined to be 12 µg/kg/day in R/R AML and a 
maximum tested do se of SL -401 of 12 µg/kg/day in BPDCN.  (An MTD was not determined in 
BPDCN.)  
Stages 2-4 : Safety Expansion and Efficacy Assessment : 
During Stage s 2-4, patients will be treated at the MTD or maximum tested dose at which multiple 
DLTs are not observed during Stage 1, or a lower dose with potentially the most favorable risk/benefit 
profile.  
SL-401 will be supplied as SL-401 Injection frozen solution (1 m g/mL) as described in  Section 7.5. A 
lyophilized formulation ( SL-401 for Injection , lyophilized powder, for solution; 1 mg/mL) also will be 
supplied. All patients enrolled in Stage 4 (both R/R and first -line) subsequent to completion of 
enrollment in Stage 3 will receive the lyophilized formulation of SL-401. Note that when the 
lyophilized formulation is introduced, patients who start treatment with SL-401 Injection frozen 
solution will continue to receive this dosage form  throughout the study. 
At the time of Protocol Amendment 11, only Stage 4 is open for enrollment. 
Tumor Assessments During Stage s 2-4 
Patients with AML ( Stage 2 only ) 
Assessment of the anti -tumor activity of SL -401 in patients with AML will be assessed by the 
Investigator as a secondary endpoint using the criteria in Section 16.1, Appendix A . The following 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  14 CONFIDENTIAL  assessments will be performed at baseline within 14 days prior to the first administration of SL -401 
and thereafter for determination of tumor response for patients with AML in Stage 2, as follows:  
• Bone marrow aspirates (± biopsy)  21 (±7) days after the start of Cycles 1 and 2.  Patients with 
evidence of bone marrow involvement prior to study treatment will also have bone marrow 
evaluations following Cycles 4 and 6 and then every 3 months from Months 6-12; every 6 months 
from  12 to 24 months; and every 12 months thereafter until there is evidence of relapsed or 
progressive disease. If the Cycle 1 (Day 21  [±7]) bone marrow examination is empty (i.e., 
hypocellular) or inadequate, a bone marrow examination should be repeated in 7 (±7) days to 
document response. If additional time is required to complete the repeat examination, consultation 
with the Medical Monitor is required . If CD123 flow cytometry or IHC stain assessment was 
performed on the bone marrow aspiration ( ± biopsy), t he results should be recorded in the 
electronic case report form (eCRF ).  
• Collection of peripheral blood samples  for determination of blasts 21 (±7) days after the start of 
Cycles 1 and 2.  Patients with evidence of peripheral blasts at baseline will also h ave peripheral 
blood samples  collected 21 (±7) days after the start of Cycles 1 and 2 and 21 (±7) days after the 
start of every 2nd cycle thereafter (Cycles 4, 6, etc.) until there is evidence of relapsed or 
progressive disease. 
Patients with BPDCN (Stages  2-4) 
Standardized assessment of potential sites of disease involvement (including skin, lymph nodes, blood, 
bone marrow, and visceral organs) and consistently-defined response criteria will be utilized.  
The BPDCN diagnosis will be made or confirmed during screening by the pathology laboratories at the 
investigative sites.  Subsequent to enrollment, pathology material will be submitted for review by the 
central patholog ist for confirmation of the BPDCN diagnosis. 
Tumor response will be assessed by the Investigators for all patients with BPDCN , with the 
In
vestigator’s assessment to be used in the primary analysis.  As a supportive assessment, tumor 
response will be assessed by an Independent Review Committee (IRC ). Tumor response will be 
assessed using the Tumor Response Criteria for Patients with BPDCN presented in  Section 16.2, 
A
ppendix B . All p atients will also be followed for duration of response and survival . The following 
assessments will be performed at baseline within 14 days prior to the first administration of SL -401 
and thereafter for determination of tumor response for patients with BPDCN: 
• Bone marrow aspirates (± biopsy) samples 21  (±7) days after the start of Cycles 1 and 2.  Patients 
with evidence of bone marrow involvement prior to study treatment will also have bone marrow 
evaluations following Cycles 4 and 6 and then every 3 months from Months 6-12; every 6 months from 12 to 24 months; and every 12 months thereafter until there is evidence of relapsed or progressive disease. 
• If the Cycle 1 (Day 21  [±7]) bone marrow examination is empty (i.e., hypocellular) or 
inadequate, a bone marrow examination should be repeated in 7 (±7) days to document 
response.  If additional time is required to complete the repeat examination, consultation with 
the Medical Monitor  is required . If CD123 flow cytometry or IHC stain assessment was 
performed on the bone marrow aspiration ( ± biopsy), the results should be recorded in the 
eCRF.   
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  15 CONFIDENTIAL  • Skin assessments, including photographs , for patients with skin involvement, and determination of 
skin disease burden using the Modified Severity Weighted Assessment Tool (mSWAT ) (see 
Section 16.3, Appendix C) 21 (±7) days after the start of Cycles 1 and 2 and 21  (±7) days after the 
start of every 2nd cycle thereafter (Cycles 4, 6, et c.) until there is evidence of relapsed or 
progressive disease.  Refer to the separate mSWAT Manual for instructions regarding the 
quantitation of malignant lesions via the mSWAT and response assessment in skin.  
• In situations in which there is substantial reduction of skin lesions (especially when 
accompanied by disappearance of BPDCN from bone marrow or other sites), a skin biopsy is 
required. The mSWAT guidance states: “A biopsy of normal appearing skin is unnecessary to 
assign a complete response.  However  a skin biopsy should be performed of a representative 
area of the skin if there is any question of residual disease (persistent erythema or pigmentary change) where otherwise a complete response would exist” ( Olsen et al.  2011 ). 
• Computed tomography (CT) scans of index lesions 21 (±7) days after the start of Cycles 2, 4 and 
6 and 21 (±7) days after the start of every 4
th cycle thereafter (for patients with baseline evidence of 
lymph node or visceral disease) until there is evidence of relapsed or progress ive disease.  For 
patients with no baseline evidence of lymph node or visceral BPDCN involvement, subsequent scans should be performed at the end of Cycle 2 (±7 days; or at time of disease progression (PD) if PD occurs prior to end of Cycle 2), 21 (±7) days after the start of Cycle 6, and at Investigator’s 
discretion thereafter.  Baseline CT scan s should be full -body (chest/ abdomen/pelvis), whereas 
follow-up scans should document response of index lesions ( Cheson et al.  2007 ). 
• Collection of peripheral blood samples  for determination of blasts 21 (±7) days after the start of 
Cycles 1 and 2.  Patients with evidence of peripheral blasts at baseline will also have peripheral 
blood samples collected 21 (±7) days after the start of Cycles 1 and 2 and 21 (±7) days af ter the 
start of every 2nd cycle thereafter (Cycles 4, 6, etc.) until there is evidence of relapsed or 
progressive disease.  
Study Centers:  
This study will be conducted at up to 10 study centers. 
Inclusion Criteria:  
1. The patient has a diagnosis of AML ( Protocol Stage 1 or 2) or BPDCN (Protocol Stages 1 -4) 
according to World Health Organization ( WHO ) classification ( AML; excluding acute 
promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN) ( Facchetti 
et al.  2008) . 
2. The patient must meet one of the following (a) or (b) or (c):  
(a) Has evidence of persistent or recurrent AML (Protocol Stage s 1 or 2) in the peripheral blood 
and/or bone marrow that  is refractory to, or has relapsed from, the ir most recent prior line of 
treatment . 
• A prior line of treatment is considered an induction regimen if it involves an approved or 
investigational cytotoxic chemotherapy agent, biological agent, and/or hypomethylating 
agent administered alone or in a combination regimen, with the intent to induc e robust 
cytoreduction (i.e., CR).  
• The previous induction regimen may have been a stem cell transplant ( SCT) with intent to 
induce a CR.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  16 CONFIDENTIAL  • Consolidation and/or maintenance (including SCT) may have been given in CR/CRi, but 
are not counted as a line of trea tment . 
• Hydroxyurea will not be considered a prior line of treatment . 
(b) Has p reviously untreated  AML (Protocol Stage s 1 and 2) and is considered to be at high risk 
for disease progression  and/or is unlikely to derive more than transient benefit from standard 
therapy by having at least one of the following: 
• Treatment -related AML, except if it is associated with favorable cytogenetics (e.g., 
inversion 16, t [16;16] , t[8;21], t[15;17]). 
• AML with antecedent hematological disease (e.g., myelodysplastic syndrome [MDS ], 
myelofibrosis, polycythemia vera ) and not a candidate for SCT  in their current disease 
state. 
(c) Has histological and/or cytological evid ence of BPDCN by pathologic assessment at the 
investigative site according to WHO classification (Facchetti et al.  2008)  by a pathologist with 
expertise in hematologic malignancies, that can be measured for treatment response and is 
either:  
• Previously untreated ( i.e., first-line) (Protocol Stage s 2-4).  
• Persistent or recurrent in the peripheral blood, bone marrow, spleen, lymph nodes, skin, or 
other sites after previous treatment with at least 1 line of systemic therapy for BPDCN, e.g., 
stem cell transplant or chemotherapy ( Protocol Stages 1, 2, and 4). A pathology specimen 
must be available for central pathology re view for all BPDCN patients enrolled in Stages 2 -
4.  
3. The patient is ≥18 years old . 
4. The patient has an ECOG performance score (PS) of 0 -2. 
5. The patient has adequate baseline organ function, including cardiac, renal, and hepatic function: 
• Left ventricula r ejection fraction (LVEF) ≥ institutional lower limit of normal as measured 
by multigated acquisition ( MUGA) scan or 2- dimensional ( 2-D) echocardiography 
(ECHO) within 28  days prior to start of therapy and no clinically significant abnormalities 
on a 12- lead electrocardiogram ( ECG ) 
• Serum creatinine ≤1.5 mg/dL  (133 µmol/L) 
• Serum albumin ≥3.2 g/dL  (32 g/L) (please note that albumin infusions are not permitted in 
order to enable eligibility)  
• Bilirubin ≤1.5 mg/dL  (26 µmol/L) 
• Aspartate transaminase ( AST ) and alanine transaminase (ALT ) ≤2.5 times the upper limit 
of normal (ULN)  
6. If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or 
urine pregnancy test within 1 week  prior to treatment. 
7. The patient has signed informed consent prior to initiation of any study- specific procedures or 
treatment . 
8. The patient is a ble to adhere to the study visit schedule and other protocol requirements, including 
follow- up for survival assessment . 
9. The patient (m ale and female) agrees to use accept able contraceptive methods for the duration of 
time on the study, and continue to use acceptable contraceptive methods for 2 months after the last infusion  of SL-401. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  17 CONFIDENTIAL  Exclusion Criteria:  
1. The patient has a diagnosis of APL (FAB M3).  
2. The patient has p ersistent clinically significant toxicities Grade ≥2 from previous chemotherapy 
(excluding alopecia, nausea, fatigue, and liver function tests [as mandated in the inclusion 
criteria ]).  
3. The patient has received treatment with chemotherapy , wide -field radia tion, or biologic therapy 
within 14 days  of study entry. 
4. The patient has received treatment with another investigational agent within 14 days of study entry. 
5. The patient has previously received treatment with SL-401. 
6. The patient has an active malignancy and/or cancer history (excluding AML , BPDCN,  or 
antecedent MDS ) that may confound the assessment of the study endpoints. Patients with a past 
cancer history (within 2 years of entry) with substantial potential for recurrence and/or ongoing 
active malignancy must be discussed with the Sponsor before study entry. Patients with the 
following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, cervical 
intraepithelial neoplasia, organ- confined prostate cancer with  no evidence of progressive disease. 
7. The patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York 
Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial 
infarction , unstable angina or stroke within 6 months prior to study entry, uncontrolled 
hypertension or clinically significant arrhythmias not controlled by medication). 
8. The patient has u ncontrolled, c linically significant pulmonary disease (e.g., chronic obstructive 
pulmonar y disease, pulmonary hypertension) that in the opinion of the Investigator  would put the 
patient at significant risk for pulmonary complications during the study. 
9. The patient has k nown active or suspected central nervous system ( CNS ) leukemia.  If suspected, 
CNS leukemia should be ruled out with relevant imaging and/or examination of cerebrospinal 
fluid . 
10. The patient is receiving immunosuppressive therapy – with the exception of low -dose prednisone 
(≤10 mg/day) – for treatment or prophylaxis of gr aft-versus- host disease (GVHD).  If the patient  
has been on immunosuppressive treatment or prophylaxis for GVHD, the treatment(s) must have been discontinued at least 14 days prior to study treatment and there must be no evidence of Grade 
≥2 GVHD . 
11. The patient has u ncontrolled intercurrent illness including, but not limited to, uncontrolled 
infection, disseminated intravascular coagulation , or psychiatric illness/social situations that would 
limit compliance with study requirements . 
12. The patient is p regnant or breast  feeding . 
13. The patient has known positive status for  human immunodeficiency virus or active or chronic 
Hepatitis B or Hepatitis C. 
14. The patient is oxygen-dependent. 
15. The patient has any medical condition which in the opinion of the Investigator  places the patient at 
an unacceptably high risk for toxicities.  
16. The patient has AML and requires more than 1g per day of hydroxyurea. (Hydroxyurea is 
permitted at doses of 1g per day or less). 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  18 CONFIDENTIAL  Investigational Product,  Dose, and Mode of Admini stration: 
SL-401 is a novel protein com prised of recombinant human interleukin -3 (IL-3) genetically fused to 
truncated diphtheria toxin protein . SL-401 targets the IL -3R, which is over-expressed on the cancer 
stem cells (CSCs)  and/or tumor bulk of a variety of leukemias and hematopoietic malignancies, 
including BPDCN and AML, relative to normal hematopoietic stem cells and other hematopoietic 
cells.  
A cycle of therapy is 21 days. SL -401 Injection is provided as an intravenous (IV) injectable and 
administered as a 15 -minute IV infusion for the first 5 consecutive days  of a 21- day cycle; refer to the 
Pharmacy Manual for details regarding SL -401 preparation and administration. The first cycle of 
SL-401 must be administered in the inpatient setting, with hospitalization beginning the day of the first 
infusion of SL-401 and ending 24 hours after the last infusion of SL-401. Subsequent cycles of SL-401 
can be administered in the inpatient setting  or in a suitable outpatient ambulatory care setting that is 
equipped for intensive monitoring of patients with hematopoietic malignancies undergoing treatment, 
per the discretion of the Investigator and institutional guidelines and capabilities.  Patients will be 
monitored for at least 4 hours following the administration of each infusion of SL-401. 
Patients who benefit from treatment and do not have evidence of clinically significant progressive disease may receive repeated cycles of SL -401 even if a response, in the judgment of the Investigato r, 
is not attained.  Patients should continue to receive  SL-401 as long as they may be benefiting from 
treatment , according to the  Investigator ; no maximum duration of therapy has been set .  
Patients will receive the following premedications approximately 60 minutes before each SL-401 
infusion : 
• Acetaminophen 650 mg (or equivalent dose of paracetamol) orally (PO)  
• Diphenhydramine 50  mg IV (or equivalent dose of another H1- histamine antagonist)  
• Methylprednisolone 50 mg IV  (or an equivalent dose of another corticosteroid)  
• Ranitidine 50 mg IV  (or an equivalent dosage of another H
2-histamine antagonist)  
During the dosing period for each cycle, individual SL-401 infusions may be delayed to allow for 
toxicity resolution, as detailed in  Section  7.5.5.  
During the first cycle, patients will receive a starting dose according to their dosing cohort in Stage 1, 
or the dose c arried into Stage s 2-4. Potential dose modifications for subsequent cycles relative to the 
prior cycle dose will be based on the severity and resolution of toxicities. Dose reductions should be 
discussed with the medical monitor on a case by case basis.  
Procedures During Dosing Period:  
During each cycle, testing and procedures that may result in withholding of a scheduled SL-401 infusion, largely based on unresolved manifestations of fluid retention and/or other relevant acute toxicities during daily dosing, are described in  Table 5, Table 6, Table 7, and Table 8 in Section  9.8. 
Withhold SL-401 infusion if any of the following occur: 
• Body temperature ≥38°C 
• Heart rate ≥130 or ≤40 bpm 
• Systolic blood pressure ( BP) ≥160 or ≤80 mmHg 
• Serum creatinine >1.8 mg/dL (159 µmol/L) 
• Serum albumin  
o In settings in which albumin is reduced to 3.0-3.5 g/dL (30-35 g/L) or by ≥0.5 g/dL 
(5 g/L) below the level at the start of the cycle, withhold SL -401 infusion and 
administer albumin 25 g IV daily or every 12 hours as clinically feas ible until serum 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  19 CONFIDENTIAL  albumin is both ≥3.5 g/dL and not reduced by ≥0.5 g/dL from the level at the start of 
the cycle prior to resuming treatment with SL -401 in the same cycle.  
o In settings in which albumin is reduced to <3.0 g/dL (30 g/L) or by more than 1.0 g/ dL 
(10 g/L) below the level at the start of the cycle (i.e., from 4.3 g/dL to 3.2 g/dL), 
withhold SL-401 infusions for the duration of that particular cycle. Albumin should be 
administered until the albumin level is at least above 3.5g/dL. Consultation with the Medical Monitor is advised.  
o Dosing in the next cycle may resume if albumin remains at 3.5 g/dL without additional albumin infusions. 
• AST >5 times the ULN or ALT >5 times the ULN (SL -401 will be withheld for remainder of 
study cycle)  
• Increase in body weight by ≥1.5 kg over pre- treatment weight on the prior treatment day. 
Refer to  Section  7.5.5 for dose modifications/delays.  M anagement procedures for capillary leak 
syndrome ( CLS) and associated symptoms are provided in Section  16.5, Appendix E.
 
Concomitant Medications:  
Recommended Medications Per Institutional Guidelines/Practices:  
It is recommended that patients receive the following types of prophylactic therapies/regimens per institutional guidelines/practices:  
• Antibacterial: ciprofloxacin, levofloxacin, or an equivalent antibiotic  
• Antifungal: fluconazole, v oriconazole, or an equivalent antifungal 
• Antiviral: acyclovir, valacyclovir or an equivalent antiviral  
Allowed Medications/Therapies:  
All patients may receive supportive care measures as clinically indicated, including prophylactic 
antibiotics, antihistami nes, antiemetics, albumin, fluids (hydration), and supportive measures. Patients 
may receive growth factor support and/or blood product transfusions as per the discretion of their 
physician. 
Albumin 25 g IV daily should be administered if serum albumin is  between 3.0-3.5 g/dL (30-35 g/L) 
on days that dosing occurs or if it is <3.0  g/dL  (30 g/L) on days when treatment has been wit hheld  or in 
the immediate post -treatment period . The Investigator  has discretion with regard to frequency of 
administration. Prohibited Medications/Therapies:  
An enrolled patient may not receive investigational or approved anticancer or anti -leukemia agents, 
including cytotoxic chemotherapy agents, hypomethylating agents (5- azacytadine, decitabine or 
others), or anticancer tyros ine kinase inhibitors  (including imatinib, ruxolitinib, sorafenib and others) 
or therapeutic monoclonal antibodies. Hydroxyurea may be administered (however its use should be 
discussed with the Medical Monitor ). 
Assessments:  
Assessments for safety, efficacy, and biological effects will be performed according to the schedules 
outlined in Table 5, Table 6, Table 7, and Table 8 in Section 9.8.  
Safety Assessments:  
Safety assessments include DLTs, adverse events (AEs), serious adverse events (SAEs), physical 
examinations, vital sign measurements, clinical laboratory evaluations, and reasons for treatment 
discontinuation due to toxicity. In addition, patients will be monitored for changes in visual acuity and 
color vision and post -trans plantation veno -occlusive disease (VOD).  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  20 CONFIDENTIAL  The AE reporting period for a patient treated in the study begins with the initiation of SL-401 and is 
continuous through 30 days after the last SL-401 infusion. All AEs that occur in treated patients during 
the AE  reporting period specified in the protocol must be reported to the Sponsor , whether or not the 
event is considered related to SL-401. Any known untoward event that occurs beyond the AE reporting 
period that the Investigator assesses as related to SL-401 should also be reported as an AE. 
Efficacy Assessments:  
For BPDCN patients, a global assessment paradigm is to be followed for determination of baseline 
disease and subsequent response evaluations, with all potential disease sites assessed during Screening, 
including the bone marrow (via aspirate and/or biopsy when an aspirate is not available), blood (via 
clinical laboratory testing for blasts and hematologic parameters), skin (via visual examination with 
determination of skin disease burden using mSWAT),  lymph nodes, liver, spleen, and other viscera 
(via CT), and lymph nodes, liver, spleen, and other viscera (via physical examination). Positive sites of 
disease identified during screening MUST be followed during the study in every response evaluation. (Disease in organs that were disease-positive at screening are to be assessed, documented and recorded 
in the clinical database, even if the disease disappeared in subsequent response evaluations.)  Sites with 
no evidence of disease during Screening must be documented as such and an assessment that baseline 
disease is not present are to be adequately documented in source and recorded in the clinical database; 
thereafter, these sites need not be followed, unless there is evidence of PD. 
Efficacy endpoints include ORR , CR rate, duration of response, PFS, and OS. Stem cell transplantation 
rate following SL -401 therapy and subsequent disease assessments will also be evaluated . Among 
patients with BPDCN in Stages 2 -4, patients with a central pathologist-confirmed diagnosis of BPDCN 
who received at least one SL -401 infusion will be considered evaluable for the primary analysis of 
efficacy.   
See Study Design for a description of efficacy assessments for patients with AML.  
Pharmacokinetic (PK) Studies:  
An intensive schedule for collection of blood samples after specific infusions during Cycle s 1 and 3 of 
SL-401 will be used to determine plasma concentrations of SL-401. Plasma concentration data over 
time will be used to characterize the PK disposition of SL-401, to assess any change in the PK 
properties of SL-401 during the 5- day course of treatment or between cycles of treatment, and relate 
the PK characteristics of SL -401 to immunogenicity, toxicity, and disease activity. The nominal blood 
sampling time schedule is summarized in  Table 9.  
Immunogenicity Studies:  
Blood samples will be collected for the detection of SL-401 reactive antibodies. 
Cardiac A ssessments:  
All patients will have 12 -lead ECGs performed according to the schedule in  Table 9 in Section 9.8 . All 
ECGs will be analyzed by a central facility.  
Statistical Methods:  
Analysis Populations:  
Safety analysis will be performed on the population of patients who have received any amount of study 
treatment. The primary population for the analysis of efficacy  will be the modified intent- to-treat 
(mITT) population, consisting of those patients who have received at least one dose of study drug. For BPDCN patients , an additional criterion for mITT patients will be a confirmed diagnosis based on 
central pathology review. BPDCN patients in the mITT population will be sai d to be evaluable. 
Additional efficacy analyses will be performed on a per-protocol (PP) population, consisting of those patients who are in the mITT population, are compliant with all major aspects of the protocol, and have 
received a minimum of 2 cycles of study treatment.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  21 CONFIDENTIAL  Sample Size:  
The sample size was originally planned to be approximately 40 -50 patients with BPDCN, including 
approximately 40 first -line patients planned to be treated with the optimal SL -401 dose as determined 
in the completed Stage 1 of this study (12 µg/kg/day).  In addition, up to approximately 36 patients with 
relapsed/refractory AML were planned to be enrolled in Stage 2 of the study.  
After the maximum number of patients with first- line BPDCN in Stage 3 were  enrolled, subsequent 
first-line BPDCN patients that meet eligibility criteria will be enrolled in Stage 4.  Furthermore, any 
patient with R/R BPDCN enrolled in this study on or after 26 October, 2016, will be allocated to Stage 
4. Enrollment will continue in Stage 4  to ensure continued access to SL -401 for BPDCN patients in a 
clinical trial setting; up to approximately 145 patients  (including ~95 BPDCN patients)  may be 
enrolled.  
Analysis Conventions: Analyses will be performed on all patients who received any quantity of SL-401 (i.e., all treated 
patients).  
Summaries will be grouped by disease (BPDCN  and AML ). For data from BPDCN patients, further 
categories for summarization will consist of line of therapy (first-line, R/R, and total) and dose 
(12 µg/kg/day and all doses). Efficacy endpoints will be summarized separately for Stage 3 patients, 
with an additional summary for all first- line and R/R BPDCN patients across all stages.  
Continuous (non- survival related) data will be summarized using descriptive statistics: number of 
observations (n), mean, standard deviation (SD), median, minimum, and maximum. Time to event data 
will be summarized using frequency and percentage of events and censored observations.  Kaplan -
Meier analysis will be performed to estimate the 25
th percentile, median, and 75th percentile for time to 
events with corresponding two-sided 95% confidence intervals.  

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  22 CONFIDENTIAL  Unless otherwise stated, confidence intervals, when presented, will be constructed at the 2 -sided 95% 
level.  For binomial variables, 95% confidence intervals will be constructed using the Clopper Exact 
method instead of normal approximation. 
Data listings will present all data collected on eCRFs by study drug dose, center, Stage of study 
enrollment, and patient number.  
Safety:  
Safety data analysis will be performed primarily on the pool of first- line BPDCN patients treated with 
the 12 µg/kg/day dose level, with additional summaries for patients with R/R BPDCN and across the 
pool of all BPDCN patients. Separate safety tab ulations will be produced for patients with AML, 
patients who are treated with the lyophilized formulation of SL-401, and an overall pool of all enrolled 
patients.  
Treatment -emergent AEs through 30 days after last SL-401 infusion will be summarized by 
MedD RA™ Version 13.1 (or higher) System Organ Class and preferred term. The incidences and 
percentages of patients experiencing each AE preferred term will be summarized  with descriptive 
statistics. AEs will also be summarized by National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI -CTCAE), Version 4.03 (or higher) grade and by causality (relationship to study 
treatment) . Dose -limiting toxicities, Grade ≥3 AEs, SAEs, and AEs resulting in dose modification or 
treatment discontinuation  will also be summarized by preferred term.  
Laboratory results will be classified according to NCI -CTCAE, Version 4.03 (or higher). Laboratory 
results not corresponding to an NCI -CTCAE term will not be graded . Incidences of laboratory 
abnormalities will be  summarized with descriptive statistics. 
Vital signs and physical examination results will be summarized with descriptive statistics.  
Efficacy:  
Efficacy assessments include CR rate (i.e., CR + CRi + CRc), DOR, ORR, PFS, and OS. Efficacy 
analyses will focus on patients with first-line BPDCN, treated at the 12 µg/kg/day dose level. The 
analysis of efficacy of SL -401 in these patients will be performed to address several objectives, based 
on data from the different stages of the study. Descriptive statistical analysis will be performed for patients with R/R disease and for AML patients, with the extent of efficacy data used for these analyses dependent on data maturity and need for regulatory submission.  
Analyses by stage are intended as follows. Stage 3 will provide the pivotal results for a potential 
registrational submission in first -line BPDCN patients as assessed by rate of CR +CRc . Stage 1 and 2 
results will be presented, similar to the interim analysis as noted in  Section 12.10. Stage 4 resul ts will 
be presented separately  and may be used to further assess consistency across drug formulations, 
dependent on the extent of available data.  
The primary evidence of efficacy will be derived from an analysis of the rate of CR +CRc , as assessed 
by the Investigator,  in patients in Stage 3, accompanied by an evaluation of the durability of these CRs 
as a key secondary endpoint . A formal statistical analysis will first be performed for the primary 
efficacy endpoint to test the hypothesis that the rate of CR +CRc  in first -line patients in Stage 3 exceeds 
the lower benchmark value of 10%. The primary analysis will be performed when all patients in Stage 
3 have been followed for a minimum of 6 months  or discontinued treatment, whichever occurs first. In 
addition, the durability of CR will be evaluated; refer to  Section 12.6.3 for analysis methods for 
duration. 
A number of additional secondary analyses will then be performed, to further evaluate the rate of  CR in 
other stages of the study and to assess additional efficacy parameters  in support of the primary analysis 
results.  The analyses of all secondary endpoints will be descriptive, with summaries of secondary 
endpoints to be evaluated and presented in the following order of importance (as noted above, these 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  23 CONFIDENTIAL  analyses will be perfo rmed on data from first -line BPDCN patients treated at the 12 µg/kg/day dose 
level):  
1. Bone- marrow CR (BMCR) and DOR for Stage 3  
2. CR rate and DOR for Stages 1 and 2  
3. CR rate and DOR for pooled data from Stages 1, 2, 3, and 4 
4. ORR and DOR for Stage s 1 and 2 
5. ORR and DOR for pooled data from Stages 1, 2, 3, and 4 
6. Proportion of patients who receive SCT based on pooled data from Stages 1, 2, 3 and 4 
7. PFS for Stage s 1, 2, 3, and 4 
8. OS for Stage s 1, 2, 3, and 4  
Study Oversight: Monitoring and Review Committees:  
The conduct and evaluation of the study will include a DSRC, IRC, and a central pathologist. A charter 
detailing the operations of each group will be written.  
Stage 1 (completed): 
During Stage 1 and the initial portions of Stage 2, decisions regarding DLT determination, dose 
escalation and cohort progression will be made by a DSRC whose membership includes Sponsor 
representatives and study Investigators.  
Stages 2 -4 (enrollment completed in Stages 2 and 3): 
In Stages 2 -4 of the study, the DSRC will conduct a safety data review on an every 1 -2-month basis. 
Periodic safety reviews will be conducted by the Sponsor. 
A central pathologist will confirm histopathological BPDCN diagnosis. Tumor response will be 
assessed by the Investigators for all patients with BPDCN, with the Investigator’s assessment to be 
used in the primary analysis. As a supportive assessment, tumor response was also evaluated by an IRC 
on a pre- specified subset of patients.  
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  24 CONFIDENTIAL  2 Abbreviations and Definitions  
AE Adverse Event  
ALL  Acute Lymphoid Leukemia  
ALP  Alkaline Phosphatase  
ALT  Alanine Transaminase  
AML  Acute Myeloid Leukemia  
ANC  Absolute Neutrophil Count  
APL  Acute Promyelocytic Leukemia  
Ara-C Cytosine Arabinoside  
AST  Aspartate Transaminase  
BM Bone Marrow  
BMA  Bone Marrow Aspiration  
BMCR  Bone Marrow Complete Response  
BP Blood Pressure  
BPDCN  Blastic Plasmacytoid Dendritic Cell Neoplasm  
BSA  Body Surface Area  
BTD  Breakthrough Therapy Designation  
BUN  Blood Urea Nitrogen  
CBC  Complete Blood Count  
CLS Capillary Leak Syndrome  
CML  Chronic Myeloid Leukemia  
CNS  Central Nervous System  
CPK  Creatine Phosphokinase  
CR Complete Response  
CRc CR [Clinical] with Minimal Residual Skin Abnormality  
CRi Complete Response with Incomplete Bone Marrow Recovery  
CSC  Cancer Stem Cell  
CT Computed Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  25 CONFIDENTIAL  DLT  Dose -Limiting Toxicity  
DSRC  Data Safety Review Committee  
DT Diphtheria Toxin  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case Report Form  
EDTA  Ethylenediamine Tetraacetic Acid  
FDA  Food and Drug Administration  
GLP  Good Laboratory Practice  
GVHD  Graft Versus Host Disease  
HIPAA  Human Insurance Portability Accountability Act  
IB Investigator Brochure  
ICF Informed  Consent Form  
ICH International Council for Harmonisation  
ICU Intensive Care Unit  
IHC Immunohistochemistry  
IND Investigational New Drug Application  
IRC Independent Review Committee  
IL-3 Interleukin -3 
IL-3R Interleukin -3 Receptor  
INR International Normalized Ratio  
IV Intravenous Administration  
LDH  Lactate Dehydrogenase  
LFT Liver function test  
LVEF  Left Ventricular Ejection Fraction  
MDS  Myelodysplastic Syndrome  
mITT  Modified intent -to-treat 
mSWAT  Modified Severity Weighted Assessment Tool  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  26 CONFIDENTIAL  MTD  Maximum Tolerated Dose  
MUGA  Multigated Acquisition Scan  
NCI National Cancer Institute  
ORR  Objective Response Rate  
OS Overall Survival  
PD Progressive Disease  
pDCs  Plasmacytoid Dendritic Cells  
PK Pharmacokinetics  
PFS Progression -free Survival  
PO Orally  
PP Per-protocol  
PR Partial Response  
PS Performance Status  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
RBC  Red Blood Cell  
R/R Relapsed/Refractory  
rIL2 Recombinant Interleukin -2 
SAE  Serious Adverse Event  
SCT Stem Cell Transplant  
SD Stable Disease  
SGOT  Serum Glutamic Oxaloacetic Transaminase  
SGPT  Serum Glutamic Pyruvic Transaminase  
TEAE  Treatment -emergent adverse event  
TLS Tumor Lysis Syndrome  
ULN  Upper Limit of Normal  
VOD  Veno -occlusive disease  
WHO  World Health Organization  
WOCBP  Women of Childbearing Potential  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  27 CONFIDENTIAL  3 Introduction and Study Rationale  
3.1 Blastic Plasmacytoid Dendritic Cell Neoplasm 
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematological 
malignancy characterized by the clonal proliferation of malignant plasmacytoid dendritic cells 
(pDCs) ( Facchetti et al. 2003). This neoplasm was originally recognized as a distinct entity in 
1994 ( Adachi et al. 1994)  and the uncertainty regarding its histogenesis was reflected by the 
multiplicity of terms that were previously used for its designation, including agranular CD4+ 
natural killer cell leukemia ( Brody et al. 1995 ), blastic natural killer leukemia/lymphoma 
(DiGiuseppe et al. 1997) , and agranular CD4+/CD56+ hematodermic neoplasm ( Petrella et al 
2002; Herling et al. 2007) . In 2001, the World Health Organization ( WHO) classification of 
tumors of hematopoietic and lymphoid tissue proposed the term blastic natural killer ( NK) cell 
lymphoma on the basis of the blastic cytology, and the expression of CD56 in the absence of other lineage specific markers . The relationship of BPDCN to pDCs was hypothesized first by 
Lucio et al. (1999) and subsequently confirmed by several studies ( Petrella et al. 2002; Jacob et 
al. 2003;  Reichard et al. 2005; Urosevic et al. 2005; Chaperot et al. 2004; Bene et al. 2003) . The 
term BPDCN was introduced in 2008 by the updated WHO classification (4th edition) ( Facchetti 
et al. 2008) .  
BPDCN most commonly affects middle -aged and older patients and is approximately 3.5-fold 
more common in men than women. The median age at diagnosis is 66 years and is lower for women than men. The true incidence and prevalence of BPDCN, like many other rare diseases without definitive and/or effective therapy, is not precisely known. However, based on a published report ( Wang et al. 2012), BPDCN may constitute approximately 0.44% of the 
incident cases of hematologic cancers annually, or approximately 700 and 1,000 incident cases annually in the United States ( US) and Europe, respectively, based on published data of 
hematologic cancer cases.  
BPDCN cells show an immature “blastic” appearance; the diagnosis rests upon the 
demonstration of CD4 and CD56 expression, together with markers more restricted to PDC  (such 
as CD123 [or the interleukin- 3 receptor; IL -3R]) and negativity for lymphoid, NK and myeloid 
lineage- associated antigens.  Immunophenotypic markers frequently, variably and infrequently 
expressed in BPDCN are detailed in  Table 1 (Chaperot et al. 2001, Facchetti et al. 2008, 
Garnache-Ottou et al. 2009, Herling et al. 2007, Marafioti et al. 2008, Shi et al 2014, Zheng et al. 
2012). The diagnosis of BPDCN is enabled by comprehensive evaluation of overall clinical 
manifestations, the morphologic appearance of blasts on skin, marrow or other biopsy, and a characteristic immunophenotypic profile, as indicated in Table 1.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  28 CONFIDENTIAL  Table 1: Immunophenotypic Marker Expression in BPDCN  
Immunophenotypic Marker  Description  
Frequently expressed in BPDCN   
CD4, CD56, CD123 (IL -R3α) Widely recognized BPDCN markers with significant expression in 
substantial majority of BPDCN cases.  
TCL1(TCL1A) (T cell 
leukemia/lymphoma)  Lymphoid marker, expressed in majority of BPDCN (and also normal pDCs); also expressed in B - and T -cell ALL.  
BDCA -2/CD303 Dendritic cell marker frequently expressed in BPDCN and infrequently expressed in other acute leukemias.  
BDCA -4/Neuropilin -1 Dendritic cell marker frequently expressed in BPDCN; may also be expressed in other acute leukemias.  
CD2AP (CD2 -associated protein)  Adaptor protein frequently expressed in pDCs and BPDCN and 
infrequently expressed in other acute leukemias.  
CD45 -RA T-lymphoid marker, frequently expressed in BPDCN; may also be 
expressed in acute lymphoid malignancies.  
Variably expressed in BPDCN   
HLA- DR Myeloid precursor with variable expression in BPDCN; may also be 
expressed in acute myeloid leukemias.  
Infrequently expressed in BPDCN   
CD11c, MPO (myeloperoxidase)  Myeloid markers, negative in majority of BPDCN cases.  
CD79a  B-lymphoid marker, negative in majority of BPDCN cases.  
CD3  T-lymphoid marker, negative in majority of BPDCN cases. 
 
The clinical features and evolution of BPDCN are homogeneous, primarily consisting of 
2 patterns (Brody et al. 1995; Herling et al. 2007; Reichard et al. 2005; Petrella et al. 2005; Petrella et al. 1999; Suzuki et al. 2005;  Assaf et al. 2007) . The first pattern (90% of cases) is 
characterized by an indolent onset dominated by cutaneous lesions followed by tumor 
dissemination.  The second pattern shows features of an acute leukemia with systemic 
involvement from the outset, and multiple skin nodules are frequently present ( Suzuki et al. 
2005) . BPDCN most typically presents with skin lesions, as well as extracutaneous malignant 
disease in the bone marrow, blood, lymph nodes, spleen, and other organs. Despite t he frequent 
appearance of a somewhat indolent clinical presentation at the outset, the course of BPDCN is 
highly aggressive and the median survival is approximately 12-14 months ( Herling et al. 2007; 
Jacob et al. 2003;  Petrella et al. 2005;  Bekkenk et al. 2004;  Feuillard et al. 2002) . The disease 
also almost always results in a terminal leukemic phase with proliferation of BPDCN blasts in 
the bone marrow and peripheral blood, leading to decreased blood cell counts with resultant 
infections, bleeding, and invariably death.   
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  29 CONFIDENTIAL  There is currently no standard of care, nor an effective treatment regimen, for BPDCN ( Riaz et 
al. 2014) . Previously untreated (first- line) BPDCN patients are typically treated with 
combination chemotherapy regimens generally used for lymphoma or acute leukemia, often 
requiring dose reductions or elimination of anthracyclines due to the predominance of elderly 
patients with this disease.  There are only a few large studies (over 40 patients) reported in the 
literature; the most recent and la rgest, with over 80 patients, reported a 56% response rate in 
first-line BPDCN with combination chemotherapy, but response criteria were not elucidated. 
Median overall survival ( OS) from diagnosis is only 8 to 14 months, with elderly patients being 
at the lower end of this range. Allogeneic stem cell transplant, mostly reserved for younger 
patients in first complete response ( CR) with good performance status, has also been employed 
but only when patients’ disease state and overall physical condition permit. Furthermore, the 
literature for the treatment of relapsed/refractory ( R/R) BPDCN is scattered, limited and 
inconsistent in the way that clinical benefit is measured and presented, and management beyond first-line is usually not described in the larger retrospective case studies; of 7 published studies 
involving ≥10 patients, there is only one documented response to ≥2
 lines of therapy.  
3.2 Acute Myeloid Leukemia 
Acute Myeloid Leukemia (AML) is characterized by the uncontrolled proliferation of immature myeloid cells in the bone marrow and peripheral blood, resulting in the development of anemia, neutropenia, and thrombocytopenia, and associated complications such as serious infections, 
bleeding, and fatigue. The American Cancer Society (2013) estimates t here will be 
approximately 1 4,590 new cases of AML in the United States during 2013, with an estimated 
10,370 deaths due to the disease. The median age at diagnosis is 6 7 years , and 5- year survival 
across all ages, treatments, and other prognostic subgroups is 24% (National Cancer Institute 
2013) . The WHO classification of AML incorporates morphology, cytogenetics, molecular 
genetics, and immunologic markers to define clinically relevant disease entities  that are 
universally applicable and prognostically valid with therapeutic implications (Bennett et al.  
1976;  Brunning et al.  2001;  Cheson et al.  1990;  Cheson et al.  2007) . 
3.2.1 First-line Therapy  
Initial treatment of AML is divided into induction chemotherapy and post-response, consolidation therapy. To optimize potential for  durable response, patients frequently receive 
some form of consolidation therapy, which is routinely given to patients age <60 and generally involves multiple courses of intensive chemotherapy or stem cell transplant (SCT) ( Dohner et al. 
2010) . Consolidation therapy is often given only once, or not given at all , to patients who are 
>60 years old. Tolerance of the induction and consolidation phases is directly related to patient characteristics such as age, the presence or absence of comorbidities, and performance status.  
Strategies for  consolidation are generally based on the risk of relapse, with higher risk patients 
receiving more aggressive therapy.  Current first -line induction treatment s for AML among 
eligible patients include chemotherapy drugs such as cytarabine, daunorubicin, and  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  30 CONFIDENTIAL  mitoxantrone . Post-response therapies include dose-intensified cytarabine, and autologous or 
allogeneic SCT.  
Although CR rates after standard first -line induction therapy in AML are relatively high, c ertain 
subgroups of patients with AML often cannot tole rate treatment strategies which optimize the 
probability of durable responses, or have a high risk of relapse even when available standard 
therapies are administered . Consequently, National Comprehensive Cancer Network Guidelines 
(2013) recommend that AML patients with an antecedent hematologic disease (e.g., 
myelodysplasia, myelofibrosis, polycythemia vera), age > 60 years , or unfavorable cytogenetics 
(e.g., deletion of 5 or 7 and >3 abnormalities) are appropriate candidates for clinical studie s with 
novel ag ents early in their disease (i.e., as first -line therapy) . 
3.2.2 Second -line Therapy  
Approximately 70% of patients who receive first -line therapy and achieve a first CR w ould be 
expected to experience recurrent disease, and a subset of patients who  do not derive benefit from 
first-line therapy would also be candidates for subsequent treatment. In second- line AML, while 
there are currently no approved treatments, typical therapies include additional chemotherapy, 
often cytarabine at various dosages and regim ens. Unless allogeneic SCT can be performed, 
patients with R/R AML have a poor prognosis ; relatively few patients are eligible for SCT due to 
donor unavailability , advanced age, and significant morbidity with reinduction efforts ( Forman 
and Rowe, 2013). 
3.2.3 Third -line Therapy  
Following failure of second- line therapy,  patients often  have depressed bone marrow function 
and are no longer optimal candidates for additional chemotherapy. There are currently no 
approved treatments for third-line AML, although therapeutic options include supportive care, 
cytarabine based combinations, and investigational therapies (e.g., hypomethylating agents). Many of these therapies impart serious toxicities – including cytopenias – that may compound 
the complications of AML itself, and, in particular, heavily- pretreated AML.  Importantly, no 
currently available treatments have been shown to extend survival in this setting. The median OS 
for AML patients after failure of second -line treatment, based on two large series, is 1.5 months 
(Giles et al.  2005;  Keating et al.  1989). 
3.3 Targeting Cancer Stem Cells  
The field of cancer stem cells (CSCs) is a new area of cancer biology that may fundamentally alter the approach to oncology drug development. CSCs have been identified in virtually all 
major tumor types, including leukemia and cancers of the brain, breast, colon, prostate, and pancreas (Jordan et al.  2006) . CSCs are the highly malignant “seeds” of a tumor that self -renew 
and generate more mature cells that comprise the bulk of the t umor, or “the tumor bulk.” As 
such, CSCs appear to be responsible for tumor initiation, propagation, and metastasis. Many of the characteristics of CSCs, such as their slow growth, anti- cell death mechanisms, and presence 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  31 CONFIDENTIAL  of multi-drug resistance proteins, may enable CSCs to resist therapeutic agents traditionally used 
to treat cancer.  This may be due to the many challenging characteristics of CSCs, including slow 
growth, presence of multi-drug resistance proteins, anti- cell death mechanisms, and increased 
activity of cellular mechanisms that repair damaged deoxyribonucleic acid. CSCs are particularly 
resistant to chemotherapy, radiation, or targeted therapy relative to tumor bulk. 
CSCs have also been shown to increase, as a percentage of total tumor cells, as a result of 
exposure to a traditional therapy ( Bao et al.  2006;  Hermann et al.  2008). Consistent with their 
pivotal role in the development of tumors and relapse, higher amounts of CSCs in patient tumors 
as a percentage of their entire cancer appear to correlate with poor prognosis. CSC fractions 
greater than 3.5% and 1% of the entire cancer correlate with poor survival outcomes in patients 
with AML and brain cancer, respectively (van Rhenen et al.  2005; Zeppernick et al.  2008) . 
3.4 IL-3 Receptor (IL-3R) Over-Expression in AML  
The alpha subunit of the IL- 3R (IL -3 α receptor = IL -3Rα, also called multi- colony stimulating 
factor) is a type I transmembrane glycoprotein belonging to the cytokine receptor superfamily; all the members of this superfamily are chara cterized by a conserved region homologous to the 
fibronectin type III domain. The IL -3R is a heterodimer of α (CD123) and β chains; (the β chain 
is shared by IL -3, IL -5, and granulocyte macrophage- colony stimulating factor receptors).  The 
receptor, found on pluripotent progenitor cells, induces tyrosine phosphorylation within the cell and promotes proliferation and differentiation within the hematopoietic cell lines . 
IL-3R is over- expressed on AML blasts and CSCs relative to normal hematopoietic stem cells 
(Jordan et al.  2000; Jordan et al. 2006; Tehranchi et al. 2010). CD34+/38- CSCs strongly express 
IL-3R, whereas IL -3R is virtually undetectable on normal CD34+/38- hematopoietic stem cells 
(Jordan et al. 2000; Jordan et al. 2006) . The differential expressi on of IL- 3R between malignant 
and normal stem cells provides a potential opportunity for a therapeutic window in which to target CSCs with an IL -3R-targeted therapy (e.g., SL -401), while minimizing toxicity to normal 
bone marrow including normal hematopoie tic stem cells.  
In addition to AML, IL-3R has also been shown to be differentially expressed on other hematological cancers, including BPDCN, myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), acute lymphoid leukemia (ALL), hairy cell leukemia, Hodgkin’s disease, and 
certain aggressive non-Hodgkin’s lymphomas (e.g., follicular cell, mantle cell, and Burkitt’s 
lymphomas) ( Tehranchi et al. 2010; Aldinucci et al. 2005; Munoz et al. 2001; Aldinucci et al. 
2002; Black et al. 2003;  Frolova et al. 2010). Moreover, IL -3R is also over-expressed on CSCs 
of multiple hematologic malignancies, including CML, MDS, and T- cell ALL ( Jordan et al.  
2006; Tehranci et al. 2010;  Florian et al. 2006;  Lhermitte et al. 2006) .  
A higher percentage of IL-3R- expressing CS Cs within a patient’s tumor relates to poor outcome 
(Vergez et al. 2011). In particular, AML patients with IL -3R-expressing CSCs that comprise 
≥3.5% of their entire leukemia have a worse prognosis than patients with IL-3R- expressing 
CSCs that comprise <3.5% of their entire leukemia (van Rhenen et al. 2005 ). Interestingly, IL -
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  32 CONFIDENTIAL  3R-rich pDCs have been found to be increased in the bone marrow of patients with multiple 
myeloma and appear to contribute to disease aggressiveness and resistance to treatment (Chauhan et al. 2009). These findings further validate that IL-3R is an important oncology target in multiple hematologic cancer indications.  
3.5 Mechanism of Action of SL-401  
Diphtheria toxin (DT) IL -3 fusion protein ( designated  SL-401 by  Stemline Therapeutics , Inc. 
[“Stemline”] ) is a novel biologic targeted therapy directed to the IL-3R. SL -401 is comprised of 
recombinant human IL- 3 genetically fused  to a truncated DT, in which the binding domain of DT 
has been replaced with IL -3. As depicted in  Figure 1, the IL -3 domain of SL-401 is able to target 
the agent to leukemia blasts and CSCs that over- express IL -3R, leading to receptor- mediated 
endocytosis and localization of SL-401 to early endosomes. The translocation domain of DT changes conformation in the acidic environment of the endosome, and the RXRR motif (residues 
191-194) located between the catalytic and translocation domains of DT is cleaved by endosomal 
furin.  The translocation domain of DT then inserts into the endosomal membrane. As the TAT -
like domain of DT (residues 201-230) interacts with cytosolic Hsp90 and thioredoxin reductase, the catalytic domain (A fragment) unfolds, is reduced, and translocates to the cytosol. Upon 
release into the cytosol, the A fragment refolds and catalytically inactivates cellular protein 
synthesis by ADP -ribosylating the diphthamide residue in domain IV of EF2, leading to 
apoptosis ( Yamaizumi et al. 1978 ; Deng et al. 2008; FitzGerald et al. 1989;  Perentesis et al.  
1992;  Louie et al. 1997;  Ratts et al. 2005;  Thorburn et al. 2004).  
Figure 1: Schematic of SL -401 Construc tion 
 
The manner by which SL- 401 kills cells is distinct from that of available cancer therapeutics.  
First, SL -401 is a targeted therapy directed to the IL-3R that is present on CSCs and/or tumor 
bulk, but not on normal hematopoietic stem cells. Second, SL-401 utilizes a payload that is not cell cycle -dependent. Therefore, it is designed to kill not just highly proliferative tumor bulk, but 
also relatively quiescent CSCs.  Lastly, SL -401 utilizes a payload that may not be subject to 
multi- drug resistance me chanisms typically used by CSCs to evade traditional therapies. The 
payload also kills cells in a manner that is distinct from that of other available therapies, which is another reason why SL-401 may be a n effective  addition to the therapeutic armamentarium 
against hematologic malignancies.   
Trans - 
location  
SL-401 DNA  

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  33 CONFIDENTIAL  3.6 Preclinical Studies  
In vitro  and in vivo activity against both leukemia blasts (i.e.,  tumor bulk) and CSCs of a variety 
of human leukemia cell lines and primary leukemia cells from patients  has been demonstrated 
using SL -401 (designated as DT388IL3 [Diphtheria Toxin Interleukin- 3 Fusion P rotein ] in these 
earlier studies)  (Angelot -Delettre et al. 2011; Alexander et al. 2000; Frankel et al. 2000).  
Potent cytotoxicity against leukemic cells in vitro  in a dose-dependent fashion was demonstrated 
for SL-401, with IC 50 (concentration that inhibits the growth of 50% of leukemia cells) values in 
the low picomolar range. Notably, and in contrast, normal bone marrow progenitor cells were 
relatively insensitive.  Anti-CSC activity  was also exhibited . In particular, SL -401 inhibited long-
term AML colony formation, an assay for stem cell activity, compared with normal human bone 
marrow.  Additionally, engraftment and growth (i.e., tumorigenicity) of AML cells  was reduced 
relative to normal human bone marrow, when these cells were treated ex vivo and reimplanted 
into immunodeficient mice, which also indicates anti- tumor activity at the level of the CSC  
(Frankel et al. 2000) . Treatment of severe comb ined immunodeficiency mice also significantly 
reduced engraftment of AML  (Feuring -Buske et al. 2002). AML engraftment was reduced by an 
average of 83% (range, 14–100) and 57% (range, 0–98) after 4 and 12 weeks, respectively (n = 6). Leukemia was not detect ed in 2 of 6 mice 12 weeks after SL -401 treatment. Repeating 
treatment every 4 weeks enhanced its effectiveness  (Black et al. 2003;  Frankel et al. 2000). 
The cytotoxicity of SL-401 relates to the level of IL -3R expression on leukemia cells  in vitro  
(Frankel et al. 2000). In studies performed to date, leukemia cells with high surface expression of 
IL-3R have been exquisitely sensitive to SL -401, with IC
50 values ranging from 1-28 pM, 
whereas low cellular expression of IL -3R has been associated with higher IC 50 values, i.e., 
∼1400 pM ( Frankel et al. 2000) . Even so, SL -401 plasma concentrations exceeding the entire 
range of IC 50 values have been readily achievable in patients receiving SL-401 at doses below 
the maximum tolerated dose in a Phase 1 -2 study described in Section  3.7.  
In addition to being active against AML cells, very potent activity against BPDCN cells  was 
demonstrated . In preclinical studies, the IC 50 values against BPDCN cell lines derived from 
patients and primary tumor cells from BPDCN patients were in the femtomolar (i.e. , 10-15 M) 
range, which is perhaps the most sensitive tumor cell type to any specific cancer therapeutic 
known (Chauhan et al. 2009). 
Interestingly, the bone marrows of patients with multiple myeloma have been demonstrated to 
contain high quantities of IL-3R- expressing pDCs.  These pDCs have since been shown to 
augment the growth of multiple myeloma and contribute to drug resistance, suggesting that killing pDCs may confer clinical benefit in patients with multiple myeloma  (Chauhan et al . 
2009) . Indeed, SL -401 has been recently been demonstrated to possess potent activity against 
multiple myeloma cell lines and primary tumor samples, which appears to be related to both direct antitumor and anti- pDC effects of the drug in myeloma ( Chauhan et al. 2014).  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  34 CONFIDENTIAL  To support the Phase 1/2 clinical study conducted under the Investigator-sponsored 
investigational new drug appli cation ( IND), repeat -dose toxicity studies with SL -401 were 
conducted in mice and cynomolgus monkeys. The study designs are summarized in Table 2. 
Table 2: Completed SL-401 Repeat -Dose Toxicity Studies, Investigator- sponsored IND  
Study Type and Duration  Dose Level(s)  Dose Regimen  
Mice   
5-day efficacy study, survival data  2 µg (≈ 100 µg/kg)  IP injection daily for 5 days  
14-day toxicity study 0.5, 1, 2, 2.5, 3, 3.5, 5, 7, 10  µg 
(≈ 25, 50, 100, 125, 150, 175, 
250, 350, 500 µg/kg)  IP injection 3 times a week for 2  weeks 
(6 doses)  
Monkeys    
14-day toxicity study 40, 60, 100 µg/kg IV injection every other day (6  doses)  
14-day toxicity study 100, 150 µg/kg IV injection every other day (6  doses)  
 
Stemline has conducted two non- Good Laboratory Practice ( GLP ) toxicity studies in 
cynomolgus monkeys and one GLP 5-Day toxicity study in cynomolgus monkeys with a 3- week 
recovery period to confirm target organs of toxicity with SL -401. The study designs are 
summarized in  Table 3. Note that the doses described in the table and subsequent summary are 
doses of SL-401. 
Table 3: Completed SL-401 Repeat -Dose Toxicity Studies with SL -401, Stemlin e IND  
Study 
Number  Study Title  Number of 
Animals  Study Type and 
Duration   Dose 
Level(s)  Dose 
Regimen  Noteworthy Findings  
2231-
001 SL-401: An 
Intravenous Dose Range Finding Study in 
Cynomolgus 
Monkeys  6; 2/sex/group Non-GLP; 5 
days 40, 60, 80 µg/kg  IV injection daily  During the study, on Day 5, the male at 80 µg/kg/day was euthanized  in extremis , 
due to SL -401-related 
clinical signs . Based on 
clinical observations as well as clinical laboratory values the maximum tolerated dose (MTD) of SL -401 was 
deter mined to be 60 
µg/kg/day when given as an intravenous slow bolus injection daily for 5 consecutive days.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  35 CONFIDENTIAL  Study 
Number  Study Title  Number of 
Animals  Study Type and 
Duration   Dose 
Level(s)  Dose 
Regimen  Noteworthy Findings  
2231-
004 SL-401: An 
Intravenous Pilot 
Dose Confirmation Study in Cynomolgus 
Monkeys  4; 1/sex/group Non-GLP; 5 
days 30, 60 µg/kg  IV injection 
daily  Evidence of sporadic 
inflammation and hepatic 
effects in both sexes at both dose levels . Based on 
clinical observations as well as clinical laboratory values 
and chemistries the 60 
µg/kg/day dose was well -
tolerated when given as an intravenous slow bolus injection  daily for 5 
consecutive days.  
2231-002 SL-401: A 5-
Day Intravenous Toxicity Study in Cynomolgus Monkeys with a 
3-Week 
Recovery Period  26; Terminal:  
3/sex/group; Recovery:  
2/sex/dose group  GLP; 5 days with a 3 -week 
recovery period  Control, 30, 60 µg/kg  IV injection daily  One female administered 60 µg/kg/day was euthanized in extremis  on Day 6, prior 
to the scheduled necropsy . 
The cause of moribundity 
was severe necrosis of renal 
cortical tubules (kidneys) . 
Additional dose -related and 
test article -related 
microscopic changes were 
present in brain choroid 
plexus, kidneys, liver, and thymus.  
 
Three toxicity studie s were conducted with SL-401 at doses ranging from 30 µg/kg/day to 
80 µg/kg/day daily for 5 days. Assessment of toxicity was based on mortality, clinical 
observations, body weights, clinical pathology, and in one study histopathology. The main SL-401 related findings noted were as follows: 
• Dose -dependent clinical signs of decreased activity, hunched posture, and sparse hair 
were observed  in males and females at all dose levels . Additionally, signs of decreased 
appetite were exhibited by all 3 females and one male (dose 60 µg/kg/day), as were 
reductions in body weight in males (5- 9%) at all dose levels and respective decreases of 6 
and 7% in females receiving doses of 80 and 40 µg/kg/day. 
• Dose -related test article related findings were observed in clinical pathology parameters; 
increased liver enzymes (aspartate transaminase [ AST ] and  alanine transaminase [ ALT ]) 
in both sexes of all dose groups after the first dose; sporadic evidence of renal injury 
(increased urea nitrogen and/or creatinine) in both sexes at all dose levels by after the 
fifth dose interval; sporadic/inconsistent effects on neutrophils, platelet, and/or reticulocyte counts, mostly at a dose of 80 µg/kg/day; and mild serum protein alterations in both sexes at all dose levels (increased globulin with decreased albumin). 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  36 CONFIDENTIAL  • Dose -related microscopic changes were present in brain choroid plexus, kidneys, liver, 
and thymus of animals treated with SL -401 at dose levels of 30 µg/kg/day and 
60 µg/kg/day . Inflammation/necrosis degeneration of the choroid plexus was present in 
terminal males and females at doses of 30 and 60 µg/kg/day and in recovery males and 
females at 60 µg/kg/day . Degeneration/necrosis of renal cortical tubules in the kidneys 
was present in females at 30 and 60 µg/kg/day  as well as terminal males at 60 µg/kg/day. 
Kidneys were within normal limits in all recovery animals . Minimal centrilobula r 
hepatocellular necrosis and mild vacuolation (centrilobular or diffuse) were present in the 
livers of terminal males at 60 µg/kg/day . Livers were within normal limits in all recovery 
animals . The thymus of one recovery male at 60 µg/kg/day was reduced in  size compared 
to controls. This finding correlated microscopically to generalized lymphoid depletion.  
• Toxicokinetic data in male and female cynomolgus monkeys demonstrated a half- life of 
approximately 0.5 hour after an intravenous bolus dose. The systemic plasma concentrations of SL-401 following doses of 40, 60, or 80 μg/kg/day showed a corresponding (reasonably proportional) increase in systemic exposure across the doses. 
There was no effect of pre- existing low level anti- DT specific antibodies . There w as no 
accumulation . Comparison of the first to fifth dose sequence showed there were no 
appreciable changes in the toxicokinetic exposure profile and there were no notable 
gender differences in exposure.   
• From data collected and evaluated during these 3 studies, it appears that the maximum 
tolerated dose (MTD) of SL-401 is between 30 and 60 µg/kg/day, when given as an intravenous slow bolus injection daily for 5 consecutive days. 
Based on the collective data from three toxicology studies conducted with SL -401, the kidney, 
liver, and blood vessel manifestations observed were highly consistent with previous toxicity studies. Inflammation and necrosis of epithelial cells lining the choroid plexus was consistent with previous toxicity studies using DT388IL3. However, severe brain hemorrhage was not observed with SL-401. The highest non-severely toxic dose from the combined toxicity studies 
in monkeys evaluating SL-401 ranged from 30 µg/kg/day to 60 μg/kg/day, which is equivalent to 
9 µg/kg/day to 20 µg/kg/day in humans based on the body surface area (BSA) normalization method. A dose of 7.07 µg/kg/day for 5 days was well-tolerated in the previous DT388IL3 clinical study, described in Section  3.7. Therefore, given the non- human primate toxicity results 
from DT388IL3 together with the full clinical safety database and the confirmatory target organ toxicity findings in 3 additional non-human primate studies with SL -401, the starting clinical 
dose was selected to be 7 µg/kg/day.  Furthermore, based on the previous clinical study, the 
maximum clinical dose was anticipated to be 12 μg/kg/day for a 5- day consecutive regimen.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  37 CONFIDENTIAL  3.7 SL-401 Clinical Studies  
3.7.1 Study 50047 
The safety and efficacy of SL-401 was evaluated in Study 50047, a multicenter, open- label, dose 
escalation Phase 1/2 study, in which enrolled patients had R/R adult AML, de novo AML unfit 
for chemotherapy, high-risk MDS , CML, or BPDCN ( Frankel et al. 2014) .  
 Recruitment occurred at 5 study centers, 4 
in the US and one in Canada. The primary study objective was to determine the MTD, 
recommend a dose for subsequent disease-directed studies, and document dose- limiting toxicities 
(DLTs ) of escalating doses of a single cycle of SL-401 as a 15 -minute IV infusion under two 
different regimens:  every other day for up to 6 doses (Regimen A) or daily for up to 5 doses 
(Regimen B).  The study also characterized the pharmacokinetic ( PK) properties (using a non-
specific biological assay to measure the plasma concentrations of SL-401) and immune 
responses associated with these regimens and determined the relationship between disease 
response and patient disease burden. Follow-up information on adverse events (AEs), laboratory 
parameters, and OS was also collected during the study. 
Nine ty-two patients were  enrolled and treated with SL-401 in the study; 70 patients had AML 
(including 59 with R/R disease), 12 patients had BPDCN, and the remainder had MDS or CML. 
The MTD for Regimen A was not identified . The MTD for Regimen B was 16.6 µg/kg/day with 
hypoalbuminemia and edema, manifestations of capillary leak  syndrome (CLS) , as the DLT at 
the 22.1 µg/kg/day dose level. Regimen B at a dose of 12.5 µg/kg/day appeared to have the most 
favorable risk/benefit profile, with a low incidence of DLTs and multiple major tumor responses. 
Hypoalbuminemia (any Grade = 58.7%; Grade ≥ 3 = 0%) and transaminase elevation (any Grade 
= 50%; Grade ≥ 3 = 25%) were the most common Grade ≥3 AE attributed to SL-401, however 
almost all episodes were transient . Time courses of liver function tests (LFTs) and albumin 
among the patients treated with Regimen B indicate that LFT elevation s tended to peak 
approximately two  weeks after the first infusion of SL-401, while albumin levels, supported by 
the administration of albumin to patients with serum albumin falling below 3 g/dL, reached a 
minimum approximately one week after the first infusion. In most cases, levels of the laboratory 
parameters resolved to near baseline levels by 14 -28 days after the first  infusion. O ther AEs 
commonly (i.e., any Grade in ≥15% of patients) attributed to SL-401 included fever (any Grade 
= 29.3%; Grade ≥ 3 = 1.1%), hypocalcemia (any Grade = 25.0%; Grade ≥ 3 = 0%), edema (any 
Grade = 18.5%; Grade ≥ 3 = 3.3%), and nausea (any Grade = 16.3%; Gr ade ≥3 = 0%).  
A single cycle of SL-401 was associated with single agent activity in patients with R/R AML, 
including 2 durable CRs of 8 and >25 months duration and 5 partial responses (PRs). OS  also 
appeared to be improved among the most heavily pretreated AML patients compared with historical survival results.  Specifically , in AML patients who had progression through at least 
two previous therapies (i.e., third- line or greater ; n = 35), the median OS was 3.6 months, more 
than double the historical median OS of 1.5 months (Giles et al. 2005) . Multiple durable 

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  38 CONFIDENTIAL  objective responses were also observed among the patients with BPDCN. Among 9 BPDCN 
patients treated with 12.5 μg/kg/day who were evaluable for response, there were 5 CRs 
(durations of 3, >3, 5, >7, and >20 months) and 2 PRs yielding a response rate of 78% (two patients treated with 12.5 μg/kg/day and one patient treated with 9.4 μg/kg/day were not 
evaluable for response).  
3.7.2 Current Study (STML -401-0114) 
Stage 1 of STML -401-0114 employed a traditional 3+3 design and has been completed. A total 
of 23 patients were enrolled in Stage 1, of whom 9 had BPDCN and 14 had R/R AML. SL -401 
was investigated at doses of 7, 9, 12, and 16 μg/kg/day IV for up to 5 consecutive days every 21 
days (i.e., a multi- cycle regimen).  (Only patients with AML received SL-401 at doses of 9 and 
16 μg/kg/day.) The maximum tested dose of SL-401 in patients with BPDCN was 12 μg/kg/day; an MTD was not identified in BPDCN.  
A complete summary of all AEs attributed to SL -401, including DLTs  seen in Stage 1 of the 
study, is available in the most recent version of the SL -401 Investigator Brochure.  
An analysis of safety data available through 28 July, 2016, for 26 patients with BPDCN showed 
that, overall, 24 (92%) patients have experience d at least 1  treatment -emergent adverse event 
(TEAE), with 22 (85%) patients experiencing at least 1  ≥Grade 3 TEAE.  The most common 
TEAE was transaminase elevation (either ALT increased [62%] or AST increased [58%]).  
Overall, 17 (65%) patients have experienced ALT increased and/or AST increased, with these 
events also being the most common ≥Grade 3 TEAE (each 54%), treatment- related TEAE 
(54%), and treatment-related ≥Grade 3 TEAE (50%). Transaminase elevations were largely transient and not dose- limiting.  
Other most commonly reported TEAEs, regardless of relationship to study drug, were nausea and peripheral edema (each 46%); fatigue, hypoalbuminemia, and pyrexia (each 42%); chills (35%); and anemia and hyperglycemia (each 31%).  
The frequency and type of TEAEs were similar between the 12  µg/kg/day and 7 µg/kg/day dose 
groups, with no indication of dose-relationship. 
Twelve (46%) of 26 patients experienced at least 1 serious adverse event (SAE) . The only SAEs 
reported for >1  patient were CLS, pyrexia, and respiratory failure (each 2 patients).  
Please consult the most recent SL -401 Investigator Brochure for comprehensive and up- to-date 
information concerning the safety profile associated with SL -401.  
An interim analysis of efficacy data was performed on 32  patients with BPDCN enrolled in the 
study through 29 August, 2016. Findings from this analysis, based on the Investigators’ 
assessment of response,  showed that of the 32 BPDCN patients evaluable for response, 
regardless of line or dose, the objective response rate ( ORR ) was 84%, and the CR rate (i.e., 
CR +CR with incomplete blood count recovery [CR i] + CR [clinical] with minimal residual skin 
abnormality [CRc] ) was 56%. Of the 19 first -line patients (all doses) evaluable for response, the 
ORR was 95%, and the CR rate was 74%.  Of the 16 first -line patients treated at 12 µg/kg/day 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  39 CONFIDENTIAL  evaluable for response, the ORR was 100%, and the CR rate was 81%. Analysis of progression-
free survival (PFS) showed that of the 16 evaluable first- line patients treated at 12  µg/kg/da y, 
11 were progression -free. This included 5 patients receiving ongoing SL-401 therapy for ~1-14+ 
months, all in CR (n=3) or PR (n=2), and 6 patients who sustained a remission while on SL -401 
(CR [n=5]; PR [n=1]) and were then successfully bridged to SCT f ollowing ~2 -6 months of SL-
401 therapy; these patients have remained relapse-free up to 16.0+ months post- first SL -401 dose 
and up to 10.2+ months post- SCT. Median PFS had not been reached.  
Of the 13 R/R patients evaluable for response, the ORR was 69%, and the CR rate was 31%.  
3.8 Discussion  and Rationale for Current Study 
The rationale for clinical development of SL -401 for patients with AML or BPDCN is based on 
the high expression of the IL-3R on AML and BPDCN blasts, the potent preclinical activity of 
SL-401 against AML and BPDCN cells, the clinical responsiveness observed to date with 
SL-401, in BPDCN in particular, and the unmet medical need for these indications. 
Clinical results with SL-401 indicate that the agent can be safely administered to patients with de 
novo AML, R/R AML, or BPDCN, with clinical benefit in terms of disease response and 
extended survival. While 16.6 μg/kg/day for 5 consecutive days was determined to be the MTD in Study 50047 and a safe starting dose for subsequent studies , the starting  dose selected for this 
Phase 1/2 study, 7 μg/kg/day  (similar to the lowest tested dose for this regimen (7.07 μg/kg/day) 
in Study 50047), allowed for an initial abbreviated ( 3 dos e level) dose escalation/confirmation 
stage  to an expected maximum tested dose (12 μg/kg/day) that appears to have the most 
favorable risk/benefit profile.  
The SL -401 drug product used in the current study is manufactured using a commercial -scale 
process that will provide study material for all pivotal studie s. Consequently, the purpose of the 
initial stage of the cur rent study was  to bridge the existing  Phase 1 /2 experience utilizing the 
earlier SL -401 drug product to SL-401 made using a commercial -scale manufacturing process . 
These initial clinical data will confirm the safety and activity of SL -401 from the commercial 
scale. Furthermore, the current study will generate clinical experience in which administration of 
multiple cycles of SL -401 can be evaluated  in patient populations that may  derive additional 
clinical benefit beyond administration of a single cycle.  
The LFT and albumin findings from SL-401 in Study 50047 indicate that most patients with 
clinically meaningful changes in these parameters following administration of SL -401 would be 
expected to recover to near baseline levels by 3 -4 weeks following the initiation of therapy.  
These results therefore support administration of cycles every 3 weeks  with the allowance to 
delay the start of a subsequent cycle to allow toxicity resolution . This has been confirmed during 
Stage 1 of the current study, where the majority of patients have been able to receive multiple 
cycles of SL -401 despite transaminase elevations and hypoalbuminemia during Cycle 1 . CLS 
was the principal DLT in Study 50047 and in the current study. Similarly, CLS is an event 
associated with treatment with approved doses of denileukin diftitox (Ontak
®), a Food and Drug 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  40 CONFIDENTIAL  Administration ( FDA )-approved treatment for patients with persistent or recurrent cutaneous T-
cell lymphoma whose malignant cells express the IL -2 receptor. Treatment of patients with SL -
401 at doses below those in which multiple cases of s evere CLS were observed  in Study 50047 is 
one element by which  the risk of this SL-401- associated toxicity will be minimized in the current 
study.  
During Study 50047, risk mitigation measures for CLS were implemented.  These included 
premedication (e.g., an  H1-histamine antagonist, acetaminophen, and a corticosteroid); 
administration of IV albumin if serum albumin decreased to <3 g/dL; and a diuretic regimen 
(e.g., furosemide) if patients experienced >10% weight gain (with no hypotension) concurrent 
with the  administration of a basal parenteral hydration to maintain intravascular volume.  In the 
peri-treatment period, vital signs, weight, serum electrolytes, and albumin were monitored. 
Similar measures have been incorporated into the current study, as describe d in Section 7.5.4. 
Additional precautions, including a requirement that patients have a normal cardiac ejection 
fraction at study entry, and requir ing withholding of treatment in the setting of albumin 
reductions or weight increases during the dosing period, similar to recommendations concerning the optimal administration of denileukin diftitox, have also been implemented ( McCann et al.  
2012, Olsen et al. 2001, Prince et al. 2009).  
Denileukin diftitox also is associated with loss of visual acuity, usually with loss of color vision, with or without retinal pigment mottling . Recovery was reported in some of the affected patients; 
however, most patients reported persistent visual impairment.  This finding is considered related 
to the IL-2 component of denileukin diftitox.  Although SL-401 targets IL-3R rather than IL -2R, 
patients will be monitored for potential vision loss in this study.  
SL-401 was granted Breakthrough Therapy Designation (BTD) by the US FDA  for the treatment 
of BPDCN in August 2016. In October 2016, the Sponsor conducted an interim analysis of efficacy data from 32 patients with BPDCN enrolled in this study between 06 October, 2014, and 
29 August, 2016. A meeting was held with FDA on 20 December, 2016, to review the results of 
this interim analysis and  discuss the continued development of SL -401 for treatment of BPDCN. 
As an outcome of that meeting, the following changes were made by Amendment 9: 
• Enrollment of patients with AML is closed.  
• Enrollment of patients with BPDCN is ongoing.  
- Any patient with first- line BPDCN enrolled in this study on or after 26 October, 
2016, is included in Stage 3; a sufficient number of patients will be enrolled to ensure 
10 evaluable patients are included, with evaluable patients being those with a 
diagnosis of BPDCN, as confirmed via central pathology review who received at least 1 dose of SL-401. These patients will constitute a standalone pivotal cohort for confirmation of efficacy of SL -401 in first- line BPDCN; for reference in this 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  41 CONFIDENTIAL  protocol, this cohort will be designated Stage 3. The primary endpoint for this pivotal 
cohort is the CR rate.  
- Any patient s with R/R BPDCN enrolled in this study on or after 26 Oct ober, 2016, 
are allocated to Stage 4 . After the maximum number of planned first- line BPDCN 
patients are enrolled in Stage 3, any additional first- line BPDCN patients are to be 
enrolled in Stage 4. BPDCN patients enrolled in Stage 4 subsequent to completion of enrollment in Stage 3 will receive the lyophilized formulation of SL -401 for 
Injection.  
- Enrollment will continue in Stage 4 until the study enrollment cap is reached.  
• The total study samp le size is increased to up to 1 20 patients (including ~70 patients with  
BPDCN) in order to adequately assess efficacy and safety of SL -401 in patients with 
BPDCN in a clinical study setting.  
• The inclusion/exclusion criteria for patients with BPDCN and SL -401 dose and treatment 
schedule are the same across Stages 2 -4, with the exception that only first- line BPDCN 
patients are eligible for Stage 3.  
• Safety monitoring to assess visual acuity and color vision, which are potential class toxicities of immunotoxins, and follow-up to determine whether treatment with SL-401 
alters the risk of veno- occlusive disease (VOD) after subsequent SCT have been added . 
Other study procedures and evaluations are the same across Stages 2 -4.  
Key elements included in Protocol Amendment 10 are as follows : 
• The total study sample size is increased to up to 130 patients (including ~80 patients with 
BPDCN) in order to ensure continued access to SL-401 for BPDCN patients in a clinical study setting.  
• Updated enrollment status . 
• Updated guidance for toxicity management, including CLS management, to continue reducing the risk of severe CLS and other SL-401- associated toxicities.   
• Updates to reflect agreements and requests made by the FDA , including agreements on 
the primary efficacy endpoint for Stage 3.  
Protocol Amendment 11 provides for additional BPDCN patients to be enrolled in Stage 4. 
Protocol Amendment 12 provides details on the timing of analyses of duration of response and 
overall survival for all cohorts, as well as modifications to certain procedures based on the approved package insert and follow up requirement for patients who received stem cell 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  42 CONFIDENTIAL  transplant fol lowing treatment with SL -401, to identify engraftment delays or failures . SL-401 
Injection frozen solution (1mg/mL) was approved by the Food and Drug Administration (FDA) 
on 21 December 2018 for the treatment of BPDCN in adults and in pediatric patients 2 years and 
older under the name ELZONRIS (tagraxofusp- erzs).  
4 Study Objectives  
4.1 Primary Objective s 
Stage 1 (completed):  
• Determine the maximum tolerated dose (MTD), or the maximum tested dose where 
multiple dose -limiting toxicities (DLTs) are not observed, of  SL-401. 
Stage 2  (completed  enrollment ): 
• Determine the efficacy of SL -401 in patients with BPDCN, as assessed by ORR. 
• Characterize the safety profile of SL -401 at the MTD or maximum tested dose in both 
patients with AML and BPDCN. 
Stage 3  (completed  enrollment ): 
• Determine the CR rate (i.e., CR + CRc)  in patients with first- line BPDCN . 
• Characterize the safety profile of SL -401 in patients with first- line BPDCN.  
Stage 4:  
• Further characterize the efficacy of SL -401 in R/R and first- line patients with BPDCN 
following the completion of Stage 2 and Stage 3, respectively, as assessed by the rate of 
CR ( i.e., CR + CRi + CRc).  
• Further characterize the safety profile of SL -401 among first- line and R/R patients with 
BPDCN.  
• Characterize the efficacy and safety of a lyop hilized formulation of SL-401 among first-
line and R/R patients with BPDCN.   
4.2 Secondary Objectives  
The secondary objectives are to :  
• Determine the CR rate (i.e., CR + CRi + CRc) for Stage 1 and Stage 2, and ORR for 
Stage 3 patients.  
• Estimate duration of response (DOR) , PFS, and OS in patients with BPDCN. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  43 CONFIDENTIAL  • Enable preliminary characterization of the estimated ORR in patients with R/R AML, 
including in subsets of patients with R/R AML based on pre- treatment blast count, 
cytogenetics, or CD123 measurement. 
• Estimate  DOR , PFS, and OS in patients with AML. 
• Characterize the pharmacokinetics (PK) and immunogenicity of SL-401. 
4.3 Exploratory Objectives 
Exploratory objectives are to characterize expression of IL -3R/CD123 (and other potentially 
relevant stem cell and dise ase markers) on leukemia cells in peripheral blood and bone marrow 
(when feasible), to evaluate potential changes in IL -3R/CD123 (and other potentially relevant 
marker) expressing populations over time, and preliminary correlation of baseline IL-3R/CD123 
(and other potentially relevant marker) expression and clinical efficacy (including response 
rates).  
5 Patient Selection  
5.1 Study Population 
Patients with BPDCN or AML a re to be enrolled in this study; refer to Section 5.2 and Section 
5.3 for details.  
5.2 Patient Inclusion Criteria  
To be included in the study, a patient must meet the following criteria:  
1. The patient has a diagnosis of AML (Protocol Stages 1 and 2) or BPDCN (Protocol 
Stages 1 -4) according to WHO classification ( AML; excluding acute promyelocytic 
leukemia [APL, FAB M3])  or confirmed by hematopathology (BPDCN) (Facchetti et al. 
2008).  
2. The patient must meet one of the following  (a) or (b) or (c):  
(a) Has evidence of persistent or recurrent AML (Protocol Stages 1 and 2) in the 
peripheral blood and/or bone marrow that  is refractory to, or has relap sed from, the ir 
most recent prior line of treatment.  
• A prior line of treatment is considered an induction regimen if it involves an 
approved or investigational cytotoxic chemotherapy agent, biological agent, 
and/or hypomethylating agent administered alone or in a combination regimen, 
with the intent to induce robust cytoreduction (i.e., CR).  
• The previous induction regimen may have been a SCT with intent to induce a CR.  
• Consolidation and/or m aintenance (including SCT) may have been given in 
CR/CRi, but are not counted as a line of treatment.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  44 CONFIDENTIAL  • Hydroxyurea will not be considered a prior line of treatment. 
(b) Has previously untreated AML (Protocol Stages 1 and 2) and is considered to be at 
high risk for disease progression and/or is unlikely to derive more than transient 
benefit from standard therapy by having at least one of the following: 
• Treatment -related AML, except if it is associated with favorable cytogenetics 
(e.g., inversion 16, t[16;16], t[8;21] , t[15;17]), and not a candidate for SCT in 
their current disease state . 
• AML with antecedent hematological disease (e.g., MDS, myelofibrosis, 
polycythemia vera) and not a candidate for SCT. 
(c) Has histological and/or cytological evidence of BPDCN by pathologic assessment at 
the investigative site according to WHO classification (Facchetti et al. 2008)  by a 
pathologist with expertise in hematologic malignancies , that can be measured for 
treatment response and is either:  
• Previously untreated ( i.e., first-line) (Protocol Stage s 2-4). 
• Persistent or recurrent in the peripheral blood, bone marrow, spleen, lymph nodes, 
skin, or other sites after previous treatment with at least 1 line of systemic therapy 
for BPDCN, e.g., stem cell transplant or chemotherapy (Protocol Stages 1, 2, and 
4). A pathology specimen must be ava ilable for central pathology review for all 
BPDCN patients enrolled in Protocol Stage s 2-4.  
3. The patient ≥18 years old.  
4. The patient has an Eastern Cooperative Oncology Group ( ECOG) performance status 
(PS) of 0 -2. 
5. The patient has adequate baseline organ fu nction, including cardiac, renal, and hepatic 
function: 
• LVEF ≥institutional lower limit of normal as measured by multigated acquisition 
(MUGA) scan or 2-dimensional (2-D) echocardiography ( ECHO ) within 28 days 
prior to start of therapy and no clinically significant abnormalities on a 12- lead 
electrocardiogram ( ECG ) 
• Serum creatinine ≤1.5 mg/dL  (133 µmol/L) 
• Serum albumin ≥3.2 g/dL  (32 g/L)  (please note that albumin infusions are not 
permitted in order to enable eligibility)  
• Bilirubin ≤1.5 mg/dL  (26 µmol/L)  
• AST and ALT ≤2.5 times the upper limit of normal (ULN)  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  45 CONFIDENTIAL  6. If the patient is a woman of child bearing potential (WOCBP), she has had a negative 
serum or urine pregnancy test wi thin 1 week prior to treatment. 
7. The patient has signed informed consent prior to initiation of any study- specific 
procedures or treatment. 
8. The patient is able to adhere to the study visit schedule and other protocol requirements, 
including follow-up for survival assessment. 
9. The patient (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study, and continue to use acceptable contraceptive methods for 
2 months after the last infusion of SL -401. 
5.3 Patient Exclusion Criteria  
A patient will not be included in the study if any of the  following criteria are met: 
1. The patient has a diagnosis of APL (FAB M3).  
2. The patient has persistent clinically  significant toxicities Grade ≥2 from previous 
chemotherapy (excluding alopecia, nausea, fat igue, and liver function tests [ as mandated 
in the inclusion criteria] ). 
3. The patient has received treatment with chemotherapy , wide-field radiation, or biologic 
therapy within 14 days of study entry. 
4. The patient has received treatment with another  investigational agent within 14 days of 
study entry. 
5. The pati ent has previously received treatment with SL -401. 
6. The patient has an active malignancy and/or cancer history (excluding AML , BPDCN,  or 
antecedent MDS ) that may confound the assessment of the study endpoints. Patients with 
a past cancer history (within 2 years of entry) with substantial potential or recurrence 
and/or ongoing active malignancy must be discussed with the Sponsor before study entry.  
Patients with the following neoplastic diagnoses are eligible: non- melanoma skin cancer, 
carcinoma in situ, cervical intraepithelial neoplasia, organ -confined prostate cancer with 
no evidence of progressive disease. 
7. The patient has clinically significant cardiovascular disease (e.g., uncontrolled or any 
New York Heart Association  Class 3 or 4 congestive heart failure, uncontrolled angina, 
history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medic ation). 
8. The patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic 
obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the 
Investigator would put the patient at significant risk for pulmonary complications during the study. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  46 CONFIDENTIAL  9. The patient has known active or suspected central nervous system ( CNS ) leukemia.  If 
suspected, CNS leukemia should be ruled out with relevant imaging and/or examination 
of cerebrospinal fluid. 
10. The patient is receiving immunosuppressive therapy – with the exception of low-dose 
prednisone (≤10 mg/day) – for treatment or prophylaxis of graft -versus -host disease 
(GVHD).  If the patient has been on immunosuppressive treatment or prophylaxis for 
GVHD, the treatment(s) must have been discontinued at least 14 days prior to study treatment and there must be no evidence of Grade ≥2 GVHD.  
11. The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation , or psychiatric 
illness/social situations that would limit compliance with study requirements . 
12. The patient is pregnant or breast feeding .  
13. The patient has known positive status for human immunodeficiency virus or active or chronic Hepatitis B or Hepatitis C . 
14. The patient i s oxygen-dependent. 
15. The patient has any medical condition which in the opinion of the Investigator places the 
patient at an unacceptably high risk for toxicities. 
16. The patient has AML and requires more than 1g per day of hydroxyurea. (Hydroxyurea is 
permitted at doses of 1g per day or less). 
5.4 Replacement of Patients  
At the discretion of the Sponsor, additional patients may be enrolled to supplement patient data 
compromised due to premature study dropout or other reasons. 
6 Investigational Plan 
6.1 Dose and Schedule Rationale  
Under an  the MTD of SL -401 as a daily × 5 regimen in a 
Phase 1/2 dose escalation study was determined to be 16.6 μg/kg/day.  The principal DLTs 
consisted of hypoalbuminemia and edema (i.e., CLS ), and the incidences of DLTs were 2 of 
2 patients at the 22.12 µg/kg/day dose level, 1 of 8 patients at the 16.6 µg/kg/day dose level, and 
1 of 18 patients at the 12.5 µg/kg/day dose level. The LFT and albumin results from the 
Investigator-sponsored study investigat ing SL-401 indicate that most patients with clinically 
meaningful changes in these parameters following administration of SL-401 would be expected to recover to near baseline levels by 3 -4 weeks following the initiation of therapy. These results 
therefore support administration of cycles every 3 weeks with the allowance to delay the start of 
a subsequent cycle to allow toxicity resolution. Furthermore, a single cycle of SL-401 
demonstrated single agent activity in patients with R/R AML or BPDCN, with the ma jority of 
major responses occurring at the 12.5 μg/kg/day  dose level.  Therefore, the risk/benefit profile of 

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  47 CONFIDENTIAL  SL-401 appeared to be most favorable at the 12.5 µg/kg/day dose level, and this is the expected 
dose that will be used in future studies of SL-401 as a single- agent given on multiple cycles 
(every 3 weeks).  
The present study serves to bridge the early Phase 1/ 2 clinical experience with SL-401 produced 
using an earlier process to SL -401 made using a commercial -scale manufacturing process. Given 
the results from the SL-401 Phase 1/2 study (Study 50047) , it wa s anticipated that the starting 
dose for Stage 2 of the present study would be 12 µg/kg/day. However , in the interest of 
optimizing patient safety and thoroughly evaluating the commercial- scale SL -401, the dose 
escalation i n Stage 1 of the study began 2 dose levels below, or 7 µg/kg/day , which was the 
lowest tested dose for this regimen (7.07 μg/kg/day) in the Phase 1/2 study evaluating SL-401 
(Study 50047).  
6.2 Overall Study Design  
This is a 4 -stage, non-randomized, open- label, dose escalation  and expansion, multicenter study.  
A cycle of therapy is 21 days.  A Data Safety Review Committee (DSRC), which will include 
Sponsor representatives, will be established to review the accruing safety data and make safety 
decisions during the study, including dose escalations in Stage 1.  
6.2.1 Stage 1: Dose Escalation  
During Stage 1, approximately 9-18 patients will be treated with SL -401 at doses of 7, 9, 12, or 
16 µg/kg/day for 5 consecutive days every 21 days. The 16 µg/kg/day dose will be evaluated 
only in patients with AML . Evaluation of higher doses (in increments of 25% or less [i.e., at 
20 µg  /kg/day and 25 µg  /kg/day levels]) in AML patients may be attempted pending evaluation 
of the safety/tolerability of the  16 µg/kg/day dose level; these evaluations would be attempted to 
identify an MTD and will be guided by the criteria (stipulated below) defining safety/tolerability of all dose levels . 
Three to 6 patients will be treated at each dose level . All patients within a cohort must complete 
the first cycle of therapy before patients from a new cohort receive SL -401 at the next higher 
dose. No intra- patient dose escalation is allowed.  The first cohort of p atients will receive SL-401 
at a dose of 7 µg/kg/day.  After  all patients in this c ohort complete the first cycle of therapy, the 
dose for the second cohort of patients will increase by 29% to 9 µg/kg/day, conditional on the DLT rules described below.  The dose for the third cohort of patients will increase by 33% to 12 
µg/kg/day , conditional on the DLT rules described below. Finally, after all patients in the third 
cohort complete the first cycle of therapy, the dose for the fourth cohort of patients, consisting only of patients with AML, will increase by 33% to 16 µg/kg/day, conditional on the DLT rules 
described below.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  48 CONFIDENTIAL  During Stage 1, DLT is defined as any of the following during the first cycle of therapy : 
(a) Any treatment -emergent Grade 4 transaminase or creatine phosphokinase (CPK) 
elevation, regardless of duration or relationship to SL-401. 
(b) Any treatment -emergent  Grade 4 hematologic toxicity (unrelated to persistent leukemia) 
lasting >21 days after the last infusion of SL-401. 
(c) Any treatment -emergent Grade ≥3 non- hematologic toxicity  (unrelated to persistent 
leukemia) , with the exception of Grade 3 laboratory toxicities that resolve to Grade ≤1 or 
baseline ≤21 days after the last infusion of SL-401, or the following Grade 3 toxicities if 
they resolve to Grade ≤1 or baseline ≤21 days after the last infusion of SL-401: 
arthralgia, myalgia, fever responding to treatment, nausea and/or vomiting (excluding cases that require tube feeding, TPN or hospitalization) or diarrhea associated with suboptimal prophylaxis or treatment.  
SL-401- related toxicities are AEs that are cons idered by the Investigator to be either possibly, 
probably or definitely related to investigational SL-401 (Please refer to protocol  Section 10.6 for 
more thorough guidance as to the assessment of “relatedness” in the context of investigational anticancer therapy).  It should be noted that although the cycle length is 21 days, cycle duration 
may extend beyond 21 days in the setting of AEs, which ar e detailed in  Section 7.5.5.   Specific, 
reversible AEs resulting in a prolongation of Cycle 1 to 28 days will not necessitate a dose-
reduction for subsequent cycles and will not be considered DLTs if they occur during Cycle 1. 
Beginning with the dose level 7 µg/kg/day of SL- 401, a decision to allow treatment at the next 
higher dose level will depend on the number of patients who experience a DLT duri ng the first 
cycle . If none of the initial 3 patients treated (0/3) experiences a DLT, then dose escalation will 
proceed and 3 new patients will be treated at the next higher dose of 9 µg/kg/day . If one of the 
initial 3 patients treated (1/3) experiences a DLT, the cohort will be expanded to include up to an 
additional 3 patients treated at the same dose 7 µg/kg/day.  If only one patient (1/6) from this 
expanded cohort experiences a DLT, then 3 new patients will be treated at the next higher dose 9 
µg/kg/day . Expansion of the 9 µg/kg/day cohort to 6 patients, if necessary, will follow the same 
rules as the 7 µg/kg/day cohort. The same DLT rules will also apply to the 12 µg/kg/day and 16 
µg/kg/day (AML specific) cohorts. 
In the event that 2 patients within a cohort have a DLT, then the MTD will be exceeded and 
further dose escalation will not occur. The MTD is defined as the dose preceding the dose level at which 2 patients experience a DLT during treatment Cycle 1.  The MTD  will be used in Stage s 
2-4 of the st udy. If the highest planned treatment dose is completed and determined to be safe 
and the MTD is not exceeded, the available PK and safety data will be reviewed to assess whether further dose escalation is justified.  A patient who does not complete the fir st cycle of 
treatment for reasons other than the occurrence of DLT will be replaced by another patient who will receive the same dose regimen.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  49 CONFIDENTIAL  In the event that a DLT occurs in 2 patients  treated  at the 7 µg/kg/day dose level , 5 µg/kg/day 
will be considered by the D SRC as an  alternative starting dose.  In this event, a new cohort of 
3 patients will receive 5 µg/kg/day for the first cycle.  The same DLT rules will apply to this dose 
level.  If 2 or more patients experience a DLT at the 5 µg/kg/day dose level, the study will be 
halted.  
Stage 1 is complete, with the MTD of SL -401 determined to be 12 µg/kg/day in R/R AML and a 
maximum tested dose of SL -401 of 12 µg/kg/day in BPDCN. (An MTD was not determined in 
BPDCN.)  
6.2.2 Stages 2 -4 
During Stages 2 -4, patients will be treated at the MTD or maximum tested dose at which 
multiple DLTs are not observed during Stage 1, or a lower dose with potentially the most 
favorable risk/benefit profile. At the time of Protocol Amendment 11, only Stage 4 is open for 
enrollment. 
SL-401 will be supplied as SL-401 Injection frozen solution (1 mg/mL) as described. A 
lyophilized formulation ( SL-401 for Injection , lyophilized, powder, for solution; 1 mg/mL) also 
will be supplied . All patients enrolled in Stage 4 (both first- line and R/R) subsequent to 
completion of enrollment in Stage 3 will receive the lyophilized formulation of SL -401. Note 
that when  the lyophilized formulation is introduced, patients who start treatment with SL -401 
Injection  frozen solution will continue to receive this dosage form throughout the study. 
6.2.2.1 Patients with AML ( Stage 2 only) 
The primary objective for patients with AML enrolled in Stage 2  is to characterize the safety 
profile of SL -401 at the MTD or maximum tested dose in patients with  AML.  Assessment of the 
anti-tumor activity of SL -401 in patients with AML will be assessed by the Investigator as a 
secondary endpoint using the criteria in Section 16.1, Appendix A. The following assessments 
will be performed at baseline within 14 days prior to the first administration of SL -401 and 
thereafter for determination of tumor response for these patients , as follows :  
• Bone marrow aspirates (± biopsy)  21 (±7) days after the start of Cycles 1 and 2 . 
Patients with evidence of bone marrow involvement prior to study treatment will also 
have bone marrow evaluations following Cycles 4 and 6 and then every 3 months from Months 6-12; every 6 months from 12 to 24 months; and every 12 months thereafter until 
there is evidence of relapsed or progressive disease. If the Cycle 1 (Day 21  [±7]) bone 
marrow examination is empty (i.e., hypocellular) or inadequate, a bone marrow 
examination should be repeated in 7 (±7) days to document response. If additional time is 
required to complete the repeat examination, consult ation  with the Medical Monitor is 
required . If CD123 flow cytometry or IHC stain assessment was performed on the bone 
marrow aspiration (± biopsy), the results should be recorded in the electronic case report 
forms (eCRF s).  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  50 CONFIDENTIAL  • Collection of peripheral blood samples  for determination of blasts 21 (±7) days after the 
start of Cycles 1 and 2. Patients with evidence of peripheral blasts at baseline will also 
have peripheral blood samples collected 21 (±7) days after the start of Cycles 1 and 2 and 
21 (±7) days after the start of every 2nd cycle thereafter (Cycles 4, 6, etc.) until there is 
evidence of relapsed or progressive disease.  
6.2.2.2 Patients with BPDCN ( Stages 2 -4) 
Standardized assessment of potential sites of disease involvement (including skin, lymph nodes, 
blood, bone marrow, and visceral organs) and consistently- defined response criteria will be 
utilized.   
The BPDCN diagnosis will be made or confirmed during Screening by the pathology laboratories at the investigative sites.  Subsequent to enrollment, pathology material will be 
submitted for central pathology review for confirmation of the BPDCN diagnosis. 
Tumor response will be assessed by the Investig ators for all patients with BPDCN, with the 
Investigator’s assessment to be used in the primary analysis. As a supportive assessment, tumor 
response will be assessed by an Independent Review Committee (IRC) in a pre-specified subset 
of patients. Tumor resp onse will be assessed using the Tumor Response Criteria for Patients with 
BPDCN  presented in Section 16.2, Appendix B . All patients will also be followed for DOR and 
survival. The following assessments will be performed at baseline within 14 days prior to the 
first administration of SL -401 and thereafter for determination of tumor response for patients in 
Stages 2 -4: 
• Bone marro w aspirates (± biopsy) samples 21  (±7) days after the start of Cycles 1 and 
2. Patients with evidence of bone marrow involvement prior to study treatment will also 
have bone marrow evaluations following Cycles 4 and 6 and then every 3  months from 
Months 6-12; every 6 months from 12 to 24 months; and every 12 months thereafter until there is evidence of relapsed or progressive disease. 
• If the Cycle 1 (Day 21 [ ±7]) bone marrow examination is empty (i.e., hypocellular) or 
inadequate, a bone marrow examination should be repeated in 7 (±7) days to 
document response. If additional time is required to complete the repeat examination, 
consult ation  with the Medical Monitor is required . If CD123 flow cytometry or IHC 
stain assessment was performed on the bone marrow aspiration (± biopsy ), the results 
should be recorded in the eCRF.  
• Skin assessments, including photographs, for patients with skin involvement, and 
determination of skin disease burden using mSWAT (see  Section 16.3, Appendix C ) 
21 (±7) days after the start of Cycles 1 and 2 and 21 (±7) days after the start of every 2
nd 
cycle thereafter (Cycles 4, 6, etc.) until there is evidence of relapsed or progressive 
disease.  Refer to the separate mSWAT Manual for instructions regarding the quantitation 
of malignant lesions via the mSWAT and response assessment in skin. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  51 CONFIDENTIAL  • In situations in which there is substantial reduction of skin lesions (especially when 
accompanied by disappearance of BPDCN from bone marrow or other sites), a skin 
biopsy is required. The mSWAT guidance states: “A biopsy of normal appearing skin 
is unnecessary to assign a complete response.  However a skin biopsy should be 
performed of a re presentative area of the skin if there is any question of residual 
disease (persistent erythema or pigmentary change) where otherwise a complete 
response would exist” (Olsen et al. 2011).  
• CT scans  of index lesions 21 (±7) days after the start of Cycles 2,  4 and 6 and 
21 (±7) days after the start of every 4th cycle thereafter (for patients with baseline 
evidence of lymph node or visceral disease)  until there is evidence of relapsed or 
progressive disease. For patients with no baseline evidence of lymph node or visceral 
BPDCN involvement, subsequent scans should be performed at the end of Cycle 2 (±7 days; or at time of disease progression (PD) if PD occurs prior to end of Cycle 2), 21 (±7) days after the start of Cycle 6, and at Investigator’s discretion the reafter.  Baseline CT 
scans should be full-body (chest/ abdomen/pelvis), whereas follow-up scans should 
document response of index lesions ( Cheson et al.  2007) . 
• Collection of peripheral blood samples  for determination of blasts 21 (±7) days after the 
start of Cycles 1 and 2. Patients with evidence of peripheral blasts at baseline will also have peripheral blood samples collected 21 (±7) days after the start of Cycles 1 and 2 and 21 (±7) days after the start of every 2nd cycle thereafter (Cycles 4, 6, etc.) until there is evidence of relapsed or progressive disease.  
6.3 Study Duration  
Patient enrollment is expected to occur over a 52-month period, with follow-up continuing for a 
minimum of 12 months on each patient . Total study duration is expected to be approximately 60 
months. Please consult Section 7.6.2 regarding recommended procedures and follow- up after 
treatment discontinuation.  
6.4 Study Completion  
The study is considered complete when sufficient information is available to enable assessment of the primary endpoint and selected secondary endpoints. The Study Completion date will be 
the date beyond which study data are no longer entered into the primary database (this study completion date generally precedes the date on which the database lock  occurs by several 
weeks/months). 
7 Study Treatment Identification, Administration, and Schedule  
7.1 Product Manufacturing and Characterization 
Refer to the Investigator Brochure (IB)  for full details of product manufacturing and 
characterization.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  52 CONFIDENTIAL  7.2 Recommended Medications Per Institutional Guidelines/Practices  
It is recommended that patients receive the following types of prophylactic therapies/regimens 
per institutional guidelines/practices:  
• Antibacterial: ciprofloxacin, levofloxacin, or an equivalent antibiotic 
• Antifungal: fluconazole, voriconazole, or an equivalent antifungal 
• Antiviral: acyclovir, valacyclovir or an equivalent antiviral 
7.3 Allowed Medications/Therapies  
All patients may receive supportive care measures as clinically indicated, including prophylacti c 
antibiotics, antihistamines, antiemetics, albumin, fluids (hydration), and supportive measures. Patients may receive growth factor support and/or blood product transfusions as per the 
discretion of their physician. 
Albumin 25 g IV daily should be administered if serum albumin is  between 3.0-3.5 g/dL (30-35 
g/L) on days that dosing occurs or if it is <3.0 g/dL  (30 g/L) on days when treatment has been 
withheld  or in the immediate post- treatment period . The Investigator has discretion with regard 
to frequency of administration per product and institutional guidelines.  7.4 Prohibited Medications/Therapies 
Please refer to  Section  11 regarding investigational or approved anticancer agents prohibited 
during study participation. 
7.5 SL-401 
7.5.1 SL-401 Description and Storage 
SL-401 is a novel biologic fusion protein comprised of recombinant human IL- 3 genetically 
fused to truncated diphtheria toxin protein. SL -401 targets the IL-3R, which is over-expressed on 
the CSCs  and/or tumor bulk of a variety of leukemias and hematopoietic malignancies, including 
BPDCN and AML, relative to normal hematopoietic stem cells and other hematopoietic cells .  
SL-401 drug product is prepared in two formulations and dosage forms.  
• SL-401 Injection is a non-preserved, sterile, liquid dosage form supplied in sterile 2 mL 
glass vials containing 1 mL of sterile SL -401 solution (1 mg/vial) and should be stor ed 
frozen at -20°C (±5°C).  
• SL-401 for Injection is a non-preserved, sterile, powder for solution supplied in sterile 
3 mL glass vials and should be stored at -20°C (±5°C). 
Document ation  stating the product’s expiry date will be provided with each shipment. 
7.5.2 Dose , Schedule and Duration of Treatment 
SL-401 is administered by IV infusion over 15 minutes for 5 consecutive days of a 21- day cycle .  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  53 CONFIDENTIAL  • In Stage 1, SL-401 is administered at escalating doses of at 7, 9, 12, or 16 µg/kg/day.  
• In Stages 2 -4, all patients  will receive SL -401 at a dose of 12 µg/kg/day. 
The dose of SL-401 will be dependent upon the patient’s baseline body weight in kg (day of 
initial infusion for Cycle 1).  This dose will be recalculated if there is a 10% (or greater) change 
in body weight from baseline. The aliquot is calculated from the µg/kg dose × patient weight in kg (including one decimal place; all patient doses are calculated in µg/kg body weight).  Dose 
changes should only occur once a cycle has been completed. Intra -cycle dose modifications will 
not be permitted.  
Patients who benefit from treatment and do not have evidence of clinically significant 
progressive disease may receive repeated cycles of SL -401 even if a response, in the judgment of 
the Investigator, is not attained. Patien ts will continue to receive SL -401 as long as they may be 
benefiting from treatment, according to the Investigator; until the study is completed. No 
maximum duration of therapy has been set.  
7.5.3 SL-401 Premedication  and Dose Preparation and Administration 
7.5.3.1 Premedication  
Patients will receive the following premedication approximately 60 minutes before each SL-401 
infusion: 
• Acetaminophen 650 mg (or equivalent dose of paracetamol) orally (PO) 
• Diphenhydramine 50 mg intravenously (IV) (or equivalent dose of another H1 -histamine 
antagonist) 
• Methylprednisolone 50 mg IV (or an equivalent dose of another corticosteroid) 
• Ranitidine 50 mg IV (or an equivalent dosage of another H2- histamine antagonist)  
7.5.3.2 SL-401 Dosage Preparation 
SL-401 is prepared for administration by the pharmacy . The total per- patient dose is calculated 
based on patient body weight in kilograms (kg) including one decimal place, and the patient’s assigned dose (µg/kg dose × patient weight in kg, including one decimal place [example: 7 µg/kg 
× 70.3kg]). The dose of SL-401 will be dependent upon the patient’s baseline body weight in kg 
(day of initial infusion for Cycle 1). This dose will be recalculated if there is a 10% (or greater) 
change in body weight from baseline. Additional dose preparation supplies and instructions for 
both SL- 401 formulations utilized in this study are described in detail within the Pharmacy 
Manual   
7.5.3.3 Inpatient and Outpatient Setting for Dose Administration  
The first cycle of SL -401 must be administered in the inpatient setting, with hospitalization 
beginning the day of the first infusion of SL-401 (or a prior day) and ending approximately 24 hours after the last infusion of SL-401. Subsequent cycles of SL -401 can be administered in 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  54 CONFIDENTIAL  the inpatient setting or in a suitable outpatient ambulatory care setting that is equipped for 
intensive monitoring of patients with hematopoietic malignancies undergoing treatment, per the discretion of the Investigator and i nstitutional guidelines and capabilities.  Patients will be 
monitored for at least 4 hours following the administration of each infusion of SL-401. 
7.5.4 Patient Monitoring Procedures During the SL -401 Dosing Period 
To assess relevant acute toxicities, testing an d procedures summarized  below are to be performed 
and results are to be reviewed prior to each scheduled SL -401 infusion (refer to Section  9.8 
Table 5, Table 6, Table 7, and Table 8 for more detail ):  
• Vital signs including blood pressure, heart rate, respiration rate, body temperature, and 
pulse oximetry :  
o During daily dosing (usually Days 1, 2, 3, 4 and 5):  
 immediately prior to infusion,  
 immediately after completion of infusion, and  
 30, 60, and 240 minutes post-infusion. 
o Days 8, 15, and 21. 
• Diagnostic blood t ests during daily dosing (usually Days 1, 2, 3, 4 and 5) and Days 8, 15, 
and 21 as follows: 
o Hematology: c omplete blood count (CBC) with differential, platelet count; 
o Serum Electrolytes and Chemistry: sodium, potassium, bicarbonate, chloride, 
blood urea nitrogen (BUN), creatinine, glucose, alanine aminotransferase (ALT), 
albumin, alkaline phosphatase (ALP), aspartate aminotransferase, (AST), 
bilirubin (total, direct, and indirect), calcium, creatine phosphokinase (CPK), magnesium, lactate dehydrogenase (LDH), phosphate, total protein, uric acid; 
o Coagulation: prothrombin time (PT) or International Normalized Ratio (INR), and 
activated pa rtial thrombin time (aPTT) . 
• Routine urinalysis on Day 1 (prior to SL -401 infusion), and Days 8, 15, and 21.  
7.5.5 Dose Delays/Modifications and Management Procedures for Toxicities Associated with 
SL-401 
During the dosing period for each cycle, individual SL -401 infusions may be delayed to allow 
for toxicity resolution . Details are presented in  Table 4. 
Monitor vital signs and check albumin, transaminases, and creatinine prior to preparing each 
dose of ELZONRIS. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  55 CONFIDENTIAL  Table 4: Recommended ELZONRIS Dose Modifications  
Parameter Severity Criteria  Dose Modification  
Serum albumin  Serum albumin < 3.5  g/dL or reduced ≥ 
0.5 g/dL from value measured prior to 
initiation of the current cycle  See CLS Management Guidelines 
(Appendix  E) 
Body weight  Body weight increase ≥ 1.5 kg over 
pretreatment weight on prior treatment day  See CLS Management Guidelines 
(Appendix  E) 
Aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT)  ALT or AST increase > 5 times the upper limit of normal  Withhold SL-401 until transaminase 
elevations are ≤ 2.5 times the upper limit of normal.  
Serum creatinine  Serum creatinine > 1.8 mg/dL (159 
micromol/L) or creatinine clearance < 60 mL/minute  Withhold SL-401 until serum 
creatinine resolves to ≤ 1.8  mg/dL (159 
micromol/L) or creatinine clearance ≥ 60 mL/minute.  
Systolic blood pressure  Systolic blood pressure ≥ 160 mmHg or ≤ 80 mmHg  Withhold SL-401 until systolic blood 
pressure is < 160  mmHg or > 80 
mmHg.  
Heart rate  Heart rate ≥ 130  bpm or ≤ 40  bpm Withhold SL-401 until heart rate is 
< 130 bpm or > 40 bpm.  
Body temperature  Body temperature ≥ 38°C  Withhold SL-401 until body 
temperat ure is < 38°C.  
Hypersensitivity reactions  Mild or moderate  Withhold SL-401 until resolution of 
any mild or moderate hypersensitivity reaction. Resume ELZONRIS at the same infusion rate.  
Severe or life -threatening  Discontinue SL-401 permanently.  
 
Dose reductions should be discussed with the medical monitor on a case by case basis.  
7.6 Treatment Discontinuation  
7.6.1 Criteria for Treatment Discontinuation  
SL-401 treatment may be discontinued for any of the following reasons:  
• Patient withdrawal of consent  
• Occur rence of unacceptable toxicity, including DLT 
• SL-401 related anaphylaxis o r Grade ≥3 hypersensitivity reaction   
• Requirement for >1 dose reduction unless there is evidence of AML/BPDCN response 
(beyond Cycle 1), in which case additional dose reductions are permitted, however these 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  56 CONFIDENTIAL  reductions must be discussed with the Medical Monitor and documented in the context of 
ongoing AML/BPDCN response 
• Disease recurrence/progression  
• Intercurrent illness that prevents further administration of SL -401 
• Patient non- compliance  
• Occurrence of pregnancy  
• Investigator’s decision 
The reason for SL-401 discontinuation and the date of discontinuation should be recorded in the 
eCRF.  
In settings in which there is preliminary but not conclusive evidence of disease progression  
(i.e., new skin lesions of indeterminate etiology, new lymph nodes ≤1.5cm, modest increase in bone marrow blast percentage subsequent to an initial marked reduction, appearance of new blast population on bone marrow evaluation by means of flow cytometry or other molecular methodology without increase in blast percentage consistent with PD), additional SL-401 cycles 
may be administered, provided that the Investigator  documents that the evidence of potential 
disease progression is inconclusive and that the overall risk/benefit assessment favors additional 
investigational therapy.  Additional SL-401 may also be administered in situations of mixed 
response BPDCN in which response/progression is not consistent between a given patient’s 
disease sites, provided that the Investigator documents that the overall risk/benefit assessment 
favors additional investigational therapy. In such situations, it is essential that relevant find ings 
and assessments are documented, and that areas of potential disease progression are followed 
closely on subsequent assessments. 
7.6.2 Procedures and Follow-up a fter Treatment Discontinuation  
The evaluation during which the Investigator determines that  SL-401 will be discontinued  should 
be considered the End of Treatment Evaluation; all tests and procedures for the End of Treatment 
Evaluation are listed  in Table 6 and Table 8 (in Section 9.8) . In addition, patients should be 
followed for a minimum of 30 days after the last infusion of SL- 401 for assessment of AEs 
(including potential new AEs and potential change/resolution of existing AEs).  
If the patient is in CR/PR at the time of discontinuation,  disease assessments should continue to 
be performed as described in  Section 8.12 on an every 6- week basis (±1 week) through 6 months 
post-C1D1 and then on an every 90-day basis or until, in the judgment of the Investigator, there 
is evidence of relapsed or progressive dis ease. Beyond the End of Treatment Evaluation and 30-
day follow up ( safety /AE assessment ), it is requested that subsequent follow-up occur 
approximately every 90 days for survival status. ( If the patient is in CR/PR at the time of 
discontinuation, disease assessments should continue to be performed as described in Section 
8.12 on an every 6-week basis (±1 week) through 6 months post-C1D1 and then on an every 90-
day basis or until, in the judgment of the Investigator, there is evidence of relapsed or 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  57 CONFIDENTIAL  progressive dis ease.  Patients who undergo SCT will be followed for the occurrence of VOD and 
engraftment delay or failure as part of survival monitoring.  
If the patient discontinues SL-401 treatment and also withdraws consent for collection of future 
information, no further evaluations should be performed and no additional data should be 
collected as part of the study.  The Sponsor will only retain and use any data collected before 
withdrawal of consent. 
Please consult Section 6.4 for recommendations concerning ongoing follow-up of patients alive 
with or without evidence of disease progression at the time of Study Completion/assessment of 
primary and critical secondary endpoints. 
8 Study Procedures  
8.1 Patient Selection  
Patients with BPDCN or R/R AML who have previously received at least one line of therapy for 
their disease, previously untreated AML that is considered high risk for disease progression, and 
who otherwise meet the inclusion/exclusion criteria will be recruited for enrollment into the 
study.  Patients will be advised of the clinical protocol by the Investigator.  If the patient is 
interested and is potentially eligible for participation in the study, he/she wi ll be provided with 
the ICF to review and sign. The ICF includes a detailed explanation of the study design and the 
potential risk s and benefit s of treatment.  Patients who agree to participate in the study will be 
provided with a copy of the signed consent form; the original signed consent document will be filed in the patient’s medical record.  Only eligible and consenting patients will be entered into 
the study. 
Patients will be screened by the site’s Investigator or study nurse/coordinator prior to study 
entry.  All patients enrolled on the study will be entered into a patient registration log at each site.  
Each screened patient will be assigned a sequential patient/study screening number with digits 
indicating site number and patient study number (e.g., XX-YYY, where XX denotes site number and YYY denotes patient study number as assigned at screening). Original screening records and 
source documents should be kept for all patients, including those who fail to meet the patient 
eligibility requirements and an y completed eCRFs should be retained for monitoring and 
auditing. Each patient’s data obtained from subsequent evaluations should be recorded and evaluated in the source documents and eCRF. Prior to treatment, the Investigator will re -confirm 
patient eligibility criteria and assignment of the correct patient study number.  
8.2 Medical History  
Medical history includes current and past medical conditions and smoking history , date of AML  
or BPDCN diagnosis, prior AML/BPDCN treatment, response to prior treatment, and date of 
relapse, if applicable. Information concerning any prior malignant diagnoses with particular focus on cytotoxic therapies received for prior malignancies (i.e. , dates/duration of anthracycline 
for prior breast cancer) is to be collected whenever feasible.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  58 CONFIDENTIAL  8.3 Disease Confirmation (Patients with BPDCN  in Stages 2 -4) 
For patients with  BPDCN enrolled in Stages 2-4, the BPDCN diagnosis will be made or 
confirmed during Screening by the pathology laboratories at the investigative sites. Subsequent 
to enrollment, pathology material will be submitted for review by the central patholog ist for 
confirmation of the BPDCN diagnosis. 
Pathology material will consist of pathology slides (or tissue blocks) and associated pathology 
reports for all organ sites evaluated for BPDCN via histopathology/ cytopathology. In situations in which submission of slides or blood smears is considered not feasible, submission of 
representative electronic images of histopathology will be permitted.  Pathology submission will 
also include reports of all immunohistochemistry evaluations for BPDCN and other hematologic-
malignancy -associated markers, and reports of flow cytometry performed on bone marrow 
aspirate (or blood if applicable) for BPDCN and other hematologic-malignancy- associated 
markers.  Submission of scatter-plots of flow cytometric evaluation is strongly encouraged.  
8.4 Prior and Concomitant Medication 
Medications taken within 28 days prior to screening and throughout the study are to be collected 
and recorded.  
8.5 ECOG Perform ance Status  
See Section  16.4 for a scoring guide.  
8.6 Physical Examination  
Physical examination includes evaluation by body system and height (at screening only).  
8.7 Vital Signs  
Vital signs include temperature, heart  rate, respiration rate, pulse oximetry, and blood pressure. 
Collection should occur after the patient has been sitting for 3-5 minutes.  
8.8 Electrocardiogram s 
All patients will have a 12 -lead ECG performed at the screening visit and pre- treatment visit 
(Study Day 0 or 1), as well as Day 21 (±3 days), and Day 28 (± 3 days ) only if delayed end of 
cycle) of each cycle. During the days when patients are undergoing PK sampling (during Cycle 
1, infusions 1 and 5; Cycle 3, infusions 1 and 5), an ECG will be performed at 3  distinct time 
points (triplicates) within 5 minutes prior to each PK sample collection pre -infusion and at 30 
and 60 minutes post-infusion ( see Table 9 in Section  9.8). An ECG should be performed after 
patient is supine for 5 minut es. All ECGs will be analyzed by a central facility . 
8.9 Clinical Laboratory Tests  
The following assessments should be done per the visit schedule and processed by the local laboratory: 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  59 CONFIDENTIAL  • Hematology: Minimally, scheduled hematology collections should include white blood 
cell (WBC) count, differential white cell count (lymphocytes, monocytes, basophils, 
eosinophils, neutrophils), red blood cell (RBC) count, hematocrit, hemoglobin and 
platelet count.  
• Serum albumin: May be a component of the serum chemistry panel. See Appendix E for 
management of changes in albumin values.  
• Serum electrolytes and chemistry: Sodium, potassium, bicarbonate, chloride, blood urea 
nitrogen (BUN), creatinine, glucose, ALT, albumin, ALP, AST, bilirubin (total, direct, 
and indirect), calcium, C PK, magnesium, LDH, phosphate, total protein, and uric acid. 
• Coagulation parameters: PT and/or INR, aPTT. 
• Urinalysis: Appearance, color, pH, specific gravity, ketones, leukocytes, protein, glucose, 
bilirubin, urobilinogen, and occult blood. 
8.10 Urine or Serum Pregnancy Test  
A urine or serum pregnancy test will be performed within 1 week prior to treatment for WOCBP who are not on acceptable birth control measures. The pregnancy test should be performed at the clinical research site and processed by the local la boratory. 
8.11 Vision Assessment  
All patients will be questioned regarding any changes in visual acuity and/or color vision. Patients who have experienced any ≥Grade 2 study drug- related changes in vision (NCI CTCAE 
v4.03 Grade) will have an ophthalmologic consultation and/or examination performed . In the 
event any abnormalities are detected, the patient will be followed up as per the recommendations 
of the consulting ophthalmologist. Management of treatment -related ocular disorders with 
inflammatory charact eristics should include corticosteroid eye drops and/or other measures, as 
indicated by an ophthalmologist. In the setting of persistent study drug-related ocular disorders 
≥Grade 2, consultation with the study’s M edical Monitor is required.  
8.12 Tumor Assessme nts and Disease Response Assessment  
8.12.1 Stage 1  
All patients must have a baseline (pre -treatment) bone marrow aspirate (± biopsy) and peripheral 
blood sample within 14 days prior to the first administration of SL-401. In addition, patients with BPDCN must have a baseline skin assessment (with biopsies and/or for patients with skin 
involvement) and full-body CT scan within 14 days prior to the first administration of SL-401. 
Subsequent assessments for response will be performed on the following schedules until, in the judgment of the Investigator, there is evidence of relapsed or progressive disease:  
• All patients in Stage 1 : bone marrow aspirates (± biopsy) 21 (±7) days after the start of 
Cycles 1 and 2, and thereafter at a schedule determined by the Investigator in consultation with the Sponsor. If the Cycle 1 ( Day 21  [±7]) bone marrow examination is 
empty (i.e., hypocellular) or inadequate, a bone marrow examination should be repeated 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  60 CONFIDENTIAL  in 7 (±7) days to document response. If additional time is required to complete the repeat 
examination, consult ation  with the Medical Monitor is required . If CD123 flow 
cytometry or IHC stain assessment was performed on the bone marrow aspiration ( ± 
biopsy), the results should be recorded in the eCRF. 
• BPDCN patients: skin assessments (with biopsies and/or photographs for patients with 
skin involvement) 21 (±7) days after the start of Cycles 1 and 2 and 21 (±7) days after the 
start of every 2nd cycle thereafter ( Cycles 4, 6, etc.).  CT scans of index lesions 21 (±7) 
days after the start of Cycles 2 and 4 and 21 (±7) days after the start of every 4th cycle 
thereafter (approximately every 12 weeks).  
Tumor response will be assessed by the Investigator using the criteria in Section  16.1, 
Appendix A (AML), and Section 16.2, Appendix B (BPDCN). 
8.12.2 Stage 2 , Patients with AML  
The following disease assessments will be performed at baseline within 14 days prior to the first 
administration of SL -401 and thereafter for determination of tumor response for patients with 
AML in Stage 2, as follows. Note that all sites of disease identified at baseline  are to be followed 
thereafter for determination of disease response.   
• Bone marrow aspirates (± biopsy)  21 (±7) days after the start of Cycles 1 and 2. 
Patients with evidence of bone marrow involvement prior to study treatment will also 
have bone marrow evaluations following Cycles 4 and 6 and then every 3 months from 
Months 6-12; every 6 months from 12 to 24 months; and every 12 months thereafter until 
there is evidence of relapsed or progressive disease. If the Cycle 1 (Day 21  [±7]) bone 
marrow examination is empty (i.e., hypocellular) or inadequate, a bone marrow examination should be repeated in 7 ( ±7) days to document response. If additional time is 
required to complete the repeat exami nation, consult ation  with the Medical Monitor is 
required . If CD123 flow cytometry or IHC stain assessment was performed on the bone 
marrow aspiration (± biopsy), the results should be recorded in the eCRF.  
• The Cycle 1 -2 Day 21 (±7 days) bone marrow assessment should occur on Day 21 
(±7 days) even in the setting of patients receiving SL-401 over 6-10 days (as opposed 
to 5 consecutive days) or in the setting of patients receiving less than 5 doses in a 
cycle . 
• Collection of peripheral blood samples  for determination of blasts 21 (±7) days after the 
start of Cycles 1 and 2. Patients with evidence of peripheral blasts at baseline will also 
have peripheral blood samples collected 21 (±7) days after the start of Cycles 1 and 2 and 21 (±7) days after the star t of every 2nd cycle thereafter (Cycles 4, 6, etc.) until there is 
evidence of relapsed or progressive disease.  
Assessment of the anti -tumor activity of SL -401 in patients with AML will be assessed by the 
Investigator on an exploratory basis using the crit eria in Section 16.1, Appendix A.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  61 CONFIDENTIAL  8.12.3 Patients with BPDCN (Stage s 2-4) 
A global assessment paradigm is to be followed, with all potential disease sites  assessed during 
screening, including the bone marrow (via aspirate and biopsy), blood (via clinical laboratory 
testing for blasts and hematologic parameters), skin (via visual examination and photography, with determination of skin disease burden using mS WAT),  lymph nodes, liver, spleen, and other 
viscera (via CT), and lymph nodes, liver, spleen, and other viscera (via physical examination). Positive sites of disease identified during screening must be followed during the study in every 
response evaluation . (Disease in organs that were disease- positive at screening are to be 
assessed, documented, and recorded in the clinical database, even if the disease disappeared in 
subsequent response evaluations.) Sites with no evidence of disease during Screening must be documented as such and an assessment that baseline disease is not present are to be adequately documented in source and recorded in the clinical database; thereafter, these sites need not be followed, unless there is evidence of PD. 
The following disea se assessments will be performed at baseline within 14 days prior to the first 
administration of SL -401 and thereafter for determination of tumor response for patients in 
Stages 2 -4, as follows. Note that all sites of disease identified at baseline are to be followed 
thereafter for determination of disease response.  
• Bone marrow aspirates (± biopsy) samples 21  (±7) days after the start of Cycles 1 and 
2. Patients with evidence of bone marrow involvement prior to study treatment will also 
have bone marrow eva luations following  Cycles 4 and 6 and then every 3 months from 
Months 6-12; every 6 months from 12 to 24 months; and every 12 months thereafter until 
there is evidence of relapsed or progressive disease. 
• If the Cycle 1 (Day 21 [ (±7]) bone marrow examination is empty (i.e., hypocellular) 
or inadequate, a bone marrow examination should be repeated in 7 (±7) days to 
document response. If additional time is required to complete the repeat examination, 
consult ation  with the Medical Monitor is required . If CD123 flow cytometry or IHC 
stain assessment was performed on the bone marrow aspiration (± biopsy ), the results 
should be recorded in the eCRF.  
• The Cycle 1 -2 Day 21 (±7 days) bone marrow assessment should occur on Day 21 
(±7 days) even in the setting of patients receiving SL-401 over 6-10 days (as opposed to 5 consecutive days) or in the setting of patients receiving less than 5 doses in a cycle . 
• Skin assessments, including photographs, for patients with skin involvement, and 
determination of skin dis ease burden using mSWAT (see Section 16.3, Appendix C)  21 
(±7) days after the start of Cycles 1 and 2 and 21 (±7) days after the start of every 2
nd 
cycle thereafter (Cycles 4, 6, etc.) until there is evidence of relapsed or progressive disease.   
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  62 CONFIDENTIAL  • Photographs : Body region(s) where skin lesions are present will be photographed. 
Digital images/photographs may be collected by the Sponsor or its representatives 
during routine monitoring visits. Care should be taken to ensure that patients cannot 
be identified from these images.  Refer to the separate Photography Guidelines for 
detailed photography instructions. 
• Quantification of skin disease burden via the mSWAT : Quantification of skin 
disease burden via the mSWAT (Section 16.3, Appendix C ) is required at the time of 
each skin assessment.  Refer to the separate mSWAT Manual for instructions 
regarding the quantitation of malignant lesions via the mSWAT and response assessment in skin.  
• Skin biopsies : In situations in which there is substantial reduction of skin lesions 
(especially when accompanied by disappearance of BPDCN from bone marrow or 
other sites), a skin biopsy is required. The mSWAT guidance states: “A biopsy of normal appearing skin is unnecessary to assign a complete response. However a skin biopsy should be performed of a representati ve area of the skin if there is any 
question of residual disease (persistent erythema or pigmentary change) where otherwise a complete response would exist” ( Olsen et al. 2011).  
• CT scans  of index lesions 21 (±7) days after the start of Cycles 2, 4 and 6 and 
21 (±7) days after the start of every 4
th cycle thereafter (for patients with baseline 
evidence of lymph node or visceral disease) until there is evidence of relapsed or progressive disease. For patients with no baseline evidence of lymph node or viscer al 
BPDCN involvement, subsequent scans should be performed at the end of Cycle 2 (±7 days; or at time of disease progression (PD) if PD occurs prior to end of Cycle 2), 21 (±7) 
days after the start of Cycle 6, and at Investigator’s discretion thereafter.  Baseline CT 
scans should be full-body (chest/ abdomen/pelvis), whereas follow-up scans should 
document response of index lesions ( Cheson et al.  2007). 
• During Stages 2 -4, subsequent to the end of Cycle 2, imaging at intervals less 
frequent than those stipulated above may be permitted when required by local 
regulations; however, this must be reviewed with the Medical Monitor (or designee).  
• For patients in Stages 2 -4, elect ronic copies of all baseline and subsequent CT scans 
will be submitted to a central archive (scans are to be submitted regardless of the presence/absence of BPDCN -related abnormalities).  
• Collection of peripheral blood samples  for determination of blasts 21 (±7) days after the 
start of Cycles 1 and 2. Patients with evidence of peripheral blasts at baseline will also have peripheral blood samples collected 21 (±7) days after the start of every 2
nd cycle 
thereafter (Cycles 4, 6, etc.) until there is evidence o f relapsed or progressive disease.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  63 CONFIDENTIAL  Tumor response will be assessed by the Investigators for all patients with BPDCN, with the 
Investigator’s assessment to be used in the primary analysis. As a supportive assessment, tumor response was also evaluated by an IRC on a pre- specified subset of patients.  Tumor response will 
be assessed using the Tumor Response Criteria for Patients with BPDCN  presented in Section 
16.2, Appendix B. All patients will also be followed for DOR and survival until study 
completion . 
8.13 Pharmacokinetic Studies  
An intensive schedule for collection of blood samples after specific infusions during Cycle 1  and 
3 of SL-401 will be used to determine plasma concentrations of SL -401. During Stage 1 and 
early portions of Stage 2, PK assessment was conducted on samples for all patients.  
The concentration of SL- 401 in plasma samples will be determined by a sensitive and specific 
sandwich enzyme -linked immunosorbent assay method at a contract laboratory according to 
industry GLP bioanalytical practices.  Plasma concentration data over time w ill be used to 
characterize the PK disposition of SL-401, to assess any change in the PK properties of SL-401 during the 5- day course of treatment or between cycles of treatment, and relate the PK 
characteristics of SL -401 to immunogenicity, toxicity, and disease activity.  
Collectively, the SL -401 plasma concentration- time data will be analysed by conventional 
noncompartmental PK methods to define the fundamental PK properties of SL-401. Furthermore, if supported by the adequacy of the data, a population PK model will be developed, in which the effects of various potentially relevant co- variants (i.e., gender, age, IL -3R 
expression, immunogenicity) on relevant PK parameters, will be evaluated.  Sample collection 
requires that the actual date and time (24 -hour clock) that the SL -401 treatment begins (start of 
infusion, SOI) and ends (end of infusion, EOI) will be recorded as will be the date and time (24-hour clock time) of all blood samples.  
Detailed instructions for collecting, processing, storing, and shipping the samples are provided in 
a separate procedure manual .
 
 
Bloo
d samples will be collected into ethylenediamine tetraacetic acid ( EDTA) tubes (lavender 
top, at least 6mL each); upon collection the samples should be inverted gently several times to 
ensure adequate mixing of the EDTA anticoagulant and whole blood. Within approximately 
30 minutes of col lection, samples should be centrifuged in a refrigerated centrifuge to separate 
the plasma.  An aliquot of the plasma (>1 mL) will be transferred to a clean tube, tightly sealed, 
labelled appropriately and stored frozen at -70 C or below prior to analysis in the validated 
immunoassay.  
Samples will be collected immediately prior to the start of the infusion of SL -401, immediately 
after end of infusion (time recorded), then 1 5, 30, 45, 60, 90, 120, 180 and 240 minutes after the 
completion  of the infusion (see Table 9 in  Section  9.8). It is recognized that it is not always 
possible to obtain the spe cimens at the precise time  points specified above, although it requested 

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  64 CONFIDENTIAL  that sites make every effort to do so; it is essential that the precise time of infusion and times of 
subsequent pharmacokinetic sampling be recorded diligently.  
The nominal blood sa mpling time schedule is summarized  in Table 9 ( in Section  9.8) for the 
following SL-401 treatment days: 
• Cycle 1, infusion 1 (i.e. , Study Day 1) . 
• Cycle 1, infusion 5 (i.e., usually Study Day 5). 
• Cycle 3, infusion 1 (i.e., Day 1 of Cycle 3 ). 
• Cycle 3, infusion 5 (i.e., usually Day 5 of Cycle 3 ). 
8.14 Immunogenicity Studies  
Peripheral  blood samples ( 10 mL) will be collected (serum red top tube, no additive) for the 
detection and characterization of SL -401 reactive antibodies according to the following schedule: 
• Cycle 1:  Day 1 (pre-infusion), Day 15 ( ±3 days) , and Day 21 ( ±3 days) . 
• Cycle 2, 3, 4, 5, or 6: Day 1 (pre -infusion) and Day 21 ( ±3 days) . Note:  A separate Day 1 
(pre-infusion) sample does not need to be drawn if the Day 21 sample from the prior 
cycle has been drawn no more than 24 hours prior to the first infusion of the next cycle to 
be given.  In that case, the data for the Day 21 sample may be used both as the Day 21 
sample for the prior infusion as well as the Day 1 (pre-infusion) sample, avoiding the 
necessity to draw 2 blood samples in close proximity.  
• A blood sample for immunogenicity studies will be collected between  16 weeks and 
20 weeks after the last SL -401 dose. 
• If there are clinical manifestations suggesting either an infusion related reaction or drug 
hypersensitivity, an immunogenicity sample should be obtained.  
• If infusions are held (postponed) for any reason, an immunogenicity sample must be 
collected within 3 ±3 days after completion of the last SL -401 infusion for the cycle.  
 
Detailed instructions for collecting, processing, storing, and shipping the samples will be 
provided in a separate procedure manual. 
In the setting of detection of SL -401 reactive antibodies, plasma  from corresponding specimens 
will be evaluated for SL-401 levels ( PK analysis).  Plasma  from patients without SL -401 reactive 
antibodies would then be utilized as a control for this PK analysis.   

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  65 CONFIDENTIAL  Following the required immunogenicity and pharmacokinetic evaluations, if additional serum or 
plasma  is available, this serum and/or plasma may be used for evaluation of other relevant 
markers (for example IL -3 levels) if considered appropriate by the Sponsor or Investigator. 
9 Schedule of Events  
The study schedule of events is summarized in Table 5, Table 6, Table 7, and Table 8 (in 
Section  9.8). 
9.1 Study Day -14 to -4: Screening  
The following evaluations will be performed on Study Day -14 to -4 to determine the patient’s 
eligibility for the study and in anticipation of study treatment.  
All Patients, All Study Stages: 
• Informed Consent  
• Inclusion / Exclusion criteria  
• Medical history, including prior therapy and concomitant medications  
• ECOG performance status  
• Physical examination  
• Urine or serum pregnancy test 
• Vital signs and weight  
• 12-lead ECG  
• ECHO or MUGA scan  (within 28 days prior to start of first cycle of study treatment)  
• Clinical laboratory tests: hematology,  serum electrolytes  and chemistry  (including 
albumin ), coagulation parameters, and urinalysis 
• Bone marrow aspiration (± biopsy) within 14 days prior to start of first cycle of study treatment . If CD123 flow cytometry or IHC stain was performed on the bone marrow 
aspirations (± biopsy), the results should be recorded in the eCRF.  
Patients with BPDCN Only  
• Full-body CT scan  (chest/abdomen/pelvis) within 14 days prior to start of first cycle of 
study treatment 
• Skin assessment  within 14 days prior to start of first cycle of study treatment (including 
quantification using mSWAT)  
Investigators will maintain a confidential log of all patients who have been screened for participation in the study whether or not the patient was eligible for study participation.  
9.2 Study Day -1 to 0: Procedures Prior to Start of Treatment 
All Patients, All Study Stages: 
• Concomitant medication assessment 
• Physical examination  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  66 CONFIDENTIAL  • Vital signs and weight  
• 12-lead ECG  
• Clinical laboratory tests: hematology, serum electrolytes and chemistry (including 
albumin) 
9.3 Cycle 1  
9.3.1 Study Days 1 – 5 (Up to Study Day 10 if Infusion(s) Held): Pre -Infusion 
All Patients, All Study Stages: 
• Inpatient admission (Study Day 1) 
• Vital signs and weight (pre -treatment weight should be recorded on each day for which 
an SL-401 infusion is planned) 
• AE and SAE monitoring 
• Clinical laboratory tests: hematology, serum electrolytes and chemistry (including 
albumin), coagulation parameters, and urinalysis 
• Collection of peripheral blood for immunogenicity (infusion 1) and PK sampling 
(infusions 1 and 5) immediately prior to the start of the infusion 
• 12-lead ECG  each day of infusion (Infusions 1 and 5 of Cycle s 1 and 3 will be triplicates  
at the specified timepoin ts) 
• Diphenhydramine 50 mg IV 60 minutes prior to infusion 
• Acetami nophen 650 mg PO (or equivalent dose of paracetamol) 60 minutes prior to 
infusion 
• Methylprednisolone 50 mg IV (or an equivalent dose of another corticosteroid) 
60 minutes prior to infusion 
• Ranitidine 50 mg IV (or an equivalent doses of another H 2-histamine  antagonist) 
60 minutes prior to infusion 
9.3.2 Study Days 1 – 5 (Up to Study Day 10 if Infusion(s) Held): Infusion 
All Patients, All Study Stages: 
• 12-lead ECG ( infusions 1 and 5) performed at 3 distinct time points (triplicates) within 5 
minutes prior to each PK sample collection at 30 and 60 minutes post-infusion 
• Collection of peripheral blood for PK sampling ( infusions 1 and 5) collected immediately 
after end of infusion (time r ecorded), then  15, 30, 45, 60, 90, 120, 180 and 240 minutes 
after the completion of the infusion 
• 15-minute IV infusion of SL-401 at required dose  
• Vital signs: immediately after completion of infusion and 30, 60, and 240 minutes post-
infusion 
• Monitoring for at least 4 hours 
• AE and SAE monitoring 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  67 CONFIDENTIAL  9.3.3 Study Day 8 ±3 D ays, or 3 ±3 Days  after Completion  of Infusions if Infusion(s) Held 
All Patients, All Study Stages: 
• Concomitant medication assessment 
• Physical examination  
• Vital signs and weight  
• Clinical laboratory  tests: hematology, serum electrolytes and chemistry (including 
albumin), coagulation parameters, and urinalysis 
• AE and SAE monitoring 
9.3.4 Study Day 15 ±3 D ays 
All Patients, All Study Stages: 
• Concomitant medication assessment 
• Physical examination  
• Vital signs a nd weight 
• Clinical laboratory tests: hematology, serum electrolytes and chemistry (including 
albumin), coagulation parameters, and urinalysis 
• AE and SAE monitoring 
9.3.5 Study Day 2 1 ±7 D ays: End of Cycle  
Note:  The end -of-cycle evaluations (Day 21 or thereafter) may also serve as the pre-infusion 
evaluations for the subsequent cycles; with the exception of vital signs, these do not need to 
be duplicated on successive days unless there is an abnormality or other clinically relevant 
reason for repeat evaluation.  
All Patients, All Study Stages: 
• Concomitant medication assessment 
• ECOG performance status  
• Physical examination  
• Vital signs and weight  
• 12-lead ECG  
• Clinical laboratory tests: hematology, serum electrolytes an d chemistry (including 
albumin), coagulation parameters, and urinalysis 
• Tumor response assessment: bone marrow aspiration (± biopsy) and peripheral blood 
sample  (AML and BPDCN) . If the Cycle 1 (Day 21  [±7]) bone marrow examination is 
empty (i.e., hypocellular) or inadequate, a bone marrow examination should be repeated in 7 (±7) days to document response. If additional time is required to complete the repeat 
examination, consult with the Medical Monitor. If CD123 flow cytometry or IHC stain was performed on the bone marrow aspirations (± biopsy), then the results should be 
recorded in the eCRF.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  68 CONFIDENTIAL  • Collection of peripheral blood (serum) for immunogenicity   
• Monitoring for changes in visual acuity and color vision 
• AE and SAE monitoring 
Patients with BPDCN Only: 
• Tumor response assessment: skin , including mSWAT 
9.3.6 Study Day 28 ±3 Days, Then Every 7 ±3 days: Delayed End of Cycle for Toxicity 
Resolution Only if Required 
All Patients, All Study Stages: 
• Concomitant medication assessment 
• ECOG performance status  
• Vital signs and weight 
• 12-lead ECG  
• Clinical laboratory tests: hematology, serum electrolytes and chemistry (including 
albumin), coagulation parameters, and urinalysis 
• AE and SAE monitoring 
9.4 Cycles 2 – 6 
Note:  The end -of-cycle evaluations (Day 21 or thereafter) may also serve as the pre-infusion 
evaluations for the subsequent cycles; with the exception of vital signs, these do not need to 
be duplicated on successive days unless there is an abnormality or other clinically relevant 
reason for repeat evaluation.  
9.4.1 Days 1 – 5 (Up to Day 10 if Infusion(s) Held): Pre -Infusion 
All Patients, All Study Stages: 
• Inpatient admission (Day 1) or treatment at a suitable outpatient facility  
• Vital signs and weight  
• AE and SAE monitoring 
• Clinical laboratory tests: hematology, serum electrolytes and chemistry (including 
albumin), coagulation parameters, and urinalysis 
• 12-lead ECG each day of infusion (Infusions 1 and 5 of Cycles 1 and 3 will be triplicates 
at the specified timepoints)  
• Collection of peripheral blood (plasma) for PK sampling ( Cycle 3  only, infusions 1 and 
5) immediately prior to the start of the infusion  
• Diphenhydramine 50 mg IV 60 minutes prior to infusion 
• Acetaminophen 650 mg (or equivalent dose of paracetamol) PO 60 minutes prior to 
infusion 
• Methylprednisolone 50 mg IV (or an equivalent dose of another corticosteroid) 60 minutes prior to infusion 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  69 CONFIDENTIAL  • Ranitidine 50 mg IV (or an equivalent doses of another H 2-histamine antagonist) 60 
minutes prior to infusion 
9.4.2 Days 1 – 5 (Up to Day 1 0 if Infusion(s) Held): Infusion 
All Patients, All Study Stages: 
• 12-lead ECG (Cycle 3  only, infusions 1 and 5) performed at 3 distinct time points 
(triplicates) within 5 minutes prior to each PK sample collection at 30 and 60 minutes 
post-infusion 
• Collection of peripheral blood (plasma) for PK sampling ( Cycle 3  only, infusions 1 and 
5) collected immediately after end of infusion  (time recorded), then  15, 30, 45, 60, 90, 
120, 180 and 240 minutes after the completion of the infusion 
• 15-minute IV infusion of SL-401 at required dose  
• Vital signs : immediately after completion of infusion and 30, 60, and 240 minutes post-
infusion 
• Monitoring for at least 4 hours 
• AE and SAE monitoring 
9.4.3 Day 8 ± 3 Days, or 3 ±3 Days after Completion of Infusions if Infusion(s) Held  
All Patients, All Study Stages: 
• Concomitant medication assessment 
• Physical examination  
• Vital signs and weight  
• Clinical laboratory tests: hematology, serum electrolytes and chemistry (including 
albumin), coagulation parameters, and uri nalysis  
• AE and SAE monitoring 
9.4.4 Day 15 ±3 D ays 
All Patients, All Study Stages: 
• Concomitant medication assessment 
• Physical examination  
• Vital signs and weight  
• Clinical laboratory tests: hematology, serum electrolytes and chemistry (including 
albumin), coagulation parameters, and urinalysis 
• AE and SAE monitoring 
9.4.5 Day 21 ±7 Days: End of Cycle 
Note:  The end -of-cycle evaluations (Day 21 or thereafter) may also serve as the pre-infusion 
evaluations for the subsequent cycles; with the exception of vital signs, these do not need to be duplicated on successive days unless there is an abnormality or other clinically relevant reason for repeat evaluation.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  70 CONFIDENTIAL  All Patients, All Study Stages: 
• Concomitant medication assessment 
• ECOG performance status  
• Physical examination  
• Vital signs and weight  
• 12-lead ECG  
• Clinical laboratory tests: hematology, serum electrolytes an d chemistry (including 
albumin), coagulation parameters, and urinalysis 
• Collection of peripheral blood for immunogenicity (serum)  
• Monitoring for changes in visual acuity and color vision 
• AE and SAE monitoring 
Patients with BPDCN Only: 
• Tumor response assessment: CT scan of index lesions as follows: 
• Stage 1: Cycles 2 and 4 and every 4th cycle thereafter .  
• Stages 2-4 with baseline BPDCN involving lymph nodes or viscera: Cycles 2, 4, and 
6 and following every 4th cycle thereafter . Without baseline BPD CN i nvolving lymph 
nodes or viscera: Cycles 2, 6 and at Investigator’s discretion thereafter. 
• Tumor response assessment: skin (Cycles 2, 4, and 6, and every 2 cycles thereafter ), 
including mSWAT 
Stages 2-4 
• Tumor response assessment: bone marrow aspiration (± biopsy). Bone marrow will be 
collected subsequent to  Cycles 2, 4 and 6 and then every 3 months from Months 6-12; 
every 6 months from 12 to 24 months; and every 12 months thereafter until there is 
evidence of relapsed or progressive disease. If CD123 flow c ytometry or IHC stain was 
performed on the bone marrow aspirations (± biopsy), the results should be recorded in 
the eCRF.  
• Collection of peripheral blood samples for determination of blasts 21 (±7) days after the start of Cycle 2, and, for patients with evidence of peripheral blasts at baseline, 21 (±7) days after the start of Cycles 1 and 2 and 21 (±7) days after the start of every 2nd cycle thereafter (Cycles 4, 6, etc.) until there is evidence of relapsed or progressive disease. 
9.4.6 Day 28 ±3 Days, Then Every 7 ±3 days: Delayed End of Cycle for Toxicity Resolution  
Only if Required 
All Patients, All Study Stages: 
• Concomitant medication assessment 
• ECOG performance status  
• Vital signs and weight  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL ): 17 January 2019  71 CONFIDENTIAL  • 12-lead ECG  
• Clinical laboratory tests: hematology, serum electro lytes and chemistry (including 
albumin), coagulation parameters, and urinalysis 
• AE and SAE monitoring 
9.5 End of Treatment 
All Patients, All Study Stages: 
• ECOG performance status  
• Physical examination  
• Vital signs and weight  
• Monitoring for changes in visual acui ty and color vision 
9.6 Safety Monitoring: Through 30 D ays after Last Infusion 
All Patients, All Study Stages: 
• AE and SAE monitoring 
• Survival status 
9.7 Survival Monitoring: Approximately Every 90 D ays after End of Treatment  until Study 
Completion  
Patients in PR/CR at End of Treatment:  
• Survival status and response/disease progression status, continuing until 
assessments of the primary and secondary objectives are completed for all 
patients; survival status may be performed by telephone contact.  
• Patients who undergo SCT will be followed for the occurrence of VOD and 
delayed or failed engraftment  as part of survival monitoring. 
9.8 Schedules of Events 
The study schedule of events is summarized in Table 5, Table 6, Table 7, and Table 8. 
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019   72 CONFIDENTIAL  Table 5: Study Events Schedule for Cycle 1 (Study Day -14 to Study Day 21) : Stage 1 (All Pts) & Stage 2 (AML Pts ) 
Tests and Observations  Study Day    
-14 to -4 Cycle 1  
Study Day      
-1 to 0  Study Days 1 -5 (Up to Study 
Day 10 if Infusion(s) Held)  
SL-401 Treatme nt 
Study Day  
8±3(q) and 
15±3 Study Day  
21±7 Study Day 28± 7, 
Then Every 7± 3 days  
 
Screening  Pre- 
treatment  Pre-Infusion  Infusion  End of Cycle  Delayed End of Cycle 
for Toxicity Resolution 
Only if Required  
Informed consent form X       
Inclusion/exclusion criteria X       
Medical history including prior therapy, 
concomitant medications  X       
Concomitant Medications   X   X X X 
ECOG performance status  X     X X 
Physical examination  X X   X X  
Pregnancy test (a) X       
Vital signs and weight(b) X X X X X X X 
12-lead ECG(c) X X X  X (Infusions 1, 5)   X X 
ECHO or MUGA scan(d) X       
Hematology(e) X X X  X X X 
Serum electrolytes(f) X X X  X X X 
Serum albumin(g) X X X  X X X 
Serum chemistry(h) X X X  X X X 
Coagulation parameters: PT/INR, aPTT  X  X  X X X 
Urinalysis(i)  X  X (Infusion 1)   X X X 
Tumor response assessment: Bone marrow 
aspiration ± biopsy(j) X     X  
Tumor response assessment: CT scan(k) X       
Tumor response assessment: Skin, including 
biopsies and/or photographs(l) X     X  
Tumor response assessment:  Peripheral blood       X  
Administration of premeds (m)   X     
SL-401 administration(n)    X    
Pharmacokinetic sampling(o)    X (Infusions 1, 5)   X (Infusions 1, 5)     
Immunogenicity sampling(p)    X (Infusion 1)   X (Day 15)  X  
AE and SAE monitoring    X X X X X 
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019   73 CONFIDENTIAL  (a) Urine or serum pregnancy test must be performed within 1 week prior to treatment in women of childbearing potential.  
(b) Vital signs should be performed after patient is sitting for 3 -5 minutes.  If during dosing period, vital signs should be taken immediately prior to infusion, immediately after 
completion of infusion, and 30, 60, and 240 minutes post -infusion.  
(c) All patients will have a 12 -lead ECG performed at the screening visit and pre -treatment visit, as well as Day 21 (and Day 28 only if delayed end of cycle) of each cycle. 
During the days when patients are undergoing PK sampling (Cycle 1, infusions 1 and 5; Cycle 3, infusions 1 and 5), an ECG will be perfor med at 3 distinct time points 
(triplicates) within 5 minutes prior to each PK sample collection pre -infusion and at 30 and 60 minutes post -infusion (see (p) and Table 9). 
(d) MUGA or 2 -D ECHO to quantify left ventricular ejection fraction (LVEF).  Must be completed within 28 days prior to start of first cycle of study treatment.  
(e) To be collected prior to SL -401 infusion if during dosing period.  Hematology includes White blood cell (WBC) count, differential white cell count, red blood cell count, 
hematocrit, hemoglobin and platelet count.  
(f) To be collected prior to SL -401 infusion if during dosing period.  Electrolyte s include sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN), and creatinine.   
(g) To be collected prior to SL -401 infusion if during dosing period.  Serum albumin may be a component of the chemistry panel (h).  See protocol for administration of albumin if 
serum albumin decreases during treatment days or in the immediate post -treatment period.  
(h) To be collected prior to SL -401 infusion if during dosing period.  Serum electrolytes and chemistry : Sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN), 
creatinine, glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase, (AST), bilirubin (total, direct, and indirect), calcium, 
creatine phosphokinase (CPK), magnesium, lactate dehydrogenase (LD H), phosphate, total protein, uric acid  
(i) To be collected prior to SL -401 infusion if during dosing period.  Urinalysis includes appearance, color, pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin, 
urobilinogen, and occult blood.  
(j) Morphology and differential WBC/blast count on aspirate.  Baseline must be performed within 14 days prior to the first administration of SL -401.  Subsequent bone marrow 
aspirates (± biopsy) will be performed 21 (± 7) days after the start of Cycles 1  and 2, and at the Investigator ’s discretion thereafter until there is evidence of relapsed or 
progressive disease.  If the Cycle 1 (Day 21 [±7]) bone marrow aspirate (±biopsy) is empty, hypocellular, or inadequate, a bone marrow examination should be repeated within 
7 (±7) days to document response.  During Stage 2, AML patients will also have bone marrow evaluations following Cycles 4 and 6, and at the Investigator ’s discretion prior 
to end of treatment and thereafter.  If CD123 flow cytometry or IHC stain was performed  on the bone marrow aspirations (± biopsy), the results should be recorded in the 
eCRF. 
(k) BPDCN patients only.  Baseline must be performed within 14 days prior to the first administration of SL -401.  Subsequent CT scans will be performed 21 (± 3) days after the  
start of Cycle 2  and 4 and 21 (± 7) days after the start of every 4th cycle thereafter  until there is evidence of relapsed or progressive disease.  Baseline CT  scans should be full -
body, whereas  follow -up scans should document response of index lesions.  
(l) BPDCN patients only, with biopsies and/or photographs for patients with skin involvement.  Baseline must be performed within 14 days prior to the first administration of Sl -
401. Subsequent skin assessments will be performed 21 (±3 ) days after the start of Cycles 1 and 2 and 21 (±7 ) days after the start of every 2nd cycle thereafter ( Cycle s 4, 6, 
etc.) until there is evidence of relapsed or progressive disease.  
(m) Refer to protocol Section 7.5.3.1  – Premedication  
(n) Following treatment with premedication, SL -401 will be administered as a 15-minute infusion for the first 5 consecutive days of a 21-day cycle.  Individual SL -401 infusions 
may be delayed to allow for toxicity resolution, all infusions should be completed within 10 days  and fewer than 5 infusions are permitted in settings of incipient CLS or 
hepatotoxicity . Patient s must be monitored for 4 hours post infusion.  
(o) Plasma samples (6  mL each) will be collected immediately prior to the start of the infusion of SL -401, immediately after end of infusion (time recorded), then 15, 30, 45, 60, 
90, 120, 180, and 240 minutes after completion of the infusion during infusions 1 (i.e., Study Day 1) and 5 (i.e., Study Day 5) (see (c)  and Table 9). 
(p) Blood samples ( 10 mL) will be collected for the detection of SL -401 reactive antibodies according on Day 1 (pre -infusion), Day 15, and Day 21 (if patient is to receive 
Cycle  2, can be Day 1, pre-infusion for Cycle 2 ). If infusions are held, please collect a sample within 3±3 days after the last  SL-401 infusion(s) of the cycle.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019   74 CONFIDENTIAL  Table 6: Study Events Schedule for Cycles 2 -6 and Subsequent Cycles : Stage 1 (All Pts) & Stage 2 (AML Pts)  
Tests and Observations  Cycle 2+  
End of 
Treatment  Safety: 
Through 
30 Days 
After Last 
Infusion  Survival: 
Every 90 
Days After 
Last Infusion  Days  1-5 (Up to Day 10 if 
Infusion(s) Held)  
SL-401 Treatment  
Day 
8±3(q) and 
15±3 Day 
21±3 Day 28± 3, Then Every 
7±3 days  
Pre-Infusion  Infusion  End of Cycle  Delayed End of Cycle 
for Toxicity Resolution 
Only if Required  
Medical history including prior therapy, 
concomitant medications          
Concomitant Medications    X X X    
ECOG performance status     X X X   
Physical examination    X X  X   
Vital signs and weight(a) X X X X X X   
12-lead ECG(b) X X (Cycle 3, 
Infusions 1, 5)   X X    
Hematology(c) X  X X X    
Serum electrolytes(d) X  X X X    
Serum albumin(e) X  X X X    
Serum chemistry(f) X  X X X    
Coagulation parameters: PT/INR, aPTT  X  X X X    
Urinalysis(g) X 
(Infusion 1)   X X X    
Tumor response assessment: Bone marrow 
aspiration ± biopsy(h)      X (h)      
Tumor response assessment: CT scan(i)    X      
Tumor response assessment: skin, including 
biopsies and/or photographs(j)    X     
Tumor response assessment:  peripheral blood     X(k)     
Administration of premeds (l) X        
SL-401 administration(m)  X       
Pharmacokinetic sampling(n) X (Cycle 3, 
Infusions 1, 5)  X (Cycle 3, 
Infusions 1, 5)        
Immunogenicity sampling(o) X 
(Infusion 1)    X     
AE and SAE monitoring  X X X X X  X  
Long -term follow -up(p)       X X 
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019   75 CONFIDENTIAL  (a) Vital signs should be performed after patient is sitting for 3 -5 minutes.  If during dosing period, vital signs should be taken immediately prior to infusion, immediately after 
completion of infusion, and 30, 60, and 240 minutes post -infusion.  
(b) All patients will have a 12 -lead ECG performed at the screening visit and pre-treatment visit, as well as Day 21 (and Day 28 only if delayed end of cycle) of each cycle. 
During the days whe n patients are undergoing PK sampling (Cycle 1, infusions 1 and 5; Cycle 3, infusions 1 and 5), an ECG will be performed at 3 distinct time points 
(triplicates) within 5 minutes prior to each PK sample collection pre -infusion and at 30 and 60 minutes post -infusion (see footnote (n) and Table 9). 
(c) To be collected prior to SL -401 infusion if during dosing period.  Hematology includes White blood cell (WBC) count, differential white cell count, red blood cell count, 
hematocrit, hemoglobin and platelet count.  
(d) To be collected prior to SL -401 infusion if during dosing period.  Electrolytes include sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN ), and creatinine.   
(e) To be collected prior to SL -401 infusion if during dosing period.  Serum albumin may be a component of the chemistry panel (f).  See protocol for administration of albumin if 
serum albumin decreases during treatment days or in the immediate post -treatment period.  
(f) To be collected prior to SL -401 infusion if during dosing period.  Serum electrolytes and chemistry : Sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN), 
creatinine, glucose, alanine aminotransferase (ALT), albumin,  alkaline phosphatase (ALP), aspartate aminotransferase, (AST), bilirubin (total, direct, and indirect), calcium, 
creatine phosphokinase (CPK), magnesium, lactate dehydrogenase (LDH), phosphate,  total protein, uric acid  
(g) To be collected prior to SL -401 infusion if during dosing period.  Urinalysis includes appearance, color, pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin, 
urobilinogen, and occult blood.  
(h) Morphology and differential WBC/blast count on aspirate.  Bone marrow aspirates (± biopsy) will be performed 21 (± 7) days after the start of Cycle  2, and, in Stage 1 , at the 
Investigator ’s discretion prior to end of treatment and thereafter until there is evidence of relapsed or progressive disease. During Stage 2, AML patients will also  have bone 
marrow evaluations following  Cycles 4 and 6 and then every 3 months from Months 6- 12; every 6 months from 12 to 24 months; and every 12 months thereafter until there is 
evidence of relapsed or progressive disease. If CD123 flow cytometry  or IHC stain  was performed on the bone marrow aspirations (± biopsy), the results should be recorded 
in the eCRF.  
(i) BPDCN patients only.  Baseline must be performed within 14 days prior to the first administration of SL -401.  In Stage 1, subsequent CT scans will be p erformed  21 (± 7) days 
after the start of Cycle 2  and 4 and 21 (± 7) days after the start of every 4th cycle thereafter  until there is evidence of relapsed or progressive disease.  Baseline CT  scans should 
be full -body, whereas  follow -up scans should document response of index lesions.  
(j) BPDCN patients only, with biopsies and/or photographs  for patients with skin involvement.  Baseline must be performed within 14 days prior to the first administration of S L-
401. Subsequent skin ass essments will be performed 21 (±7 ) days after the start of Cycle s 1 and 2 and 21 (±7 ) days after the start of every 2nd cycle thereafter ( Cycle s 4, 6, 
etc.) until evidence of relapsed or progressive disease. Quantification of disease burden via the mSWAT is required at the time of each skin assessment.  
(k) Patients with evidence of peripheral blasts at baseline will have p eripheral blood samples collected 21 (±7) days after the start of Cycles 1 and 2 and 21 (±7) days after the 
start of every 2nd cycle thereaf ter (Cycles 4, 6, etc.)  until there is evidence of relapsed or progressive disease.  
(l) Refer to protocol Section 7.5.3.1  – Premedication  
(m) Following tre atment with premedication, SL -401 will be administered as a 15-minute infusion for the first 5 consecutive days of a 21-day cycle.  Individual SL -401 infusions 
may be delayed to allow for toxicity resolution ; all infusions should be completed within 10 days  and fewer than 5 infusions are permitted in settings of incipient CLS or 
hepatotoxicity . Patient s must be monitored for 4 hours post infusion.  
(n) Plasma samples (6  mL each) will be collected immediately prior to the start of the infusion of SL -401, immediately after end of infusion (time recorded), then 15, 30, 45, 60, 
90, 120, 180, and 240 minutes after the start of the infusion during infusions 1 (i.e., Day 1) and 5 (i.e., Day 5) of Cycle 3 (see footnote (b) and Table 9).  
(o) Blood samples ( 10 mL) will be c ollected for the detection of SL -401 reactive antibodies according on Day 1 (pre -infusion), Day 15, and Day 21 (if patient is to receive 
additional cycles, can be Day 1, pre-infusion for next cycle).  If infusions are held, please collect a sample within 3±3 days the last  SL-401 infusion(s) of the cycle.  
(p) After the follow -up visit, patients will then be followed every 90 days for survival status.  The survival follow -up may be by telephone contact . If the patient is in CR/PR at the 
time of discontinuation, disease assessments should continue to be performed as described in Section 8.11 on an every 6-week basis (±1 week) through 6 months post -C1D1 
and then on an every 90-day basis or until, in the judgment of the Investigator, there is evidence of relapsed or progressive disease.   
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019   76 CONFIDENTIAL  Table 7: Study Events Schedule for Cycles 1 & 2 (Study Day -14 to Study Day 21): BPDCN Patients in Stages 2-4 
Tests and Observations  Study Day    
-14 to -4 Cycles 1 & 2  
Study Day  
-1 to 0  Cycle Days 1 -5 (Up to Study 
Day 10 if Infusion(s) Held)  
SL-401 Treatment  
Study Day  
8±3(q) and 
15±3  Cycle Day  
21±7  Cycle Day 28±7,  
Then Every 7±3 days  
 
Screening  Pre- 
treatment  Pre-Infusion  Infusion  End of Cycle  Delayed End of Cycle 
for Toxicity Resolution 
Only if Required  
Informed consent form X       
Inclusion/exclusion criteria X       
Medical history including prior therapy, 
concomitant medications  X       
Concomitant Medications   X   X X X 
ECOG performance status  X     X X 
Physical examination  X X   X X  
Pregnancy test (a) X       
Vital signs and weight(b) X X X X X X X 
12-lead ECG(c) X X X  X (Infusions 1, 5)   X X 
ECHO or MUGA scan(d) X       
Hematology(e) X X X  X X X 
Serum electrolytes(f) X X X  X X X 
Serum albumin(g) X X X  X X X 
Serum chemistry(h) X X X  X X X 
Coagulation parameters: PT/INR, aPTT  X  X  X X X 
Urinalysis(i)  X  X (Infusion 1)   X X X 
Tumor response assessment: Bone marrow 
aspiration ± biopsy(j) X     X  
Tumor response assessment: CT scan(k) X     X (Cycle 2) (k)  
Tumor response assessment: Skin, including 
biopsies and/or photographs(l) X     X  
Tumor response assessment:  Peripheral blood       X  
Administration of premeds (m)   X     
SL-401 administration(n)    X    
Pharmacokinetic sampling(o)    X (Infusions 1, 5)   X (Infusions 1, 5)     
Immunogenicity sampling(p)    X (Infusion  1)  X 
(C1D15 only)  X  
Vision assessment  X     X  
AE and SAE monitoring    X X X X X 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019   77 CONFIDENTIAL  (a) Urine or serum pregnancy test must be performed within 1 week prior to treatment in women of childbearing potential.  
(b) Vital signs should be performed after patient is sitting for 3 -5 minutes.  If during dosing period, vital signs should be taken immediately prior to infusion, immediately after 
completion of infusion, and 30, 60, and 240 minutes post -infusion.  
(c) All patients will have a 12 -lead ECG performed at the screenin g visit and pre -treatment visit, as well as Day 21 (and Day 28 only if delayed end of cycle) of each cycle. 
During the days when patients are undergoing PK sampling (Cycle 1, infusions 1 and 5; Cycle 3, infusions 1 and 5), an ECG will be performed at 3 dis tinct time points 
(triplicates) within 5 minutes prior to each PK sample collection pre -infusion and at 30 and 60 minutes post -infusion (see (p) and Table 9). 
(d) MUGA or 2 -D ECHO to quantify left ventricular ejection fraction (LVEF).  Must be completed within 28 days prior to start of first cycle of study treatment.  
(e) To be collected prior to SL -401 infusion if during dosing period.  Hematology includes White  blood cell (WBC) count, differential white cell count, red blood cell count, 
hematocrit, hemoglobin and platelet count.  
(f) To be collected prior to SL -401 infusion if during dosing period.  Electrolytes include sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN), and creatinine.   
(g) To be collected prior to SL -401 infusion if during dosing period.  Serum albumin may be a component of the chemistry panel (h).  See protocol for administration of albumin if 
serum albumin decreases during treatment days  or in the immediate post -treatment period.  
(h) To be collected prior to SL -401 infusion if during dosing period.  Serum electrolytes and chemistry: Sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN), 
creatinine, glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase, (AST), bilirubin (total, direct, and indirect), calcium, 
creatine phosphokinase (CPK), magnesium, lactate dehydrogenase (LDH), phosphate, total protein, uric acid  
(i) To be collected pr ior to initial SL -401 infusion of the cycle.  Urinalysis includes appearance, color, pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin, 
urobilinogen, and occult blood.  
(j) Morphology and differential WBC/blast count on aspirate.  Baseline m ust be performed within 14 days prior to the first administration of SL -401.  For BPDCN patients in 
Stage s 2-4 , subsequent bone marrow aspirates (± biopsy) will be performed 21 (±7) days after the start of Cycles 1 and 2.  If the Cycle 1 (Day 21 [±7]) bone m arrow aspirate 
(± biopsy) is empty, hypocellular, or inadequate, a bone marrow examination should be repeated within 7 (±7) days to document  response . If CD123 flow cytometry stain was 
performed on the bone marrow aspirations (± biopsy), the results should be recorded in the eCRF.   
(k) Baseline CT must be performed within 14 days prior to the first administration of SL -401.  For patients with baseline evidence of lymph node or visceral disease involvement, 
subsequent Stage s 2-4 CT scans will be performed 21 (±7)  days after the start of Cycle s 2, 4 and 6, and 21 (±7) days after the start of every 4th cycle thereafter (approximately 
every 12 weeks) until there is evidence of relapsed or progressive disease.  For patients with no baseline evidence of lymph node or visceral BPDCN involvement, subsequent  
scans should be performed at the end of Cycle 2 (±7 days;  or at time of disease progression if PD occurs prior to end of Cycle 2), 21 (±7) days after the start of Cycle 6, and at 
Investigator ’s discretion thereafter . Baseline CT scan s should be full -body, whereas follow -up scans should document response of index lesions.  
(l) For patients with skin involvement.  Baseline must be performed within 14 days prior to the first administration of Sl -401.  Subsequent skin assessments will be performed 21 
(±7) days after the start of Cycle s 1 and 2 and 21  (±7) days after the start of every 2nd cycle thereafter ( Cycle s 4, 6, etc.) until there is evidence of relapsed or progressive 
disease. Quantification of sk in disease burden via the mSWAT instrument is required at the time of each skin assessment.   
(m) Refer to protocol  Section 7.5.3.1  – Premedication and Administration  
(n) Following treatment with premedication, SL -401 will be administered as a 15-minute infusion for the first 5 consecutive days of a 21-day cycle.  Individual S L-401 infusions 
may be delayed to allow for toxicity resolution; all infusions should be completed within 10 days and fewer than 5 infusions are permitted in settings of incipient CLS or 
hepatotoxicity.  Patient must be monitored for 4 hours post infusion.  
(o) Plasma samples (6 mL each) will be collected immediately prior to the start of the infusion of SL -401, immediately after end of infusion (time recorded), then 15, 30, 45, 60, 
90, 120, 180, and 240 minutes after completion of the infusion during infusions 1 (i.e., Study Day 1) and 5 (i.e., Study Day 5) of Cycles 1 & 3  (see Table 9).  
(p) Blood samples (10 mL) will be collected for the detection of SL -401 reactive antibodies on Day 1 (pre -infusion), Day 15, and Day 21 (if patient is to receive Cycle 2 , can be 
Day 1, pre -infusion for Cycle 2 ). If infusions are held, please collect a sample within 3±3 days after completion of the last SL -401 infusion of the cycle . 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019   78 CONFIDENTIAL  Table 8: Study Events Schedule for Cycles 3 -6 and Subsequent Cycles: Stages 2-4 (BPDCN Patients)  
Tests and Observations  Cycle 3+  
End of 
Treatment  Safety: 
Through 
30 Days 
After Last 
Infusion  Survival: 
Every 90 
Days After 
Last Infus ion Days1 -5 (Up to Day 10 if 
Infusion(s) Held)  
SL-401 Treatment  
Day 
8±3(q) and 
15±3(q) Day 
21±7  Day 28±7, Then Every 
7±3 days  
Pre-Infusion  Infusion  End of Cycle  Delayed End of Cycle 
for Toxicity Resolution 
Only if Required  
Medical history including prior therapy, 
concomitant medications          
Concomitant Medications    X X X    
ECOG performance status     X X X   
Physical examination     X  X   
Vital signs and weight(a) X X  X X X   
12-lead ECG(b) X X (Cycle 3, 
Infusions 1, 5)   X X    
Hematology(c) X  X X X    
Serum electrolytes(d) X  X X X    
Serum albumin(e) X  X X X    
Serum chemistry(f) X  X X X    
Coagulation parameters: PT/INR, aPTT  X  X X X    
Urinalysis(g) X (Infusion 1)   X X X    
Tumor response assessment: Bone marrow 
aspiration ± biopsy(h)     X(i)     
Tumor response assessment: CT scan(i)    X     
Tumor response assessment: skin, including 
biopsies and/or photographs(j)    X     
Tumor response assessment:  peripheral blood     X(k)     
Administration of premeds (l) X        
SL-401 administration(m)  X       
Pharmacokinetic sampling(n) X (Cycle 3, 
Infusions 1, 5)  X (Cycle 3, 
Infusions 1, 5)        
Immunogenicity sampling(o) X (Infusion 1)    X     
Vision assessment      X X   
AE and SAE  monitoring  X X X X X  X  
Long -term follow -up(p)       X X 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019   79 CONFIDENTIAL  (a) Vital signs should be performed after patient is sitting for 3 -5 minutes.  If during dosing period, vital signs should be taken immediately prior to infusion, immediately after 
completion of infusion, and 30, 60, and 240 minutes post -infusion.  
(b) All patients will have a 12 -lead ECG performed at the screening visit and pre-treatment visit, as well as Day 21 (and Day 28 only if delayed end of cycle) of each cycle. 
During the days when patients are undergoing PK sampling (Cycle 1, infusions 1 and 5; Cycle 3, infusions 1 and 5), an ECG will be performed at 3 distinct time points 
(triplicates) within 5 minutes prior to each PK sample collection pre -infusion and at 30 and 60 minutes post -infusion (see (m) and Table 9). 
(c) To be collected prior to SL -401 infusion if during dosing period.  Hematology includes White blood c ell (WBC) count, differential white cell count, red blood cell count, 
hematocrit, hemoglobin and platelet count.  
(d) To be collected prior to SL -401 infusion if during dosing period.  Electrolytes include sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN), and creatinine.   
(e) To be collected prior to SL -401 infusion if during dosing period.  Serum albumin may be a component of the chemistry panel (f).  See protocol for administration of albumin if 
serum albumin decreases during treatment days or i n the immediate post -treatment period.  
(f) To be collected prior to SL -401 infusion if during dosing period.  Serum electrolytes and chemistry: Sodium, potassium, bicarbonate, chloride, blood urea nitrogen (BUN), 
creatinine, glucose, alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase, (AST), bilirubin (total, direct, and indirect), calcium , 
creatine phosphokinase (CPK), magnesium, lactate dehydrogenase (LDH), phosphate, total protein, uric acid  
(g) To be collected prior t o initial SL -401 infusion of the cycle.  Urinalysis includes appearance, color, pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin, 
urobilinogen, and occult blood.  
(h) Morphology and differential WBC/blast count on aspirate . In Stage s 2-4 , patients with evidence of bone marrow involvement prior  to study will have bone marrow 
evaluations following  Cycles 4 and 6 and then every 3 months from Months 6-12; every 6 months from 12 to 24 months; and every 12 months thereafter until there is 
evidence of relapsed or progressive disease. If CD123 flow cytometry stain was performed on the bone marrow aspirations (± biopsy), the results should be recorded in the 
eCRF. 
(i) Baseline CT must be performed within 14 days prior to the first administration of SL -401.  For patients with baseline evidence of lymph node or visceral disease involvement, 
subsequent Stage s 2-4 CT scans will be performed 21 (±7) days after the start of Cycles 1 , 2, 4 and 6, and 21 (±7) days after the start of every 4th cycle thereafter 
(approximately every 12 weeks) until there is evidence of relapsed or progressive disease.  For patients with no baseline evidence of lymph node or visceral BPDCN 
involvement, subsequent scans should be performed at the end of Cycle 2 (±7 days; or at time of disease progression if PD occurs prior to end of Cycle 2), 21 (±7) days after 
the start of Cycle 6, and at Investigator ’s discretion thereafter . Baseline CT scan s should be full -body, whereas follow -up scans should document response of index lesions.  
(j) For patients with skin involvement.  Baseline must be performed within 14 days prior to the first administration of Sl -401.  Subsequent skin assessments will be performed 21 
(±7) days after the start of Cycle s 1 and 2 and 21  (±7) days after the start of every 2nd cycle thereafter ( Cycle s 4, 6, etc.)  until there is evidence of relapsed or progressive 
disease. Quantification of skin disease burden via the mSWAT instrument is required at the time of each skin assessment.  
(k) Peripheral blood samples will be collected 21  (±7) days after the start of Cycles 1 and 2 and, for patients with evidence of peripheral blasts at baseline,  21 (±7) days after the 
start of every 2nd cycle thereafter (Cycles 4, 6, etc.)  until there is evidence of relapsed or progressive disease. 
(l) Refer to protocol Section 7.5.3.1  – Premedication and Administration  
(m) Following treatment with premedication, SL -401 will be administered as a 15-mi nute infusion for the first 5 consecutive days of a 21-day cycle.  Individual SL -401 infusions 
may be delayed to allow for toxicity resolution; all infusions should be completed within 10 days and fewer than 5 infusions are permitted in settings of incipien t CLS or 
hepatotoxicity.  Patient must be monitored for 4 hours post infusion.  
(n) Plasma samples (6 mL each) will be collected immediately prior to the start of the infusion of SL -401, immediately after end of infusion (time recorded), then 15, 30, 45, 60, 
90, 120, 180, and 240 minutes after the start of the infusion during infusions 1 (i.e., Day 1) and 5 (i.e., Day 5) of Cycles 1 & 3  (see Table 9).  
(o) Blood samples (10 mL) will be collected for the detection of SL -401 reactive antibodies on Day 1 (pre -infusion), Day 15, and Day 21 (if patient is to receive additional cycles, 
can be Day 1, pre-infusion for next cycle).  If infusions are held, please collect a s ample within 3±3 days after the last SL -401 infusion of the cycle.  
(p) After the follow -up visit, patients will then be followed every 90 days for survival status.  The survival follow -up may be by telephone contact.  If the patient is in CR/PR at the 
time of discontinuation, disease assessments should continue to be performed as described in Section 8.12 on an every 6-week basis (±1 week) through 6 months  post-C1D1 
and then on an every 90-day basis or until, in the judgment of the Investigator, there is evidence of relapsed or progressive disease.  Patients who undergo SCT will be 
followed for the occurrence of VOD and delayed or failed engraftment as part of survival monitoring.  
(q) For Cycles 5 and beyond (Stage s 2-4 ), the Day 8 and 15 concomitant medication and AE evaluations may be conducted via telephone and the laboratory evaluations may be 
performed at local laboratories for patients who live a considerable distance from the study center.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  80 CONFIDENTIAL  Table 9: Time Points for Pharmacokinetic Blood Draws and ECGs 
Time Point  Cycle: Day/Dose  
Cycle 1:  
Day 1/ Infusion  1 Cycle 1:  
Day 5/ Infusion  5 Cycle 3:  
Day 1/ Infusion  1 Cycle 3:  
Day 5/ Infusion  5 
ECG  PK ECG  PK ECG  PK ECG  PK 
Pre-Infusion  X X X X X X X X 
Immediately After End of 
Infusion (time recorded)  X  X  X  X 
15 Minutes Post -Infusion   X  X  X  X 
30 Minutes Post -Infusion  X X X X X X X X 
45 Minutes Post -Infusion   X  X  X  X 
60 Minutes Post -Infusion  X X X X X X X X 
90 Minutes Post-Infusion   X  X  X  X 
120 Minutes Post -Infusion   X  X  X  X 
180 Minutes Post -Infusion   X  X  X  X 
240 Minutes Post -Infusion   X  X  X  X 
ECGs will be performed at 3 distinct time points (triplicates) within 5 minutes prior to each PK sample 
collection at the time points indicated.  
10 Adverse Events and Safety Evaluation 
The AE reporting period for a patient treat ed in the study begins with the initiation of SL -401 
and is continuous through 30 days after the last SL-401 infusion. All AEs that occur in treated 
patients during the AE reporting period specified in the protocol must be reported to the Sponsor 
or designee, whether or not the event is considered related to SL -401. Any known untoward 
event that occurs beyond the AE report ing period that the Investigator assesses as related to SL -
401 should also be reported as an AE.  
All patients should be monitored per institutional guidelines for at least 4 hours following the 
administration of each infusion of SL -401. The Principal Investigator, who is a physician, or 
medical staff responsible for study conduct and safety evaluations, should be available during the 
administration SL -401 and follow- up to assess, treat, or report as necessary any AE or serious 
adverse event (SAE) that may occur.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  81 CONFIDENTIAL  10.1 Definitions  
All observed or volunteered AEs regardless of suspected causal relationship to SL -401 will be 
reported as described below.  
10.1.1 Adverse Event (AE)  
An AE is any untoward medical occurrence in a study patient who is administer ed a medicinal 
product (drug or biologic); the event may or may not have a causal relationship with the 
medicinal product. Examples of AEs include, but are not limited to the following: 
• Clinically significant symptoms and signs including:  
o Worsening of signs and symptoms of the disease under study ; disease progression 
without worsening of signs and symptoms as assessed by bone marrow aspiration  or 
other methods should not  be reported as AEs.  
o Signs and symptoms resulting from drug overdose, abuse, misuse, withdrawal, 
sensitivity, dependency, interaction,  or toxicity.  
o All possibly related and unrelated illnesses, including the worsening of a preexisting 
illness.  
o Injury or accidents. Note that if  a medical condition is known to have caused the 
injury or accident (hip fracture from a fall secondary to dizziness), the medical 
condition (dizziness) and the outcome of the accident (hip fracture from a fall) should 
be reported as 2 separate AEs. 
• Abnorm alities in physiological testing or physical examination findings that require 
clinical intervention or further investigation (beyond ordering a repeat confirmatory test).  
• Laboratory abnormalities that meet any of the following (Note: merely repeating an 
abnormal test, in the absence of any of the below conditions, does not constitute an AE . 
Any abnormal test result that is determined to be an error does not require reporting as an AE): 
o Test result that is associated with accompanying symptoms  
o Test result that requires additional diagnostic testing or medical/surgical intervention  
o Test result that leads to significant additional concomitant drug treatment or other 
therapy  
o Test result that is considered to be an AE  by the Investigator or Sponsor  
Note that VOD, en graft ment  delay or failure occurring post- SCT and any changes in visual 
acuity and/or color vision will be followed as adverse events of special interest.  
10.1.2 Serious Adverse Event (SAE) 
An AE that meets one or more of the following criteria/outcomes is classified as serious:  
• Results in death; 
• Is life -threatening (at immediate risk of death);  
• Requires admittance to the hospital or prolongation of existing hospitalization; 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  82 CONFIDENTIAL  • Results in persistent or significant disability/incapacity;  
• Results in congenital anomaly/birth disfigurements among the offspring of the patients;  
• Events with medical significance or needing medical intervention to prevent the 
occurrence of any of the above events.  
Medical judgment should be exercised in deciding whether expedited reporting is appropriate in 
other situations, such as important medical events that may not be immediately life -threatening 
or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. Serious also includes any other event that the Investigator or Sponsor judges to be serious, or which is defined as serious. 
Adverse events associated with inpatient hospitalization, or prolongation of an existing 
hospitalization, are considered serious. Any initial admission, even if the duration is less than 
24 hours is considered serious. In addition, any transfer within the hospital to an acute/intensive care unit is considered serious. However, the following hospitalizations should not be considered serious: 
• Hospitalization or prolonged hospitalization in the absence of precipitating clinical AEs 
as follows: o Admission for treatment of preexisting condition not associated with the development 
of a new  AE or with a worsening of the preexisting condition 
o Administrative admission (e.g., for a yearly physical exam)  
o Protocol-specified admission during the study (e.g., admission for SL -401 treatment ) 
o Preplanned treatments or surgical procedures 
o Admission exclusively for the administration of blood products 
Progress ion of the disease under study (including signs and symptoms of progression) should not 
be reported as SAEs unless the outcome is fatal during the study or within the safety reporting 
period. If the disease under study has a fatal outcome during the study or within the safety 
reporting period, then the event leading to death must be recorded as an AE  and as a SAE with 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event s (CTCAE ) 
Grade 5 . PD is NOT an SAE; however some sequelae of disease progression (i.e., pain, 
thrombocytopenia) may be reported as AEs or SAEs  (generally not related to investigational 
therapy).  
The onset date of an SAE is defined as the date on which the event initially met serious criteria (e.g., the date of admission to a hospital). The end date is the date on which the event no longer met serious criteria (e.g., the date the patient was discharged from a hospital)  or upon death. 
10.2 Period of Observation 
Clinical signs and symptoms, and AEs (regardless of relationship to study treatment) will be collected continuously from the first day of SL -401 treatment to 30 days following the last 
infusion of SL-401. All SAEs and AEs judged to be related to study treatment will be collected 
throughout the follow-up period. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  83 CONFIDENTIAL  Conditions that the patient experienced prior to SL -401 treatment should be recorded in the 
patient medical history section of the eCRF.  All the AEs should be followed-up until the 
symptoms dissipate or become stable even if AEs continue beyond the period of observation. 
AEs unresolved at the end of the observation period will be considered “ongoing” with an 
undetermined outcome; however, if after the period of observation completes but prior to the 
completion of the study, additional outcome information becomes available, it will be reported. 
The severity of the signs, symptoms, or AEs should be determined using the NCI CTCAE, Version 4.03. A complete CTCAE list can be downloaded at 
http://evs.nci.nih.gov/ftp1/CTCAE/About.html . 
All clinically meaningful abnormal test results should be retested.  Abnormal test results that are 
difficult to associate with the study drug should be followed until normalized or until the 
abnormity could be clearly attributed to another cause. Abnormal test results should not be reported as AEs unless they meet the criteria outlined in  Section 10.1.1. 
10.3 Pre-existing Conditions 
A pre -existing condition will not be reported as an AE unless the condition worsens by at least 
one CTCAE grade during the study. The pre-existing condition, however, must be recorded in the screening eCRF as a pre- existing condition and all related concomitant medication 
administered for the condition recorded in the baseline (prior) concomitant medication eCRF.  
10.4 Pregnancy  
WOCBP and men with partners of childbearing potential must be using an adequate method of 
contraception to avoid pregnancy throughout the study and for up to 2 months after the study in 
such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization 
(hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea ≥12 consecutive months; or women on hormone replacement therapy 
with documented serum follicle -stimulating hormone level ≥35 mIU/mL). Even women who are 
using oral, implanted, or injectable contraceptive hormones or mechanical products, such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, are practicing abstinence, or whose partner is sterile (e.g., vasectomy), should be considered to 
be of childbearing potential. 
WOCBP must have a negative serum or urine pregnancy test during Screening within 1 week 
prior to dosing. If the pregnancy test is positive, the patient must not receive study therapy and must not be enrolled in the study. 
Sexually active WOCBP must use an effective method of birth control during the course of the 
study, in a manner such that the risk of failure is minimized. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  84 CONFIDENTIAL  Prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy 
during study participation and the potential risk factors for an unintentional pregnancy. This 
information will be included in the ICF that must be signed by the patient.   
In addition, all WOCBP or fertile men with partners of childbearing potential should be 
instructed to contact the Investigator immediately if they suspect they or their partner might be 
pregnant (e.g., missed or late menstrual period) at any time during study participation.  
If following initiation of study treatment, it is subsequently discovered that a patient is pregnant or may  have been pregnant at the time of exposure to study therapy, including during at least 2 
months after product administration, study therapy will be permanently discontinued in an appropriate manner. Exceptions to discontinuation may be considered for life threatening conditions only after consultation with the Sponsor and Medical Monitor or as otherwise specified in this protocol. The Investigator must immediately notify the Sponsor and Medical 
Monitor of this event. 
Protocol-required procedures for study discontinuation and follow-up must be performed on the 
patient unless contraindicated by pregnancy (e.g., x- ray studies).  Other appropriate pregnancy 
follow-up procedures should be considered if indicated. In addition, the Investigator  must report 
to the Sponsor follow-up information regarding the course of the pregnancy, including perinatal and neonatal outcome. Infants should be followed for a minimum of 8 weeks  postpartum. 
10.5 Documentation and Reporting of Adverse Events by Investigator 
The Investigator is to report all directly observed AEs as well as those spontaneously reported by 
the patient using concise medical terminology.  In addition, each patient will be questioned about 
AEs at each clinic visit following initiation of treatment.  The question asked will be “Since your 
last clinic visit have you had any health problems?” or a similar non-leading question to assess 
health status.  
The AE reporting period for this study begins upon initiation of SL -401 treatment and ends 
30 days after the last infusion of SL-401. All AEs are to be reported on the AE eCRFs.  
All AEs that occur in study  patients during the AE reporting period specified in the protocol 
must be reported to the Sponsor or designee, whether or not the event is considered study treatment -related.  In addition, any untoward event that occurs beyond the AE  reporting period 
that the Investigator assesses as related to the investigational product should also be reported as an AE. 
Each AE is to be classified by the Investigator as seri ous or non-serious. This classification of 
the gravity of the event determines the reporting procedures to be followed. If a SAE  occurs, 
reporting will follow local and international regulations, as appropriate. 
For any event that meets one of the SAE criteria, t he Investigator  
Safety within 24 hours  of the knowledge of the occurrence. To report the SAE, the SAE form is 
to be completed electronically in the electronic data capture (EDC) system for the study.  When 

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  85 CONFIDENTIAL  the form is com pleted,  personnel will be notified electronically and will retrieve 
the form.  If the event meets serious criteria and it is not possible to access the internet, an email 
to should be sent to  or a call made 
to the  
 within 24 hours of awareness. When the 
EDC system becomes available, the SAE information must be entered within 24 hours of the 
system becoming available.  
Each SAE should be followed until resolution, or until such time as the Investigator determines 
its cau
se or determines that, it h as become stable.   
Within 24 hours of receipt of follow-up information, the Investigator must update the SAE form 
electronically in the EDC system for the study and submit any supporting documentation (e.g., subject discharge summary or autopsy reports) to  via fax or e- mail. If it 
is not possible to access the EDC system, refer to the procedures outlined above for initial reporting of SAEs.  
The Sponsor will report AEs, which are unexpected and reported as serious and associated with 
use of the study drug, to the US Food and Drug Administration (FDA) and all participating clinical sites.  For events, which are fatal or life threatening, unexpected, and associated with use 
of the investigational product, a 7- Day Alert Report will be submitted to the FDA within 7 
calendar days of receipt of the SAE information. For all other events that are serious, unexpected, and associated with the use of the investigational medicinal product, a written report will be made no more than 15 calendar days from the date the Sponsor learns of the event. 
Reports of delayed or failed engraftment post-SCT will be reported as 15- day safety reports.   
10.6 Assessment of Causal Relationship to SL -401 
In this study, the investiga tional medicinal product is SL-401. The relationship of an AE  to the 
investigational product should be classified using the following guidelines: 
• Related:  A temporal relationship exists between the event onset and administration of SL -
401. It cannot be rea dily explained by the patient’s clinical state, intercurrent illness, or 
concomitant therapies.  In case of cessation or reduction of the dose, the event abates or 
resolves and reappears upon rechallenge. This includes events that are considered 
possibly, probably, or definitely related to SL -401.  

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  86 CONFIDENTIAL  • Not Related:  Evidence exists that the AE has an etiology other than the study drug (e.g., 
pre-existing condition, underlying disease, intercurrent illness, or concomitant 
medication).  This includes events that are considered probably not or not related to SL-
401. It should be emphasized that ineffective study drug treatment should not be 
considered as causally related in the context of AE reporting (in other words, disease 
progression is not considered an AE; however some sequelae of disease progression may 
be reported as AEs and should generally be reported as AEs not related to investigational 
therapy).  
An Investigator who is qualified in medicine must make the determination of relationship to the 
investigational product for each AE. The Investigator should decide whether, in his or her medical judgment, there is a reasonable possibility that the event may have been caused by the 
investigational product. The following factors  for study drug relationship should be referenced 
when making a determination of “related” or “not related .” 
• The temporal sequence from study drug administration: The event should occur after the 
study drug is given . The length of time from study drug  exposure to event should be 
evaluated i n the clinical context of the event. 
• Underlying, concomitant, intercurrent diseases: Each report should be evaluated in the 
context of the natural history and course of the disease being treated and any other disease 
the subject may have.  
• Concomitant medic ation: The other medications the subject is taking or the treatment the 
subject receives should be examined to determine whether any of them might be 
recognized to cause the event in question. 
• Known response pattern for this class of study drug: Clinical and/or preclinical data may 
indicate whether a particular response is likely to be a class effect.  
• Exposure to physical and/or mental stresses:  The exposure to stress might induce adverse 
changes in the recipient and provide a logical and better explanation  for the event. 
• The pharmacology and PK of the study drug : the known pharmacologic properties 
(absorption, distribution, metabolism, and excretion) of the study drug should be 
considered. 
10.7 Grading of Adverse Event Severity  
To report AE s on the eCRFs, the Investigator will use the severity grading as descri bed in NCI-
CTCAE, Version 4.03. 
Every effort should be made by the Investigator to assess the AE  according to CTCAE criteria.  If 
the Investigator is unable to assess severity because the term is not described in NCI- CTCAE 
Version 4.03, severity of MILD, MODERATE, SEVERE, LIFE- THREATENING, or DEATH 
may be used to describe the maximum intensity of the AE . For purposes of consistenc y, these 
intensity grades are defined as follows:  
• Mild  (Grade 1) : does not interfere with patient’s usual function  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  87 CONFIDENTIAL  • Moderate (Grade 2) : interferes to some extent with patient’s usual function  
• Severe (Grade 3) : interferes significantly with patient’s usual f unction 
• Life-threatening  (Grade 4) : results in immediate risk of patient’s death  
• Death  (Grade 5) : results in patient’s death  
Note the distinction between the severity and the seriousness of an AE. A severe event is not 
necessarily a serious event.  For example, a headache may be severe (interferes significantly with 
patient’s usual function) but would not be classified as serious unless it met one of the criteria for 
serious events. 
It is requested that when reporting AEs for which potentially redundant CTCA E terms exist, 
Investigator s utilize the more clinically -oriented terminology (for example, “anemia” is 
prefera ble to “hemoglobin decreased”).  
It is also requested that in the setting of a hypersensitivity reaction or suspected hypersensitivity 
reaction considered by the Investigator to be related to investigational therapy, that Investigator s 
report both the specific symptoms associated with the reaction (i.e., “urticaria,” ”chills,” “dyspnea,” etc.) and also report the appropriate term indicating the hype rsensitivity reaction 
(“allergic reaction ,” or “infusion related reaction” or “anaphylaxis” if appropriate [General 
Disorders and Immune System Disorders; CTCAE v4.x, pages 23 and 26]). 
11 Excluded Prior and Concomitant Medications and Therapy  
An enrolled pa tient may not receive investigational or approved anticancer or anti- leukemia 
agents , including cytotoxic chemotherapy agents , hypomethylating agents (5 -azacytadine, 
decitabine or others), or anticancer tyrosine kinase inhibitors (including imatinib, ruxolitinib, 
sorafenib and others) or therapeutic monoclonal antibodies. Hydroxyurea may be administered 
(however its use should be discussed with the Medical Monitor ). 
12 Statistical Analysis  
12.1 General Considerations 
Study STML -401-0114 contains patients with both AML and first- line and R/R BPDCN . The 
current development strategy for SL -401 is to first pursue marketing authorization for an 
indication in first- line BPDCN patients, with potential additional indications in R/R BPDCN 
and/or AML, depending on the study results. Therefore, this statistical analysis section will focus 
primarily on the first- line BPDCN indication, with generally similar analytical approaches to be 
taken with the other potential indications upon achievement of sufficient data. 
Analyses w ill be performed on all patients who received any quantity of SL-401 (i.e., all treated 
patients) . The baseline value for a given variable is defined as the last measurement for the 
variable prior to the first infusion of SL-401. Study Day 1 for each individual patient is defined 
as the date the patient receives their first infusion of SL-401. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  88 CONFIDENTIAL  Unless otherwise stated, all analyses will be performed using SAS Version 9 and all hypothesis 
tests will be conducted at a two -sided significance level of 0.05 or at a one- sided significance 
level of 0.025. P-values will be presented with 3 decimals and p-values that are less than 0.001 will be presented as <0.001. Selected data summaries will be presented by disease (BPDCN  and 
AML ), with the primary data presentations provided for data from patients with BPDCN. For 
data from BPDCN patients, further categories for summarization will consist of line of therapy 
(first -line, R/R, and total) and dose (12 µg/kg/day and all doses). Efficacy endpoints will be 
summ arized separately for Stage 3 patients , with an additional summary for all first-line and R/R 
BPDCN patients across  all study stages . Stage 4 will be analyzed separately.  
Continuous (non- survival related) data will be summarized using descriptive statistic s: number 
of observations (n), mean, standard deviation (SD), median, minimum, and maximum. Time to 
event data will be summarized using frequency and percentage of events and censored 
observations. Kaplan -Meier analysis will be performed to estimate the 25
th percentile, median, 
and 75th percentile for time to events  with corresponding two -sided  95% confidence intervals.  
Unless otherwise stated, confidence intervals, when presented, will be constructed at the 2-sided 95% level. For binomial variables , 95% c onfidence intervals will be constructed using the 
Clopper Exact method instead of normal approximation. 
Data listings will present all data collected on eCRFs by study drug dose, center, Stage of study 
enrollment, and patient number.  12.2 Populations for Analy sis 
Safety analysis will be performed on the population of patients who have received any amount of 
study treatment. The primary population for the analysis of efficacy will be the modified intent-to-treat (mITT) population, consisting of those patients who are eligible based on screening 
criteria, and have received at least one dose of study drug . For BPDCN patients an additional 
criterion for mITT patients will be a confirmed diagnosis based on central pathology review. BPDCN patients in the mITT population will be said to be evaluable. Additional efficacy analyses will be performed on a per -protocol (PP) population, consisting of those patients who 
are in the mITT population, are compliant with all major aspects of the protocol, and have received a minimum of 2 cycles of study treatment.  
12.3 Determination of Sample Size  
The sample size was originally planned to be approximately 40-50 patients with BPDCN, 
including approximately 40 first -line patients pla nned to be treated with the optimal SL-401 dose 
as determined in the completed Stage 1 of this study (12 µg/kg/day). In addition, up to approximately 36 patients with R/R AML were planned to be enrolled in Stage 2 of the study.  
In Stage 3, a  sufficient nu mber of patients were  enrolled to ensure 10 evaluable patients were  
included, with evaluable patients being those with a diagnosis of BPDCN, as confirmed via 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  89 CONFIDENTIAL  central pathology review who received at least 1 dose of SL-401. The sample size allocated for 
Stage 3 is intended to satisfy specific statistical criteria established by the Sponsor at the request 
of the US FDA.  
 
 
The 
primary efficacy analysis for Stage 3 compares the lower bound of a two-sided 95% Clopper 
Exact confidence interval surrounding the observed CR rate to a clinically meaningless value of 
10%. Statistical significance is determined if the lower bound of this confidence interval falls 
above the rate of 10%. Assuming a CR rate of at least 60%, a sample size of a minimum of 10 
first-line BPDCN patients provides at least 90% power for this the primary efficacy assessment . 
 
 
 
 
To avoid possible selection bias, all first- line BPDCN patients enrolled in this time period are 
included in the Stage 3 analysis. This sample size also ensures there are 10 patients in the PP analysis population.  
After  the maximum number of patients with first- line BPDCN in Stage 3  were enrolled , 
subsequent first -line BPDCN pat ients are enrolled in Stage 4. Furthermore, any patient with R/R 
BPDCN enrolled in this study on or after 26 October , 2016, will be allocated to Stage 4. 
Enrollment will continue in Stage 4 up until enrollment of up to approximately 145 patients  or 
prior termination of the study.  
12.4 Demographics and Baseline Characteristics  
Demographic  (e.g., gender, age, race) and baseline characteristics (e.g., ECOG performance 
status, height, weight, and prior therapy) will be summarized by SL -401 dose group with 
descriptive statistics.  
12.5 Analyses of Safety Data  
Safety assessments include DLTs, AEs, SAEs, physical examinations, vital sign measurements, ECGs, clinical laboratory evaluations, and reasons for treatment discontinuation due to toxicity. Safety data anal ysis will be performed primarily on the pool of first- line BPDCN patients treated 
with the 12 µg/kg/day dose level, with additional summaries across all BPDCN patients, patients 
with R/R disease and the pool of all BPDCN patients. Separate safety tabulatio ns will be 
produced for patients with AML, patients who are treated with the lyophilized formulation of 
SL-401, and an overall pool of all enrolled patients. 

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  90 CONFIDENTIAL  Treatment -emergent AEs through 30 days after last SL -401 infusion will be summarized by 
MedDRA™ Ve rsion 13.1 (or higher) System Organ Class and preferred term. The incidences 
and percentages of patients experiencing each AE preferred term will be summarized with 
descriptive statistics . AEs will also be summarized by National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI -CTCAE), Version 4.03 (or higher) grade and by 
causality (relationship to study treatment).  Dose -limiting toxicities, ≥Grade 3 AEs, SAEs, and 
AEs resulting in dose modification or treatment discontinuation will a lso be summarized by 
preferred term.   
Laboratory results will be classified according to NCI -CTCAE, Version 4.03. Laboratory results 
not corresponding to an NCI- CTCAE term will not be graded.  Incidences of laboratory 
abnormalities will be summarized with descriptive statistics.  
Vital signs, physical examination results, and ECGs will be summarized with descriptive 
statistics.  
12.6 Analys is of Efficacy Data  in First- Line BPDCN  
Efficacy assessments include CR rate ( i.e., CR + CRi + CRc), DOR , ORR, PFS, and OS. The  
following sections refer specifically to  patients with first- line BPDCN, treated at the 
12 µg/kg/day dose level. The following sub- sections refer specifically to patients with first- line 
BPDCN, treated at the 12 µg/kg/day dose level. The analysis of effic acy of SL -401 in these 
patients will be performed to address several objectives, based on data from the different stages 
of the study. 
Analyses by stage are intended as follows. Stage 3 will provide the pivotal results for a potential 
registrational submis sion in first- line BPDCN patients as assessed by rate of CR +CRc . Stage 1 
and 2 results will be presented, similar to the interim analysis as noted in Section 12.10. Stage 4 
results will be presented separately an d may be used to assess consistency across drug 
formulations. 
12.6.1 Order of Statistical Analys es of Efficacy  
The primary evidence of efficacy will be derived from an analysis of the rate of CR +CRc , as 
assessed by the Investigator,  in patients in Stage 3, accompanied by an evaluation of the 
durability of these CRs as a key secondary endpoint. A formal statistical analysis will first be 
performed for the primary efficacy endpoint to test the hypothes is that the rate of CR in first- line 
patients in Stage 3 exceeds the lower benchmark value of 10%. The primary analysis will be 
performed when all patients in Stage 3 have been followed for a minimum of 3 cycles or 
discontinued treatment, whichever occurs first.  In addition, the durability of CR will be 
evaluated; refer to Section 12.6.3 for analysis methods for duration.  
A number of additional secondary analyses will then be performed, to further evaluate the rate of CR in other stages of the study and to assess additional efficacy parameters in support of the 
primary analysis results.  The analyses of all secondary endpoints will be descriptive , with  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  91 CONFIDENTIAL  summaries of secondary endpoints to  be evaluated and presented in the following order of 
importance (as noted above, these analyses will be performed on data from first- line BPDCN 
patients treated at the 12 µg/kg/day dose level) : 
1. Bone- marrow CR (BMCR)  and DOR for Stage 3  
2. CR rate and DOR for Stages 1 and 2 
3. CR rate and DOR for pooled data from Stages 1, 2, 3, and 4 
4. ORR and DOR for Stage s 1 and 2 
5. ORR and DOR for pooled data from Stages 1, 2, 3, and 4 
6. Proportion of patients who receive SCT based on pooled data from Stage s 1, 2, 3 and 4 
7. PFS for Stage s 1, 2, 3, and 4 
8. OS for Stage s 1, 2, 3, and 4 
Response will be assessed using International Working Group (IWG) criteria for AML (for 
patients with AML) ( Cheson et al. 2003) and  a modified version of the Revised Response 
Criteria for Malignant Lymphoma (for patients with BPDCN) ( Cheson et al. 2007). Disease 
response in skin will be assessed using the weighted BSA/modified Severity Weighted 
Assessment tool (mSWAT) score (for patie nts with BPDCN) ( Olsen et al. 2011). For the patients 
with BPDCN, assessment of response and disease progression will include evaluation of all sites of disease involvement at baseline, which may include skin, lymph nodes, spleen, liver, peripheral blood, and bone marrow. Up to 6 of the largest dominant nodes or nodal masses should be identified as index lesions for radiographic response assessments. Response criteria for 
AML and BPDCN are summarized in Sections 16.1 and 16.2, respectively, and the mSWAT 
template is presented in Section 16.3.  
12.6.2 Response Rate  
For rates of response, including CR and ORR, as appropriate, two -sided 95% Clopper Exact 
confidence intervals around the response rate will be presented . For CR +CRc  in first -line 
patients in Stage 3, statistical significance at the one -sided 0.025 will be declared if the lower 
bound of this confidence interval exceeds the lower clinical benchmark level of 10%. An 
analysi s of the rate of bone-marrow CR (BMCR) will also be performed, by pooling data from 
patients who had either CR or PR with complete bone-marrow response (reduction to <5% blast cells), as a proportion of all patients with marrow disease (≥ 5% blast cells) a t baseline.   
12.6.3 Duration of Response 
DOR is defined as the time from when measurement criteria are first met for CR/CRi/CRc 
(whichever is recorded first) until the date that the criteria for relapse after CR/CRi/CRc is met.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  92 CONFIDENTIAL  For patients who receive bone marrow transplant after CR/CRi/CRc is observed, duration of 
response will include time to disease relapse post -transplant. Patients who are lost to follow -up 
or who do not relapse after CR/CRi/CRc as of the cut- off for analysis will be censored at the date 
of last radiologic assessment while on study. The same definition will be used for ORR, with the 
obvious modification that data from patients with either CR or PR will be included. 
Analysis of duration of response will be performed by Kaplan- Meier time to even t analysis  to 
estimate the 25th percentile, median , and 75th percentile  of times to event, number, and 
percentage of events, censored observations, and appropriate confidence intervals. Additional 
descriptive analysis will be performed separately for patients who do and do not receive bone 
marrow transplant. 
12.6.4 Bridge to SCT  
The proportion of patients who become eligible and receive SCT will be analyzed, using the data 
from Stage 1 -4. Patien ts may receive SCT subsequent to CR or PR ; therefore , this analysis will 
be performed by response category as well as overall.  
12.6.5 Progression-free Survival 
Progression-free survival is defined as the time from the date of first infusion of SL-401 to the date of progressive disease (PD) or death from any cause, whichever occurred first. The 
distribution for progression free survival will be estimated by Kaplan -Meier methodology. 
12.6.6 Overall Survival 
OS is defined as the time from the date of first infusion of SL -401 to the date of death from any 
cause.  The distribution for OS will be estimated by Kaplan -Meier methodology. 
12.6.7 Exploratory and Subgroup Analyses 
Exploratory and subgroup analyses may be performed to assess the influence of demographic 
and baseline characteristics on the rate of CR.  In general, the exploratory and subgroup analyses 
will use the pooled data from first-line BPDCN patients from Stages 1, 2, 3, and 4. 
12.7 Additional Efficacy  Analyses  
Analysis of efficacy data from patients with R/R disease at study entry will be performed for all 
such patients, pooled Stage 1 and 2, using descriptive methods similar to those intended for the 
analysis of first -line BPDCN patients . Data from patients enrolled into Stage 4 will be presented 
separately; response data from the pool of Stages 3 and 4 may also be presented to augment the 
results from the pivotal Stage 3 . A pooled, descriptive analysis of R/R patients across Stages 1, 2, 
and 4 will be performed. 
Additional efficacy analysis, including assessments of CR, DOR, and ORR, may be performed 
on patients treated with the lyophilized formulation of the SL-401 product. Analysis will be 
performed separately for R/R and first -line BPDCN patients. Efficacy for patients with AML 
will be analysed separately upon achievement of sufficient data.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  93 CONFIDENTIAL  Efficacy data from first -line BPDCN patients treated with an initial dose other than 12 µg/kg/day 
dose level will be summarized.  
12.8 Pharmacokinetic and Immunogenicity Analyses  
Planned PK and immunogenicity analyses will be describe d in separate analysis plans.  
12.9 Blinding 
This is an open- label study.  
12.10 Interim Analyses  
In Stage s 2-4 of the study, the DSRC will conduct a safety data review on an every 1-2-month 
basis .  
An informal interim analysis was performed on efficacy data from Stages 1 and 2  
 (see Section 3.7.2) . This analysis was 
performed on the 32 patients enroll ed in the study through 29 August , 2016; note that no further 
enrollment of first-line BPDCN patients occurred until October, 2016. 
 
 
12.11 Final Analysis  
The final safety and efficacy analyses will be performed upon study completion. Study 
completion is the date in which every patient who is alive had at least 12 months of follow up data.  
12.12 Study Oversight Committees  
Study conduct will be monitored by the following oversight committees: a DSRC and  an IRC.  
The roles of these committees are outlined briefly as follows, and will also be delineated in detail in designated committee charters.   
• The DSRC includes Sponsor representatives and study Investigator s. The DSRC will 
review cumulative safety data and make decisions regarding DLT determination, dose escalation , and cohort progression during Stage 1. The DSRC  may also make other 
recommendations pertinent to patient safety, both in Stage 1 and Stages 2-4, and will 
periodically review data during Stages 2-4 on an every 1 -2-month basis . 
• Tumor response will be assessed by the Investigators for all patients with BPDCN, with 
the Investigator’s assessment to be used in the primary analysis.  A central pathologist 
will confirm histopathological BPDCN diagnosis.  As a supportive assessment, tumor 
response was also evaluated by an IRC on a pre- specified subset of patients  in Stages 2 -4. 
The IRC will be comprised of clinicians with expertise in hematologic and/or 
dermatologic malignancies  who are not involved in the clinical study , and will review 

SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  94 CONFIDENTIAL  data as reported by the Investigator s for the assessment of response. It is anticipated that 
the IRC will meet several times per year.  
13 Emergency Procedures   
13.1 Emergency Contact  
In emergencies, the Investigator should contact the Medical Monitor by telephone at the number 
listed on the title page of the protocol. 
13.2 Emergency Identification of Investigational Products 
Since this is an open- label study, the investigational treatment and  patient number will be 
identified on the package labeling. 
13.3 Emergency Treatment  
During a patient’s participation in the study, the Investigator and/or institution should ensure that 
adequate medical care is provided to a patient for any AEs, including clinically significant laboratory values, related to the study.  
14 Ethical and Regulatory Considerations  
14.1 Good Clinical Practice  
As the Sponsor of this clinical study, Stemline Therapeutics Inc. has the overall responsibility for the conduct of the study, including assurance that the study meets the requirements of applic able 
regulatory authorities.  Stemline will maintain compliance with the FDA Code of Federal 
Regulations, ICH Guideline E6, Declaration of Helsinki, and Good Clinical Practice (GCP) 
Guidelines. The study must receive approval from an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) prior to commencement. The Investigator will conduct all aspects of this study in accordance with applicable national, state, and local laws of the pertinent 
regulatory authorities.  
The Sponsor is responsible for ensuring IRB approvals are obtained , providing Investigators with 
information required to conduct the study, ensuring proper investigative site monitoring, verifying that appropriate patient informed consent is obtained, submitting an IND application to 
FDA, and ensuring that the IRB and regulatory agencies are promptly informed of significant new information regarding the study. 
14.2 Delegation of Investigator Responsibilities  
The Investigator must ensure that all persons assisting with the study are adequ ately informed 
about the protocol, any amendments to the protocol, the study treatments, and their study- related 
duties and functions. The Investigator should maintain a list of sub-investigators and other 
appropriately qualified persons to whom he or she has delegated significant study- related duties.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  95 CONFIDENTIAL  14.3 Patient Information and Informed Consent 
Before being admitted to the clinical study, the patient must consent to participate after the 
nature, scope, and possible consequences of the clinical study have been  explained in a language 
understandable to him or her. An Informed Consent Form (ICF) that includes information about 
the study will be prepared and given to the patient. This document will contain all ICH, GCP, 
and locally required regulatory elements . The ICF must specify who informed the patient about 
the study and be approved by the Institution’s IRB. Copies of the ICF used in the study must contain the IRB-approval stamp (if applicable) and version date. The Investigator must keep the 
original executed  ICF including the patients’ signatures and the signing dates properly stored in a 
secured location at the study site.  
After reading the informed consent document, the patient must give consent in writing. The 
written informed consent will be obtained prior to conducting any study- related procedures or 
tests. The patient’s consent must be confirmed at the time of consent by the dated signature of 
the person conducting the informed consent discussions. If the patient agrees to participate in the 
study, the patient and the Investigator must sign both copies of the ICF. An original copy of the signed consent document must be given to the patient or the patient ’s legally authorized 
representative. The signed ICF must be available for verification by the Sponsor’ s designated 
monitors or regulatory authorities . 
The date of the signed ICF will also be noted in the patient’s medical chart . Patients should be 
informed of new information learned during the study, which may affect their decision to 
continue participatio n in the study. The Investigator should inform the patient’s primary 
physician about the patient’s participation in the study if the patient has a primary physician and 
if the patient agrees to the primary physician being informed.  
14.4 Confidentiality  
The Inve stigator(s) and the Sponsor or its authorized representative will preserve the 
confidentiality of all patients and donors participating in the study, in accordance with GCP, local regulations and to the extent applicable the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). 
Patient names will not be supplied to the Sponsor or its authorized representative. Only the 
patient study numbers and (if permitted by the institution) patient initials will be recorded in the 
eCRF, and if the patient name appears on any other document (e.g., pathologist report), it must be obliterated before a copy of the document is supplied to the Sponsor or its authorized representative.  Study findings stored on a computer will be stored in accordance with local data 
protection laws. Patients  will be told that representatives of the Sponsor, its authorized 
representative, IRB or IEC, or regulatory authorities may inspect their medical records to verify the information collected, and that all personal information m ade available for inspection will be 
handled in strictest confidence and in accordance with local data protection law. The Investigator 
will maintain a personal patient identification list (patient numbers with the corresponding 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  96 CONFIDENTIAL  patient names) to enable records to be identified. 
14.5 Protocol Amendments 
Any changes that affect patient safety or welfare will be submitted to the IRB/ IEC and 
Regulatory Authority (where applicable) for approval prior to implementation. The Investigator 
and the Sponsor must approve all amendments.  No amendment will be implemented until 
approved and signed by all parties. Exceptions to this are when the Investigator considers that the 
patient’s safety is compromised.  
Once the study has started, amendments should be made only in except ional cases.  The changes 
then become part of the study protocol. 
14.6 IRB/IEC Approval and Reporting 
The Investigator must obtain appropriate IRB /IEC  approval prior to study initiation. A copy of 
the written approval from the IRB and a copy of the approved ICF should be sent to the Sponsor 
or its delegate . It is also necessary to submit a list of the IRB members (including their Institution 
affiliations, gender makeup, and occupations) or supply a statement from the IRB specifying that 
the membership complies with applicable regulations. 
The study protocol, ICF, the IB, available safety information, patient recruitment procedures 
(e.g., advertisements), information about payments and compensation available to the patients 
and documentation evidencing the Investigator’s qualifications should be submitted to the IRB/IEC  for ethical review and approval according to local regulations, prior to the study start. 
The written approval should identify all documents reviewed by name and version. 
Any changes to the protocol must be approved by the Sponsor in writing unless the change is 
proposed to assure safety of the patient. In the non-emergent setting, following agreement on the proposed changes, an amendment to the protocol will be submitted by the Sponsor to the IRB for approval prior to implementation of the change. Any change made emergently must be documented in the patient's medical record.  
If required by legislation or the IRB/IEC, the Investigator must submit to the IRB/IEC:  
• Information on serious or unexpected AEs as soon as possible; 
• Periodic reports on the progress of the study. 
14.7 Closure of the Study 
The Sponsor, its authorized representative, or the Investigator has the right to close this study at any time.  The IRB/IEC must be informed, if required by legislatio n. Should the study be closed 
prematurely, all unused SL-401 will be reconciled with dispensing records, documented, and, if 
directed by the Sponsor, destroyed at the study site after completion of accountability by the site 
monitor. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  97 CONFIDENTIAL  14.8 Record Retention  
The S ponsor will maintain copies of correspondences, records of shipment and disposition of 
study drug, adverse effects, and other records related to the clinical study and the signed 
Investigator agreements . Patient records must be retained even if the patient  has died. 
Study documents must be retained by the Investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the investigational product. These documents 
should be retained for a longer period, however, if required by the applicable regulatory 
requirements or by an agreement with the Sponsor. It is the responsibility of the Sponsor to inform the Investigator when storage of these documents is no longer required. The Investigator should contact the Sponsor if the site’s archiving arrangements change at any time. 
14.9 Liability and Insurance  
Liability and insurance provisions for this study are provided in the Investigator’s contract with 
Stemline . 
14.10 Financial Disclosure  
Prior to study initiation the Investigator will be asked to sign a clinical trial agreement. All Investigator s will be requir ed to sign a Financial Disclosure Form in accordance with 21 CFR 
Part 54; Financial Disclosure by Clinical Investigators.  
14.11 Study Monitoring and Auditing 
All aspects of the study will be carefully monitored by the Sponsor or its designee for compliance to ap plicable government regulations with respect to current good clinical practice 
and current standard operating procedures. Monitoring functions will be performed in compliance with 21CFR§812.43(d) and 21CFR§812.46. Direct access to the on -site study 
documentation and medical records must be ensured by the Investigator . 
14.11.1 Study Monitoring and Source Data Verification  
The Investigator is responsible for the validity of all data collected at the site and must accept the various monitoring procedures employed by the Sponsor. The purpose of monitoring is to verify the rights and well- being of human patients are protected; that study data are  accurate, complete, 
and verifiable with source data; that the study is conducted in compliance with the protocol, GCP 
and the applicable regulatory requirements. 
Sites will be monitored to identify and reconcile any differences between the completed eCRFs 
and medical records, and review source documents for accuracy, completeness, and legibility . 
The monitor will review completed data forms and study documentation for accuracy, 
completeness, and protocol compliance. In addition, the Sponsor will evaluate any protocol 
deviations and take corrective action as necessary.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  98 CONFIDENTIAL  The Sponsor will review significant new information, including unanticipated AEs and ensure 
that such information is provided to all reviewing IRBs. This information will also be provided 
to the FDA, other regulatory authorities, and Investigators worldwide in accordance with local regulations. The monitor’s responsibilities include site visits, review of eCRFs, source 
documents and results, and ensuring clear communication between Investigators and the Sponsor. 
The monitor will query any missing or spurious data with the Investigator, which should be 
resolved in a timely manner . A monitoring log will be maintained recording each visit, the 
reason for the visit, the monitor’s signature, and Investigator’s or designee’s confirmation signature.  
14.11.2 Study Documentation  
The Investigator must provide the Sponsor with the following documents prior to enrollment and maintain the accuracy of these documents throughout the course of the study. 
• Completed and signed Form 1572. 
• All applicable country- specific regulatory forms.  
• Current signed and dated curricula vitae for the Investigator , sub-investigators, and other 
individuals having significant Investigator responsibility who are listed on the Form 1572 or equivalent, or the clinical study information form. 
• Copy of the current medical license of the principal Investigator, any sub -investigators 
and any other individuals having significant responsibility as listed in the Form 1572. 
• A financial disclosure form for the Principal Investigator and any other persons listed in 
the Form 1572. 
• Copy of the IRB/IEC approval letter for the protocol and informed consent. All 
advertising, recruitment, and other written information provided to the patient must be 
approved by the IRB/IEC. Written assurance of continuing approval (at least annually) as 
well as a copy of the annual progress report submitted to the IRB/IEC must also be 
provided to the Sponsor. 
• Copy of the IRB/IEC-approved informed consent document. 
• A list of the IRB/IEC members or a FWA/DHHS number.  
• Copy of the protocol sign- off p age signed by the Investigator. 
• Fully executed Clin ical Trial Agreement including b udget. 
• A written document containing the name, location, certification number, and date of 
certification of each laboratory to be used for laboratory assays and those of other 
facilities conducting tests . This document should be returned along with the laboratory 
director’s curricula vitae and active medical license. A l ist of normal laboratory values 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  99 CONFIDENTIAL  and units of measure for all laboratory tests required by the protocol is to be provided. 
The sites will also be asked to maintain a Delegation of Authority Log, pharmacy logs, 
temperature logs, patient identification log and monitoring visit logs during this study.  
14.11.3 Site Audits  
For the purpose of compliance with Good Clinical Practices (GCP) and regulatory agency 
guidelines, it may be necessary for Sponsor authorized Quality Assurance personnel and/or 
authorized personnel from a regulatory agency to conduct an audit/inspection of an 
Investigational site . These site reviews may be planned or spontaneous and occur at any stage 
during the study. The purpose of an audit is to assess the quality of data with regard to accuracy, 
adequacy, and consistency, and to assure that studies are in accordance with GCP, protocol, and 
regulatory a gency guidelines. 
The Investigator should promptly notify the Sponsor or its authorized representative of any audits by any regulatory authorities and promptly forward copies of any audit reports received to 
the Sponsor or its authorized representative. 
Electronic data systems will be in accordance with applicable aspects of 21 CFR Part 11, ICH 
Guidelines, GCP, and HIPAA. 14.12 Documentation and Use of Study Findings 
14.12.1 Documentation of Study Findings 
Source documentation will be maintained to document the treatment and study course of a 
patient and to substantiate the integrity of the study data submitted for review to regulatory 
agencies . Source documentation for Stemline studies will include, but not be limited to, 
worksheets, hospital and/or clinic or office records documenting patient visits including study and other treatments or procedures, medical history and physical examination information, 
laboratory and special assessments results, drug accountability records, and medical 
consultations (as applicable). 
Laboratory and diagnostic reports including but not limited to: local lab oratory hematology and 
chemistry results, bone marrow biopsy reports, bone marrow aspirate reports, photographs (de-
identified), ECHO readings , and MUGA readings may be collected by the study monitor during 
the course of the study. Every effort should be made by the site  to de-identify personal patient 
information from these reports and replace the information  with the patient’ s study identification 
number.  
14.12.2 Use of  Study Findings  
All information concerning the product, as well as any matter concerning the operations of the 
Sponsor, such as clinical indications for the drug, its formula, methods of manufacture, and other scientific data relating to it, that have been  provided by the Sponsor and are unpublished, are 
confidential and must remain the sole property of the Sponsor. The Investigator will agree to use 
the information only for the purposes of carrying out this study and for no other purpose unless 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  100 CONFIDENTIAL  prior writt en permission from the Sponsor is obtained. The Sponsor has full ownership of the 
eCRFs completed as part of the study.  
All publications and presentations of the results of the Study are governed by the applicable 
provisions of the Clinical Trial Agreement between the Sponsor and the institution. By signing 
the study protocol, the Investigator  agrees that the results of the study may be used for the 
purposes of national and international registration, publication, and information for medical and 
pharmaceuti cal professionals by the Sponsor. If necessary, the authorities will be notified of the 
Investigator’s name, address, qualifications, and extent of involvement in the study. The 
Investigator may not publish or present any information on this study without the express written 
approval of the Sponsor. Additionally, the Sponsor may, for any reason, withhold approval for publication or presentation. If the Investigator is to be an author of a publication manuscript prepared by the Sponsor, the Sponsor will allow the Investigator 30 days for full review of the 
manuscript before publication. Such manuscript or materials should be provided for Sponsor 
review only after the final database is available.  
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  101 CONFIDENTIAL  15 References  
Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N -CAM) in a patient with 
cutaneous CD4-positive lymphoma. Am J Hematol  1994;47:278-282. 
Aldinucci D, Olivo K, Lorenzon D, et al. The role of interleukin -3 in classical Hodgkin's 
disease. Leukemia Lymphoma 2005;46:303-311. 
Aldinucci D, Poletto D, Gloghini A, et al. Expression of functional interleukin -3 receptors on 
Hodgkin and Reed-Sternberg cells. Am J Pathol 2002;160:585-596. 
Alexander RL, Kucera GL, Klein B, Frankel AE. In vitro  interleuki n-3 binding to leukemia 
cells predicts cytotoxicity of a diphtheria toxin/IL -3 fusion protein. Bioconjug Chem 
2000;11:564-8. 
American Cancer Society. Cancer Facts and Figures 201 3. Available from: 
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/ac
spc-036845.pdf . 
Angelot -Delettre F, Frankel AE, Liu JS, et al. The IL -3Rα-targeted drug SL -401 selectively 
kills blastic plasmacytoid dendritic cell neoplasm cells. Blood (ASH Annual Meeting 
Abstracts), 2011: 2588. 
Assaf C, Gellrich S, Whittaker S, et al. CD56 -positive haematological neoplasms of the skin: a 
multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation 
for Research and Treatment of Cancer. J Clin Pathol 2007;60:981-989. 
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote 
radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-
60. 
Bekkenk MW, Jansen PM, Meijer CJ, et al.  CD56+ hematological neoplasms presenting in the 
skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004;15:1097-1108. 
Bene MC, Feuillard J, Jacob MC, et al.  Plasmacytoid dendritic cells: from the plasmacytoid T -
cell to type 2 dendritic cells CD4+CD56+ malignancies.  Semin Hematol 2003; 40:257-266. 
Bennett JM, Catovsky D, Daniel MT, et al.  Proposals for the classification of the acute 
leukaemias. French -American -British (FAB) co -operative group. Brit J Haematol 
1976;33:451-458. 
Black JH, McCubrey JA, Willingham MC, et al.  Diphtheria toxin -interleukin -3 fusion protein 
(DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.  
Leukemia 2003;17:155- 159. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  102 CONFIDENTIAL  Brody JP, Allen S, Schulman P, et al.  Acute agranular CD4 -positive natural killer cell 
leukemia. Comprehensive clinicopathologic studies including virologic and in vitro  culture 
with inducing agents. Cancer, 1995. 75(10): p. 2474-83. 
Brunning RD, Matutes E, Harris NL, et al.  Acute myeloid leukaemia: introduction. In: Jaffe 
ES, Harris NL, Stein H, et al.  eds.: Pathology and Genetics of Tumors of Haematopoietic and 
Lymphoid Tissues. Lyon, France: IARC Press, 2001. World Health Organization 
Classification of Tumors, 3,77-80. 
Chaperot L, Bendriss N, Manches O et al. Identification of a leukemia counterpart of the 
plasmacytoid dendritic cells. Blood 2001; 97(10): 3210-17. 
Chaperot L, Perrot I, Jacob MC, et al.  Leukemic plasmacytoid dendritic cells share phenotypic 
and functional features with their normal counterparts. Eur J Immunol 2004;34:418-426. 
Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic 
cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009;16:309-323. 
Chauhan D, Ray A, Sharma DD, et al.  Effect of a novel agent SL -401, targeting interleukin -3 
receptor (IL -3R) on plasmacytoid dendritic cell (pdc)-induced myeloma cell growth and 
osteolytic bone diseas e. J Clin Oncol 32:5s, 2014 (suppl; abstr 8699). 
Cheson BD, Cassileth PA, Head DR, et al.  Report of the National Cancer Institute -sponsored 
workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-819. 
Cheson B D, Bennett JM, Kopecky KJ, et al.  Revised recommendations of the international 
working group for diagnosis, standardization of response criteria, treatment outcomes, and 
reporting standards for therapeutic trials in acute myeloid leukemia. J  Clin Oncol 
2003;21:4642-4649. 
Cheson BD, Pfistner B, Juweid ME, et al.  The International Harmonization Project on 
Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-
586. 
Craddock C, Tauro S, Moss P, Grimwade, D.  Biology and management  of relapsed acute 
myeloid leukaemia.  Br J Haematol 2005;129:18-34. 
Deng Q and Barbieri JT. Molecular mechanisms of the cytotoxicity of ADP -ribosylating 
toxins. Annu Rev Microbiol 2008;62:271-288. 
DiGiuseppe JA, Louie DC, Williams JE, et al. Blastic natural killer cell leukemia/lymphoma: a 
clinicopathologic study. Am J Surg Pathol 1997; 21:1223-1230.  
Dohner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia 
in adults: recommendations from an international expert panel, on behalf of the European 
LeukemiaNet. Blood 2010; 115:453-474. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  103 CONFIDENTIAL  Facchetti F, Vermi W, Mason D, et al. The plasmacytoid monocyte/interferon producing cells. 
Virchows Arch 2003;443:703-717. 
Facchetti F, Petrella, T.  Blastic plasmacytoid dendritic cells neoplasm. In: Swerdlow SH, 
Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW., ed. WHO 
Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). 4th ed. Lyon, 
France: International Agency for Research on Cancer 2008:145-7. 2008. 
Feuillard J.  Clinical and biologic features of CD4+CD56+ malignancies.  Blood 2002:1556 -
1563. 
Feuring -Buske M, Frankel AE, Alexander RL, et al.  A diphtheria toxin -interleukin 3 fusion 
protein is cytotoxic to primitive acute myeloid leukemia pr ogenitors but spares normal 
progenitors. Cancer Res 2002;62:1730-1736. 
FitzGerald D, Pastan I. Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 
1989;81:1455-63. 
Florian S, Sonneck K, Hauswirth AW, et al.  Detection of molecular targets on the surface of 
CD34+/CD38-- stem cells in various myeloid malignancies. Leuk emia  Lymphoma 
2006;47:207-222. 
Frankel AE, McCubrey JA, Miller MS, et al. Diphtheria toxin fused to human interleukin -3 is 
toxic to blasts from patients with myeloid leukemias. Leukemia 2000;14:576-585.  
Frankel EF, Woo JH, Ahn C, et al.  Activity of SL -401, a targeted therapy directed t o 
interleukin -3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.  Blood. 2014; 
124(3): 385–392. 
Frolova O, Frankel A, Korchin, B, et al. IL3R Directed Agents, SL -401 and SL -501, Inhibit 
the Growth of Leukemia Stem Cells In CML. Presented at the 2010 American Society of Hematology Annual Meeting and Exposition, New Orleans, LA. 
Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 
2013; 121:1077-1082. 
Garnache -Ottou F, Feullard J, Ferrand C et al. Ext ended diagnostic criteria for plasmacytoid 
dendritic cell neoplasm. Br J Haematol 2009; 145: 624-636.  
Giles F, O'Brien S, Cortes J, et al.  Outcome of patients with acute myelogenous leukemia after 
second salvage therapy.  Cancer 2005;104:547-554. 
Herling M, Jones D.  CD4+/CD56+ hematodermic tumor: the features of an evolving entity and 
its relationship to dendritic cells.  Am J Clin Pathol  2007;127:687-700.  
Hermann PC, Huber SL, Heeschen C. Metastatic cancer stem cells: a new target for anti -
cancer therapy?  Cell Cycle 2008;7:188-93.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  104 CONFIDENTIAL  Jacob MC, Chaperot L, Mossuz P, et al.  CD4+ CD56+ lineage negative malignancies: a new 
entity developed from malignant early plasmacytoid dendritic cells.  Haematologica 
2003;88:941-955.  
Jordan CT, Upchurch D, Szilvassy SJ, et a l. The interleukin -3 receptor alpha chain is a unique 
marker for human acute myelogenous leukemia stem cells. Leukemia 2000;14:1777-1784.  
Jordan CT, Guzman ML, Noble M.  Cancer Stem Cells.  N Engl J Med 2006; 355:1253 -1261.  
Keating MJ, Kantarjian H, Smith TL, et al.  Response to salvage therapy and survival after 
relapse in acute myelogenous leukemia.  J Clin Oncol 1989;7:1071-1080.  
Lhermitte L, de Labarthe A, Dupret C, et al.  Most immature T -ALLs express Ra -IL3 (CD123): 
possible target for DT-IL3 therapy. Leukemia 2006;20:1908-1910. 
Louie GV, Yang W, Bowman ME, et al. Crystal structure of the complex of diphtheria toxin 
with an extracellular fragment of its receptor. Mol Cell 1997;1:67-78. 
Lucio P, Parreira A, Orfao A.  CD123hi dendritic cell lymphoma: an unusual case of non -
Hodgkin lymphoma. Ann I ntern Med 1999;131:549-550. 
Marafioti T, Paterson JC, Ballabio E.  Novel markers of normal and neoplastic human 
plasmacytoid dendritic cells. Blood 2008; 111:3778-3792. 
McCann S, Akilov OE, Geskin L. Adverse even ts of denileukin diftitox and their management 
in patients with cutaneous T- cell lymphoma.  Clin J Oncol Nursing 2012;16(5):E164-172. 
Munoz L, Nomdedeu JF, Lopez O, et al.  Interleukin -3 receptor alpha chain (CD123) is widely 
expressed in hematologic malign ancies.  Haematologica 2001;86:1261-1269. 
National Cancer Institute  2013 . SEER Stat Fact Sheets: Acute Myeloid Leukemia.  Available 
from: http://seer.cancer.gov/statfacts/html/amyl.html. 
National Comprehensive Cancer Network Guidelines Version 2.2013: Acut e Myeloid 
Leukemia. 
Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin 
diftitox for the treatment of cutaneous T -cell lymphoma. J Clin Oncol 2001;19:376-388. 
Olsen EA, Whittaker S, Kim YH.  Clinical end points and response criteria in mycosis 
fungoides and Sezary syndrome: a consensus statement of the International Society for 
Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the 
Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment 
of Cancer.  J Clin Oncol 2011; 29:2598-2607. 
Perentesis JP, Miller SP, Bodley JW. Protein toxin inhibitors of protein synthesis. Biofactors 
1992;3:173-84. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  105 CONFIDENTIAL  Petrella T, Bagot M, Willemze R, et al.  Blastic NK -cell lymphomas (agranular CD4+CD56+ 
hematodermic neoplasms): a review.  Am J Clin Pathol 2005;123:662-675. 
Petrella T, Comeau MR, Maynadie M, et al.  'Agranular CD4+ CD56+ hematodermic 
neoplasm' (blastic NK -cell lymphoma) originates from a population of CD56+ precursor cells 
related  to plasmacytoid monocytes. Am J Surg Pathol 2002;26:852-862. 
Petrella T, Dalac S, Maynadie M, et al.  CD4+ CD56+ cutaneous neoplasms: a distinct 
hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg 
Pathol 1999;23:137-146. 
Prince HM, Duvic M, Martin A et al. Phase III placebo -controlled trial of denileukin diftitox 
for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;28:1870-1877. 
Ratts R, Trujillo C, Bharti A, et al. A conserved motif in transmembrane helix 1 o f diphtheria 
toxin mediates catalytic domain delivery to the cytosol. Proc Natl Acad Sci U S A 
2005;102:15635-40. 
Reichard KK, Burks EJ, Foucar MK, et al.  CD4(+) CD56(+) lineage -negative malignancies 
are rare tumors of plasmacytoid dendritic cells.  Am J Surg Pathol 2005;29:1274-1283. 
Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on 
molecular biology, diagnosis, and therapy. Cancer Control. 2014 Oct;21(4):279-89. 
Shi Y, Wang E. Blastic plasmacytoid dendritic cell  neoplasm: a clinicopathologic review. 
Arch Pathol Lab Med 2014: 138: 564-69. 
Smith M, Barnett M, Bassan R, et al.  Adult acute myeloid leukemia.  Crit Rev Oncol Hemat 
2004;50:197-222. 
Suzuki R, Nakamura S, Suzumiya J, et al.  Blastic natural killer cell ly mphoma/leukemia 
(CD56 -positive blastic tumor): prognostication and categorization according to anatomic sites 
of involvement. Cancer  2005;104:1022-1031. 
Tehranchi R, Woll PS, Anderson K, et al.  Persistent malignant stem cells in del(5q) 
myelodysplasia in remission.  N Engl J Med 2010;363:1025-1037. 
Urosevic M, Conrad C, Kamarashev J, et al.  CD4+CD56+ hematodermic neoplasms bear a 
plasmacytoid dendritic cell phenotype. Hum Pathol 2005;36:1020-1024. 
van Rhenen A, Feller N, Kelder A, et al. High stem cell fr equency in acute myeloid leukemia 
at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 
11:6520-6527. 
Vergez F, Green AS, Tamburini J, et al. High levels of CD34+CD38low/ -CD123+ blasts are 
predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest -Est des 
Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 2011; 96:1792-1798. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  106 CONFIDENTIAL  Wang H, Cao J, Hong X.  Blastic plasmacytoid dendritic cell neoplasm without cutaneous 
lesion at presentation: case report and literature review.  Acta Haematol  2012;127:124-127. 
Yamaizumi M, Mekada E, Uchida T, et al. One molecule of diphtheria toxin fragment A 
introduced into a cell can kill the cell. Cell 1978;15:245-250. 
Zeppernick F, Ahmadi R, Campos B, Dict us C, Helmke BM, Becker N, et al. Stem cell marker 
CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-9. 
Zheng G, Schmeig J, Guan H et al. Blastic plasmacytoid dendritic cell neoplasm: 
cytopathologic findings.  
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  107 CONFIDENTIAL  16 Appendices  
16.1 Appendix A. Tumor Response Criteria for Patients with AML  
Response  Location  Criteria  
Complete 
Remission (CR)  Marrow  • Normaliz ation of blast percentage (≤5%)  
• No detectable Auer rods  
Peripheral Blood  • Normalization neutrophil count (≥1,000/µL) and platelet count 
(≥100,000/µL)  
• Absence of leukemic blasts  
Extramedul lary • No extramedul lary disease (CNS or soft tissue)  
CR with 
incomplete blood 
count recovery 
(CRi)  Marrow  • Normalization of blast percentage (≤5%)  
Peripheral Blood  • Incomplete recovery of neutrophil and/or platelet count  
• Absence of leukemic blasts  
Extramedul lary • No extramedul lary disease  (CNS or soft tissue)  
Partial Remission 
(PR)  Marrow  • Decrease by ≥50% in blast percentage to  5 - 25% or to ≤5% with 
Auer rods present  
Peripheral Blood  • Normalization neutrophil count (≥1,000/µL) and platelet count 
(≥100,000/µL)  
Stable Disease 
(SD)   • Failure to achieve at least a PR, but no evidence of progression for 
at least 8 weeks  
Relapse after 
CR/CRi  Marrow  • Blast percentage >5% (if no peripheral blasts, then confirmation 
aspirate required ≥1 week later)  
Relapse after PR  Marrow  • Blast percentage ≥25% (if no peripheral blasts, then confirmation 
aspirate required ≥1 week later)  
Progressive 
Disease (PD)  Marrow  • ≥50% increase in blasts from baseline  
Peripheral Blood  One or more of the following:  
• ≥50% decrease from peak remission levels in platelets or 
granulocytes;  
• Reduction in hemoglobin concentration by at least 2 g/dL;  
• Transfusion dependence  
Source:  Cheson BD, Bennett JM, Kopecky KJ, et al.  Revised recommendations of the international working group for diagnosis, 
standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leu kemia. 
J Clin Oncol 2003; 21:4642- 4649.  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  108 CONFIDENTIAL  16.2 Appendix B. Tumor Response Criteria for Patients with BPDCN  
Response  Location  Criteria  
Complete 
Response (CR)  Marrowb • Normaliz ation of blast percentage (≤5%) b 
Peripheral Blood  • Normalization of neutrophil count (≥1,000/µL) and platelet count 
(≥100,000/µL)  
• Absence of leukemic blasts  
Skina • 100% clearance of all skin lesions from baseline; no new lesions 
in patients without lesions at baselinea 
Nodal Masses  • Regression to normal size on CT  
Spleen, Liver  • Not palpable, nodules disappeared  
CR with 
incomplete blood 
count recovery 
(CRi)  Marrowb • Normalization of blast percentage (≤5%)  b 
Peripheral Blood  • Incomplete recovery of neutrophil and/or platelet count  
• Absence of leukemic blasts  
Skina • 100% clearance of all skin lesions from baseline; no new lesions 
in patients without lesions at baselinea  
Nodal Masses  • Regression to normal size on CT  
Spleen, Liver  • Not palpable, nodules disappeared  
CR [clinical] with 
minimal residual 
skin abnormality  
(CRc)  Marrowb • Normalization of blast percentage (≤5%) b 
Peripheral Blood  • Normalization of neutrophil count (≥1,000/µL) and platelet count 
(≥100,000/µL)  
• Absence of leukemic blasts  
Skina • Marked clearance of all skin lesions from baseline; residual 
hyperpigmentation or abnormality with BPDCN identified on 
biopsy (or no biopsy performed) a 
Nodal Masses  • Regression to normal size on CT  
Spleen, Liver  • Not palpable, nodules disappeared  
Partial Response 
(PR)  Marrowb • Decrease by ≥50% in blast percentage to 5 − 25%  b 
Peripheral Blood  • Normalization of neutrophil count (≥1,000/µL) and platelet count 
(≥100,000/µL)  
Skina • 50% − <100% clearance of all skin lesions from baseline; no new 
lesions in patients without lesions at baselinea 
Nodal Masses  • ≥50% decrease in SPD of up to 6 largest dominant masses; no 
increase in size of other nodes  
Spleen, Liver  • ≥50% decrease in SPD of nodules (for single nodule in greatest 
transverse diameter); no increase in size of liver or spleen  
Stable Disease 
(SD)   • Failure to achieve at least a PR, but no evidence of progression for 
at least 8 weeks  
Relapse after 
CR/CRi/CRc  Marrowb • Blast percentage >5% (if no peripheral blasts, then confirmation 
aspirate required ≥1 week later)  b 
Peripheral Blood  • Presence of leukemic blasts  
Skina • Increase in skin score  greater than the sum of nadir plus 50% 
baseline scorea 
Nodal Masses  • Appearance of a new lesion(s) >1.5 cm in any axis, ≥50% increase 
from nadir in SPD of more than one node, or ≥50% increase from nadir in longest diameter of a previously identified node  >1 cm in 
short axis  
Spleen, Liver  • >50% increase from nadir in the SPD of any previous lesions  
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  109 CONFIDENTIAL  Relapse after PRc Marrowb • Blast percentage ≥25% (if no peripheral blasts, then confirmation 
aspirate required ≥1 week later) b 
Skina • Increase in skin score greater than the sum of nadir plus 50% 
baseline scorea 
Nodal Masses  • Appearance of a new lesion(s) >1.5 cm in any axis, ≥50% increase 
from nadir in SPD of more than one node, or ≥50% increase from 
nadir in longest diameter of a previously identified node >1 cm in 
short axis  
Spleen, Liver  • >50% increase from nadir in the SPD of any previous lesions  
Progressive 
Disease (PD) c Marrowb • ≥50% increase in blasts from baseline  (and blast percentage >5%)b 
Peripheral Blood  One or more of the following:  
• ≥50% decrease from peak remission levels in platelets or 
granulocytes;  
• Reduction in hemoglobin concentration by at least 2 g/dL;  
• Transfusion dependence  
Skina One or more of the following:  
• ≥25% increase in skin disease from baselinea 
• Any new tumors in patients  without tumors at baseline  
Nodal Masses  • Appearance of a new lesion(s) >1.5 cm in any axis, ≥50% increase 
from nadir in SPD of more than one node, or ≥50% increase from nadir in longest diameter of a previously identified node >1 cm in 
short axis  
Spleen, Liver  • >50% increase from nadir in the SPD of any previous lesions  
Source:  Cheson BD, Pfistner B, Juweid ME, et al.  The International Harmonization Project on Lymphoma. 
Revised response criteria for malignant lymphoma.  J Clin Oncol 2007;25:579- 586. 
Abbreviations: CT, computed tomography; SPD, sum of the product of the diameters.  
All parameters detailed above (including bone marrow, blood, skin [including mSWAT quantification], lymph 
nodes and viscera) are to be assessed both at baseline and stipulat ed subsequent timepoints.  Responses are 
determined via comparison to baseline values (or post -treatment nadir values as stipulated in the above table).  
a The percentage of clearance or increase in skin disease is calculated using the Modified Severity Wei ghted 
Assessment Tool (mSWAT), which is provided in  Section 16.3/Appendix C.  Detailed guidance and examples 
regarding the calculation of an mSWAT assessment based on the size and nature of a patient’s skin lesions are 
provided in a separate document.  
b In settings in which there is a change in the blast population on bone marrow evaluation by means of flow 
cytometry or other molecular methodology without a similar degree of change in the morphologic blast percentage, the morphologic percentage should be utilized to determine response/progression; however the findings from flow cytometry (or other molecular methodology) should be recorded as part of the study record.   
c In settings in which there is preliminary but not conclusive evidence of disease progression (i.e., new skin 
lesions of indeterminate etiology, new lymph nodes ≤1.5cm, modest increase in bone marrow blast percentage 
subsequent to an initial marked reductio n, appearance of new blast population on bone marrow evaluation by 
means of flow cytometry or other molecular methodology without increase in blast percentage consistent with PD), additional SL -401 cycles may be administered, provided that the Investigator  documents that the evidence 
of potential disease progression is inconclusive and that the overall risk/benefit assessment favors additional investigational therapy.  Additional SL -401 may also be administered in situations of mixed response BPDCN in 
which response/progression is not consistent between a given patient’s disease sites, provided that the 
Investigator  documents that the overall risk/benefit assessment favors additional investigational therapy.  In such 
situations, it is essential that relevant f indings and assessments are documented, and that areas of potential disease 
progression are followed closely on subsequent assessments.  
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  110 CONFIDENTIAL  16.3 Appendix C. Modified Severity Weighted Assessment Tool 
Body Region  %BSA in Body 
Region  Assessment of Involvement in Patient’s Skin  
Patcha Plaqueb Tumorc 
Head  7    
Neck  2    
Anterior trunk  13    
Arms  8    
Forearms  6    
Hands  5    
Posterior trunk  13    
Buttocks  5    
Thighs  19    
Legs  14    
Feet 7    
Groin  1    
Subtotal of weighted BSA     
Weighting factor  × 1 × 2 × 4 
Weighted subtotal     
Note: mSWAT score equals summation of weighted subtotals.   
Abbreviations: BSA, body surface area; mSWAT, modified Severity Weighted Assessment Tool . Detailed 
guidance and examples regarding the calculation of an mSWAT assessment based on the size and nature of a 
patient’s skin lesions are provided in a separate document.  
aAny size lesion without induration or significant elevation above the surrounding uninvolved skin; poikiloderma 
may be present.  
bAny size lesion that is elevated or indurated; crusting, ulceration, or poikiloderma may be present.  
cAny solid or nodular lesion ≥1 cm in diameter with evidence of deep infiltration in the skin and/or vertical 
growth.  
 
 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  111 CONFIDENTIAL  16.4 Appendix D. ECOG Performance Status  
Grade  Description  
0 ABLE TO CARRY OUT ALL NORMAL ACTIVITIES WITHOUT RESTRICTION. 
1 RESTRICTED IN PHYSICALLY STRENUOUS ACTIVITY BUT AMBULATORY AND ABLE 
TO CARRY OUT WORK OF A LIGHT OR SEDENTARY NATURE.  
2 AMBULATORY AND CAPABLE OF ALL SELF -CARE BUT UNABLE TO CARRY OUT ANY 
WORK ACTIVITIES: UP AND ABOUT MORE THAN 50% OF WAKING HOURS.  
3 CAPABLE OF LIMITED SELF -CARE; CONFINED TO BED OR CHAIR MORE  THAN 50% OF 
WAKING HOURS.  
4 COMPLETELY DISABLED; CANNOT CARRY ON SELF -CARE; TOTALLY CONFINED TO 
BED OR CHAIR. 
SL-401 Diphtheria Toxin Interleukin -3 Fusion Protein Stemline Therapeutics, Inc.  
 Protocol STML -401-0114  
Amendment 12 (FINAL): 17 January 2019  112 CONFIDENTIAL  16.5 Appendix E. CLS Management Guidance 
Time of Presentation  CLS  
Sign/Symptom  Recommended  
Action  ELZONRIS Dosing 
Management  
Prior to first dose of 
ELZONRIS in cycle 1  Serum albumin <  3.2 g/dL  Administer  ELZONRIS when serum albumin ≥ 3.2 g/dL . 
During ELZONRIS dosing Serum albumin <  3.5 g/dL  
Administer 25g intravenous albumin (q12h or more 
frequently as practical) until serum albumin is ≥ 3.5 g/dL 
AND not more than 0.5 g/dL lower than  the value measured 
prior to dosing initiation of the current cycle . Interrupt  ELZONRIS 
dosing until the 
relevant CLS  
sign/symptom has 
resolved1. 
Serum albumin reduced by ≥ 0.5 g/dL 
from the albumin value measured prior 
to ELZONRIS dosing initiation of the 
current cycle   
A predose body weight that is increased by ≥  1.5 kg over the previous 
day’s predose weight  Administer 25g intravenous  albumin (q12h or more 
frequently as practical), and manage fluid status as indicated clinically (e.g., generally with intravenous fluids 
and vasopressors if hypotensive and with diuretics if normotensive or hypertensive ), until body weight increase 
has re solved (i.e. the increase is no longer ≥ 1.5 kg greater 
than the previous day’s predose weight).   
Edema, fluid overload and/or hypotension Administer 25g intravenous  albumin (q12h, or more 
frequently as practical) until serum albumin i s ≥ 3.5 g/dL . 
 Administer 1 mg/kg of methylprednisolone (or an equivalent) per day, until resolution of CLS  sign/symptom 
or as indicated clinically . 
 
Aggressive management of fluid status and hypotension if 
present, which could include intravenous fluids and/or 
diuretics  or other blood pressure management , until 
resolution of CLS sign/symptom  or as clinically indicated .    
1  ELZONRIS administration may resume in the same cycle if all CLS signs/symptoms have resolved and the patient did not require measures to treat hemo dynamic instability. 
ELZONRIS administration should be held for the remainder of the cycle if CLS signs/symptoms have not resolved or the patient required measures to treat hemodynamic 
instability (e.g. required administration of intravenous fluids and/or vasopressors to treat hypotension) (even if resolved), and ELZONRIS administration may only resume in the 
next cycle if all CLS signs/symptoms have resolved, and the patient is hemodynamically stable.  